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Background: In the late 1990s, new developments in knee replacement were identiﬁed as a priority for
research within the NHS. The newer forms of arthroplasty were more expensive and information was
needed on their safety and cost-effectiveness.
Objectives: The Knee Arthroplasty Trial examined the clinical effectiveness and cost-effectiveness of four
aspects of knee replacement surgery: patellar resurfacing, mobile bearings, all-polyethylene tibial
components and unicompartmental replacement.
Design: This study comprised a partial factorial, pragmatic, multicentre randomised controlled trial with
a trial-based cost–utility analysis which was conducted from the perspective of the NHS and the
patients treated. Allocation was computer generated in a 1:1 ratio using a central system, stratiﬁed by
eligible comparisons and surgeon, minimised by participant age, gender and site of disease. Surgeons
were not blinded to allocated procedures. Participants were unblinded if they requested to know the
prosthesis they received.
Setting: The setting for the trial was UK secondary care.
Participants: Patients were eligible for inclusion if a decision had been made for them to have primary
knee replacement surgery. Patients were recruited to comparisons for which the surgeon was in equipoise
about which type of operation was most suitable.
† ledgement sectionvii
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Murray et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
ABSTRACT
viiiInterventions: Patients were randomised to receive a knee replacement with the following: patellar
resurfacing or no patellar resurfacing irrespective of the design of the prosthesis used; a mobile bearing
between the tibial and femoral components or a bearing ﬁxed to the tibial component; a tibial component
made of either only high-density polyethylene (‘all polyethylene’) or a polyethylene bearing ﬁxed to a metal
backing plate with attached stem; or unicompartmental or total knee replacement.
Main outcome measures: The primary outcome was the Oxford Knee Score (OKS). Other outcomes were
Short Form 12; EuroQol 5D; intraoperative and postoperative complications; additional surgery; cost; and
cost-effectiveness. Patients were followed up for a median of 10 years; the economic evaluation took a
10-year time horizon, discounting costs and quality-adjusted life-years (QALYs) at 3.5% per annum.
Results: A total of 116 surgeons in 34 centres participated and 2352 participants were randomised: 1715
in patellar resurfacing; 539 in mobile bearing; 409 in all-polyethylene tibial component; and 34 in the
unicompartmental comparisons. Of those randomised, 345 were randomised to two comparisons. We can
be more than 95% conﬁdent that patellar resurfacing is cost-effective, despite there being no signiﬁcant
difference in clinical outcomes, because of increased QALYs [0.187; 95% conﬁdence interval (CI) –0.025
to 0.399] and reduced costs (–£104; 95% CI –£630 to £423). We found no deﬁnite advantage or
disadvantage of mobile bearings in OKS, quality of life, reoperation and revision rates or cost-effectiveness.
We found improved functional results for metal-backed tibias: complication, reoperation and revision rates
were similar. The metal-backed tibia was cost-effective (particularly in the elderly), costing £35 per
QALY gained.
Conclusions: The results provide evidence to support the routine resurfacing of the patella and the use of
metal-backed tibial components even in the elderly. Further follow-up is required to assess the stability of
these ﬁndings over time and to inform the decision between mobile and ﬁxed bearings.
Trial registration: Current Controlled Trials ISRCTN45837371.
Funding: This project was funded by the NIHR Health Technology Assessment programme and the
orthopaedic industry. It will be published in full in Health Technology Assessment; Vol. 18, No. 19. See the
NIHR Journals Library website for further project information.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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In the late 1990s, new developments in knee replacement were identiﬁed as a priority for research within
the NHS. The newer forms of arthroplasty were more expensive and information was needed on their
safety and cost-effectiveness. The Knee Arthroplasty Trial (KAT) was commissioned by the Health
Technology Assessment (HTA) programme to address this need.Objectives
The trial examined four key questions relating to knee replacement:
1. Should the patella be resurfaced or not? There is considerable variability in the use of resurfacing in the
UK, with many surgeons routinely resurfacing the patella and many not. There is no clear evidence as
to which approach is best.
2. Should mobile or fixed bearings be routinely used? Mobile bearings have the theoretical advantages of
decreased wear and improved kinematics, which should result in an improvement in functional
outcome and a decrease in the long-term failure rate. The main theoretical disadvantage is instability
and dislocation of the bearing. It is not clear whether mobile bearings have clinical advantages
or disadvantages.
3. Should the tibial component be all polyethylene or have a polyethylene bearing supported by a metal
backing? Previous randomised controlled trials (RCTs) and meta-analyses of these trials found no
difference in clinical outcome between the two types of tibial component. As all-polyethylene
components are substantially cheaper than metal-backed components, the general recommendation is
that all-polyethylene devices should be used in the elderly to reduce costs.
4. Should unicompartmental or total knee replacement generally be used? There is some evidence to
suggest that unicompartmental replacement is associated with improved functional results, fewer
complications, a faster recovery and lower costs than total replacements, but also a higher failure rate.
It is not clear whether the advantages outweigh the disadvantages.Methods
The trial was a partial factorial, pragmatic, multicentre RCT designed to assess clinical outcomes,
complications and cost-effectiveness. The primary outcome measure was functional status as measured by
the Oxford Knee Score (OKS). Other outcome measures were as follows: quality of life as measured by the
Short Form 12 (SF-12) and EuroQoL 5D (EQ-5D); intraoperative and postoperative complications including
the need for additional surgery; cost; and cost-effectiveness. Participants were followed up for a median of
10 years. A trial-based cost–utility analysis was conducted to evaluate whether patellar resurfacing, mobile
bearings and all-polyethylene tibial components are cost-effective from the costing perspective of the NHS
and the health perspective of the patients undergoing knee replacement. The economic evaluation took
a 10-year time horizon, with future costs and quality-adjusted life-years (QALYs) discounted at
3.5% per annum.xxv
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SCIENTIFIC SUMMARY
xxviResults
In total, 116 surgeons in 34 UK centres participated in the trial. From July 1999 to January 2003,
4070 potentially eligible participants were identiﬁed and 2374 (58%) gave their consent and were
randomised. Of these, 22 participants were subsequently found to have been randomised in error, which
left 2352 participants formally in the trial: 1715 in the comparison assessing the patellar resurfacing;
539 in the comparison assessing the mobile bearing; 409 in the comparison assessing the metal backing;
and 34 in the comparison assessing total versus unicompartmental knee replacement. There were
345 participants randomised to more than one comparison.
We found no signiﬁcant difference in clinical outcome, in terms of pain and function, complications,
readmission or reoperations, between participants with and without patellar resurfacing. However,
there was a non-signiﬁcant trend towards improved quality of life [mean QALY difference 0.187;
95% conﬁdence interval (CI) –0.025 to 0.399; p = 0.08] and decreased costs (mean cost difference –£104;
95% CI –£630 to £423; p = 0.70) associated with resurfacing, suggesting that we can be more than 95%
conﬁdent that patellar resurfacing is cost-effective compared with no resurfacing at a threshold of £7250
per QALY gained. Of the non-resurfaced cases, 2.8% had late resurfacing, which was of little beneﬁt.
This late resurfacing was done in the ﬁrst 5 years. Of the resurfaced group, 1% had reoperations for
complications of the resurfacing during the second 5 years. Our ﬁndings were independent of whether or
not the trochlear design was anatomical.
We found no conclusive evidence of any risks or beneﬁts associated with mobile bearings in terms of
postoperative functional status, quality of life, reoperation and revision rates or cost-effectiveness. There
was a 2% incidence of instability or bearing dislocation in the mobile bearing group and none in the ﬁxed
bearing group. Although mobile bearings were more expensive for the hospital than ﬁxed bearings, these
initial costs were partly offset by decreases in the cost of subsequent follow-up. Overall, mobile bearings
increased costs by £85 (95% CI –£911 to £1081; p = 0.87) and QALYs by 0.051 (95% CI –0.333 to 0.435;
p = 0.79) and had a 59% chance of being cost-effective.
We found that the functional results with a metal-backed tibia were better than with an all-polyethylene
tibia. This difference was statistically signiﬁcant with the EQ-5D and SF-12 but not with the OKS. The
complication, reoperation and revision rates were not signiﬁcantly different, although the major
reoperation rate for the all-polyethylene tibia (3%) was more than twice that for the metal-backed tibia
(1%). The group randomised to all-polyethylene tibial components accrued lower costs (mean
difference –£10; 95% CI –£872 to £851; p = 0.98) and fewer QALYs (mean difference –0.293;
95% CI –0.706 to 0.119; p = 0.16) than those randomised to metal backing. The economic analysis
showed that the metal-backed tibia was cost-effective compared with the all-polyethylene tibia, costing
£35 per QALY gained for the population as a whole and being particularly cost-effective in those aged
≥ 70 years (95% probability).
Between designing and recruiting for KAT, the technique for unicompartmental replacement changed, as
surgeons started using a minimally invasive approach. As a result, surgeons were keen to learn the new
technique rather than randomise participants. Owing to the poor recruitment rate, recruitment to this
comparison in KAT was stopped.Conclusions
This trial is the largest RCT of knee replacement ever conducted and provides a wealth of data on the
management and outcomes following knee surgery. It has achieved very high levels of follow-up, with a
median of 10 years, and has important implications for clinical practice. The success of KAT has
demonstrated that large pragmatic trials with economic evaluations are possible in orthopaedics and
provides an exemplar for the conduct of such studies.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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If a patient has not undergone primary patellar resurfacing, the ﬁndings do not support late resurfacing, as
this is of little, if any, beneﬁt.
We found no evidence of a difference between mobile and ﬁxed bearings in function and quality of life.
Moreover, there was no signiﬁcant difference in complication, reoperation or revision rates, and there was
substantial uncertainty around estimated cost-effectiveness. We did, however, identify two disadvantages
of mobile bearings that could encourage surgeons to use ﬁxed-bearing devices. First, there was a 2%
incidence of instability or bearing dislocation in the mobile bearing group. Second, although there was no
signiﬁcant difference in overall costs in the long term, there was a short-term saving for the hospital for
ﬁxed bearings, as they are appreciably cheaper.
The ﬁndings from KAT strongly suggest that the metal-backed tibias are beneﬁcial and cost-effective.
We believe that the previous recommendation that all-polyethylene tibias should be used to save money
in the elderly is a false economy, as they are not only more costly in the elderly but also less effective.
Although recruitment to the comparison of unicompartmental knee replacement versus total knee
replacement was stopped in KAT, the experience gained from KAT informed a new study, known as
TOPKAT (Total Or Partial Knee Arthroplasty Trial). The TOPKAT study, funded by the National Institute
for Health Research HTA board, ﬁnished its recruitment in September 2013 (HTA project reference
number 08/14/08).
With the increasing longevity of knee replacement patients, longer follow-up is required to assess the
long-term sustainability of these ﬁndings. Longer follow-up will also help to answer some important
outstanding questions. In the patellar resurfacing trial there was, with increasing follow-up, an increasing
number of reoperations for complications of resurfacing and a decreasing number of late resurfacings.
If this trend continues, the data may no longer support routinely resurfacing the patella. In the mobile
bearing trial, there was a trend towards increased cost-effectiveness of mobile bearings in patients aged
< 70 years and ﬁxed bearings in patients aged ≥ 70 years. Further follow-up is required to obtain clearer
evidence to inform the use of mobile or ﬁxed bearings. In the metal-backing trial, we found a trend
towards an increased revision rate with all-polyethylene tibias. If this continues, the evidence will provide
a strong clinical reason to avoid all-polyethylene tibias. We found some evidence of potential interactions
between the various different randomisations. Further follow-up is required to determine if these
are important.
We believe the 10-year KAT data set is the best knee replacement data set available, as it includes
information about complications, revisions, patient-reported outcomes and health economics. Further work
is needed to analyse the data set in detail to answer many of the current key issues in knee replacement
surgery not related to the randomisations.Trial registration
This trial is registered as ISRCTN45837371.Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research, with additional industry funding for research support in clinical centres
from: Howmedia Osteonics; Zimmer; J&J De Puy; Corin Medical; Smith & Nephew Healthcare Ltd.;
Biomet Merck Ltd.; Wright Cremascoli.xxvii
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Health Technology Assessment programme-commissioned call
In the late 1990s, new developments in knee replacement were identiﬁed as a priority for research within
the NHS. Although they held the promise of better results, the newer forms of arthroplasty were more
expensive and information was needed on their safety and cost-effectiveness. This report describes the
Knee Arthroplasty Trial (KAT), which was commissioned by the Health Technology Assessment (HTA)
programme to address this need. When the trial was funded, it was recognised that any differential
performance of the alternative prostheses that were to be compared would become apparent only after
a long period of follow-up. Therefore, a plan to report ﬁndings after 10 years was built into the study from
the start, and results up to a median of 10 years after surgery are described in this report.Aims
The trial was designed to address questions about four developments in knee replacement surgery:
1. Is it better to resurface the patella as part of a knee replacement or not?
2. Are polyethylene moving components (‘mobile bearing’) between the tibia and femur better than
standard designs with a ﬁxed bearing?
3. Are tibial components made out of just high-density polyethylene (‘all polyethylene’) better than those
with a metal backing plate and stem, and polyethylene bearing (‘metal-backed’)?
4. Is it better to replace a single compartment of the knee (unicompartmental replacement) or to replace
the whole knee joint [total knee replacement (TKR)]?Clinical background including updated review of evidence base
Total knee arthroplasty is now a common and established surgical procedure. Long-term observational
studies have shown that there is variability in the failure rates of different designs of knee replacement,
with the best having a 20-year survivorship of about 90%.1–3 Overall, up to 20% of patients are not
satisﬁed with the result of their knee replacement. Continued developments in design have aimed at
further improving function and quality of life and increasing the duration of prosthetic survival.
A substantial proportion of patients have a poor functional result and persistent knee pain after knee
replacement.4,5 Many of these poor results are attributed to problems arising from the patellofemoral joint,
and there is considerable debate regarding whether the patella should be resurfaced at the time of the
primary total knee arthroplasty. Theoretically, patellar resurfacing should decrease the incidence of pain
related to the patellofemoral joint, although the resurfacing can fail. Previous evidence in the form of
non-randomised cohort studies, small randomised controlled trials (RCTs) and systematic reviews has not
resolved the uncertainty regarding the beneﬁts of patellar resurfacing.6–21
Many previous RCTs had insufﬁcient sample sizes to detect clinically worthwhile differences in outcomes.
There is great variability in the use of patellar resurfacing. Some surgeons routinely do not resurface,
whereas others routinely do resurface. There is also a subgroup that sometimes resurfaces the patella, but
there is no clear consensus as to which patients should undergo resurfacing.
Theoretically, by using mobile rather than ﬁxed bearings between the tibial and femoral components the
performance and longevity of knee replacement could be improved.22,23 Mobile bearings are usually
designed to be more congruent than ﬁxed bearings and, therefore, have larger contact areas, which
should reduce wear. However, as there are two bearing surfaces, the decrease in wear may be limited.1
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2They also tend to have less constraint than ﬁxed bearings, which should limit the shear stress at the
bone–implant interfaces. Strong interfacial forces and osteolysis resulting from polyethylene wear debris
are the most important causes of loosening, which is the most common cause of knee replacement failure.
By allowing an appropriate amount of mobility, a mobile bearing design could optimise kinematics and
thus improve function. However, mobile bearings can dislocate or be associated with instability. Previous
non-randomised cohort studies, RCTs and systemic reviews did not resolve the beneﬁts of using a mobile
versus a ﬁxed bearing.24–29 Again, the evidence base suffers from limited evidence from RCTs with
sufﬁcient sample sizes to detect worthwhile differences.
Another common variation is the design of the tibial component. Use of a metal-backed base plate has
theoretical advantages in that it distributes load more evenly across the implant–bone interface than an
all-polyethylene tibia, and thus should decrease the risk of loosening. In addition, as the bearing is
modular, the surgeon can select the thickness and constraints of the bearing after the components are
ﬁxed. However, metal backing reduces the thickness of the polyethylene that can be implanted in the
available space, thus increasing the internal stresses within the polyethylene and increasing the risk of
wear. Furthermore, metal backing is more expensive, and good medium- and long-term results have
been reported for the use of non-metal-backed components.30,31 Limited comparisons between
non-metal-backed and metal-backed components have been performed, and to our knowledge no
deﬁnitive difference has been determined.4,32 As there is no apparent clinical advantage of metal-backed
tibias and as they are more expensive, it is generally recommended that all-polyethylene tibias should be
used in the elderly to save money.33,34
Overall, in the NHS about 7% of knee replacements are unicompartmental. There is, however, great
variability: in different institutions unicompartmental knee replacements are used for between 0%
and 70% of knee replacements. The results from specialist centres that implant large numbers of
unicompartmental knee replacements have demonstrated that unicompartmental replacements give a
faster recovery, lower morbidity, lower cost, better function and better pain relief than total replacements.
However, in national registers, even though the risk of serious complications, such as death and infection,
is lower with unicompartmental than with total replacement, the revision rate is about three times higher.
There is clearly a need to establish the relative advantages and disadvantages of unicompartmental and
TKRs so as to determine whether the use of unicompartmental replacement should or should not be
encouraged. Although the only randomised study we are aware of did suggest that unicompartmental
replacement is better than total, it was too small to form the basis of any strong recommendation.13Outline of reportReﬂecting the multiple research questions to be addressed, KAT was designed as a partial factorial,
pragmatic, multicentre RCT to assess the clinical outcomes, complications and cost-effectiveness of the
four aspects of knee replacements. The full details of the design and methods adopted are presented in
Chapter 2. Chapter 3 presents the results of the comparison of patellar resurfacing versus no resurfacing;
Chapter 4 presents the results of the comparison of the polyethylene moving component (mobile bearing)
between the tibia and femur with standard designs with ﬁxed bearing; Chapter 5 presents the results of
the comparison of the metal backing plate for the tibial component of the TKR with a single high-density
polyethylene component; and Chapter 6 presents the results of the comparison of unicompartmental
replacement of the knee with TKR. Chapter 7 discusses the implications of the project as a whole, ﬁnishing
with a summary of the implications for practice and recommendations for further research.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18190 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 19Chapter 2 Methods and practical arrangementsStudy designThe trial was a partial factorial, pragmatic, multicentre RCT designed to assess the clinical outcomes,
complications and cost-effectiveness of four aspects of knee replacements. The detailed protocol is
included as Appendix 1.
The intention was to evaluate the newer designs as they would be used within the UK NHS setting. The
plan was therefore to involve a large number of UK centres in which knee replacement was undertaken
and to make comparisons based on outcomes important to people undergoing knee replacement and to
those responsible for providing orthopaedic services. Eligible surgeons (see below) could recruit to any of
the comparisons. However, the design acknowledged that some surgeons would have strong beliefs about
some of the factors under investigation and that there would be some who would not wish to randomise
between some factors but be comfortable to recruit to others. Surgeons could therefore choose which
comparisons to contribute to [and which comparison(s) to randomise any given participant to] on the basis
of equipoise, randomising participants to those aspects of component design for which they were not
certain which arm was most suitable for that participant. Equipoise formed a central part of this
recruitment strategy to help ensure that participants were randomised only when current evidence was
insufﬁcient to inform decisions about component design and to help boost recruitment of surgeons.
Although most participants were enrolled into just a single comparison, surgeons could enrol an individual
participant into more than one comparison, thereby decreasing the total sample size needed to achieve
the necessary statistical power for each comparison. In particular, participants could be randomised to
patellar resurfacing versus no resurfacing as well as to either all polyethylene versus metal-backed or
mobile bearing versus ﬁxed bearing. However, as all mobile bearing components are metal-backed,
participants could be randomised in only one of these comparisons. Additionally, the design did not allow
participants randomised in the unicompartmental versus TKR comparison to be randomised in any other
comparison. For those participants randomised in two comparisons, a factorial design was used within the
process for random allocation to ensure balance of allocation within and across comparisons (hence the
description of the design as a partial factorial trial) (Figure 1).35
Important changes to the design after trial commencement
The rate of recruitment to the fourth comparison – unicompartmental versus TKR – proved to be very slow,
despite efforts to encourage enrolment. Only 34 participants were recruited to this element of KAT, and,
with the agreement of the data monitoring committee, a decision was taken to close recruitment to this
component early in August 2002. The body of this report, therefore, describes in full only the three
remaining comparisons, to which recruitment was successful. The very limited information gained from the
unicompartmental versus TKR comparison is presented in Chapter 6.Clinical centresOrthopaedic surgeons within the UK were eligible to take part if they performed knee replacements
routinely. To participate, they had to be prepared to allow the choice between the speciﬁc options in at
least one of the trial comparisons to be decided by random allocation. Before participating in the trial, the
surgeons formally chose the comparisons to which they would contribute – as expected, surgeons did
differ in terms of which comparisons they would allow their patients’ surgical management to be
randomly allocated.3
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FIGURE 1 Diagrammatic representation of the partial factorial elements of KAT. n is the number of participants
randomised to that intervention.
METHODS AND PRACTICAL ARRANGEMENTS
4Study populationAll patients under the care of a collaborating surgeon were potentially eligible for inclusion if a decision
had been made to have primary knee replacement surgery. A patient was not eligible for a trial
comparison if the surgeon considered that a particular type of operation was clearly indicated (e.g. if a
patient required a highly constrained knee replacement to replace function of the collateral ligaments).
A patient remained eligible only if the surgeon remained convinced that there was no indication for one
particular choice within the trial; for example, a patient with a very thin patella would not be eligible for
the patellar resurfacing comparison because the surgeon would not have chosen patellar resurfacing for
such a patient.
As described above, individual patients could be recruited for more than one comparison if that was
clinically appropriate. However, only a minority of participants were included in more than one comparison.Consent to participatePotential participants were sent information about the trial comparisons in which the surgeon responsible
for their care had agreed to participate (patient information leaﬂets are reproduced in Appendix 1). Exact
arrangements for recruitment depended on the local admission procedures, but, in general, information
about the trial was given in two stages. A letter of invitation, together with information about the parts
of the trial in which the surgeon had agreed to participate, was sent to potential participants at home.
Information was also sent to their general practitioners (GPs) in case they were consulted. More detailed
information concentrating on the options for which the patient was eligible was given to potential
participants during discussions with a surgeon or research nurse at a pre-assessment clinic or when
admitted before surgery.
All eligible patients who agreed to participate in the trial signed the KAT consent form (see Appendix 1).
This form conﬁrmed that the participant had been given the information they required and that the study
had been explained to them. They also conﬁrmed that they understood that they would be sent a postal
questionnaire each year.Health technology policies comparedThe four comparisons made in KAT were:
l Patellar resurfacing versus no resurfacing – surgeons were randomised to resurface the patella or not,
irrespective of the design of the prosthesis used.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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mobile bearing – the surgeon was randomised to use the metal-backed cruciate-retaining or
substituting design that he or she used routinely, or alternatively a mobile-bearing design that was
essentially similar.
l Single high-density all-polyethylene component versus a tibial component with a polyethylene bearing
ﬁxed to a metal backing plate with a stem.
l Unicompartmental versus TKR.
Full information on the clinical details of each health technology under investigation is presented in more
detail in the separate results chapters (see Chapters 3–6).Treatment allocationParticipants were formally entered into the trial by telephoning an automated service within the trials
ofﬁce in Aberdeen. During this process, basic descriptive information was given ﬁrst (surgeon; patient’s
name, sex and date of birth), followed by the patient classiﬁcation part of the American Knee Society score
(AKS) (unilateral, bilateral, generalised arthritis) and the comparison(s) to which the participant would be
recruited. Once these details had been supplied, the random allocation was given in return. The allocation
was computer generated in ratios of 1 : 1 after stratiﬁcation by eligible comparisons and surgeon, and
minimisation according to the patient’s age (< 60 years, 60–79 years or ≥ 80 years), the patient’s gender
(male or female) and the site of disease (one knee, both knees or general arthritis).
Recruitment was carried out on the day before surgery (or sooner) to allow theatre staff to prepare
appropriate equipment and prostheses. Each patient could be entered into the trial only once. In the event
of a patient being admitted for bilateral knee replacements, the knee indicated by the patient to be the
most painful was the knee that was considered for randomisation.Clinical managementWithin the randomised comparisons, all prostheses had suitable alternative designs, as outlined above. Surgeons
followed their standard practice, that is the technique that they utilised did not require any modiﬁcation for the
purposes of the trial, and the outcomes were thus not inﬂuenced by a so-called learning-curve effect. We did not
inﬂuence surgeons regarding whether they should utilise cruciate-retaining or substituting implants. All other
aspects of care, such as prophylaxis against deep-vein thrombosis (DVT) and discharge from hospital, were left
to the discretion of the responsible surgeon.Data collectionPreoperative, intraoperative and postoperative data on surgery, knee components used, length of stay,
operation time and complications were collected prospectively on standard forms (reproduced in
Appendix 1). Data describing functional status [using the Oxford Knee Score (OKS)] and quality of life
[using Short Form questionnaire-12 items (SF-12) and EuroQoL 5D (EQ-5D)] were collected directly from
postal questionnaires completed by participants at baseline, 3 months after the operation, at 1 year and
annually thereafter (see Appendix 1). Following one postal reminder, participants who had not returned
the questionnaire were telephoned and offered the option of completing the questionnaire over the
telephone. A number of other measures were taken to promote ongoing interest in, and commitment to,
the trial including participant newsletters and annual Christmas cards.
Annual and 3-monthly questionnaires also included questions about GP, physiotherapy and outpatient
consultations related to the study knee and any hospital admissions. Information on hospital admissions5
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6and further surgery was supplemented with routinely collected information, when available, from the
Hospital Episode Statistics (HES) database in England and Information Services Division (ISD) in Scotland.
Although all participants consented to routine data on mortality being obtained from the Ofﬁce for
National Statistics (ONS) at the time of randomisation, in June 2006, it became necessary to obtain
additional consent for all participants in Scotland to conduct routine mortality monitoring through the NHS
Information Centre. In addition to obtaining participant consent to access medical information from
routine sources at baseline, the Data Access and Advisory Group reviewed and approved the release of
HES data at 5 and 10 years. Participants’ case notes were reviewed if either questionnaires or routine data
indicated further surgery or admissions.Principal study outcome measuresThe primary outcome measure was functional status as measured by the OKS,36 which was developed
speciﬁcally to measure outcomes of knee replacement and has been shown by a range of independent
studies to perform well compared with alternative instruments.37–39 Other outcome measures were as
follows: quality of life as measured by the SF-1240 and three-level EQ-5D;41,42 intraoperative and
postoperative complications including the need for additional surgery; cost; and cost-effectiveness.
[SF-12 version 2 was used throughout the majority of the trial, although patients recruited early in the
study completed version 1 at baseline.]Sample sizesThe size of the effect on the OKS sought in each comparison (and hence the sample size chosen) was
based on the size of the difference in the OKS that seemed likely, as judged on the basis of current
experience, and the size of the effect that was likely to offset any adverse effects and cost differences of
the prosthetic design variable. All power calculations assumed that there was no interaction between
comparisons: that is that the impact of each comparison was unaffected by whether or not the participant
also underwent patellar resurfacing (see Statistical analyses of clinical end points). The difference in OKS
sought was three points for the comparisons involving the tibial all-polyethylene backing, the mobile
bearing and the unicompartmental arthroplasty, with 350 participants providing 80% statistical power and
470 participants providing 90% power to detect this difference (p < 0.05). The difference sought was
1.5 points for the patellar resurfacing comparison, with 1400 participants providing 80% power to detect
this difference (p < 0.05). All sample size calculations were based on a standard deviation of 10 points
for the OKS.
The rationale for the three-point difference in OKS was based partly on anchoring evidence and partly on
distributional or statistical evidence.43 Evidence from an anchoring perspective came from a study in which
patients completing the OKS were also assessed by an orthopaedic surgeon using the AKS.44 Overall, the
average difference in OKS between patients assessed by the surgeon, as in adjacent categories of the AKS,
was 3.5 points. In terms of distributional evidence, an overview of statistical evidence of the performance
of the OKS concluded that a minimal clinically important difference (MCID) was a third to a half of the
standard deviation of OKS, that is three to ﬁve points.45 Overall, three points was selected as a MCID for
sample size calculations for the metal-backed and mobile bearing comparisons and a more conservative
1.5 points for the patellar resurfacing comparison.Statistical analyses of clinical end pointsThe comparisons were analysed and reported as separate trials in order to estimate the ‘main effects’ of
the alternative approaches within each comparison, as prespeciﬁed in the protocol (Appendix 1).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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follow-up had been achieved. Participant ﬂow through the trial is summarised using a CONSORT
(Consolidated Standards of Reporting Trials) style diagram.46 Baseline characteristics are tabulated using
descriptive statistics reported as appropriate for type of variable being summarised.
The functional status and quality-of-life outcomes within each trial comparison were compared by linear
mixed models that adjusted for baseline scores and minimisation factors; random effects for participant
and surgeon; and time point, which was incorporated using a dummy variable for each year that
interacted with treatment allocation to allow the treatment effect to vary over time. Data were analysed
on the basis of the procedure allocated irrespective of the treatment actually received (intention-to-treat
principle). Participants were included in the model if they received any surgery and provided at least one
follow-up measurement of outcome. Participants were excluded from outcome-speciﬁc models if they died
before surgery, received no surgery or provided no follow-up data for that outcome. Missing baseline data
were imputed using surgeon-speciﬁc mean scores for that particular outcome. Analysis was carried out
on all available follow-up data to 10 years; no attempt was made to impute missing follow-up data.
Descriptive statistics are reported at each time point and represented graphically over time by allocated
group. Estimated effects of the intervention and 95% conﬁdence intervals (CIs) at each time point are also
tabulated and graphed through time; a marginal estimate of treatment effect over the whole 10-year
period is presented (with 95% CIs) to aid ease of interpretation. It was anticipated that differences in
revision rates may have inﬂuenced the primary outcome. If a participant had a revision (deﬁned using the
strictest deﬁnition of failure in the paragraph below), then all that participant’s observations post the
revision date were replaced by the reported value prior to revision. The primary outcome analysis was then
replicated to test the robustness of the results to potentially differential revision rates. All analyses were
implemented using xtmixed in Stata 12.1 (StataCorp, College Station, TX).
Clinical outcomes on reoperation within the ﬁrst 10 years are tabulated and described using appropriate
summary statistics. These outcomes were analysed within a survival analysis framework with time to failure
of knee prosthesis as the event. Time to failure of the knee prosthesis was deﬁned in three different ways.
The strictest deﬁnition of failure was time to ﬁrst major reoperation or prosthetic-related reoperation
(see tables in Chapters 3, 4 and 5 for comparison-speciﬁc deﬁnitions); second, time to any reoperation;
and, third, the most liberal deﬁnition, time to any reoperation or OKS on an annual questionnaire
dropping to below the level of the self-reported baseline score. All outcomes were plotted using
Kaplan–Meier time-to-failure plots and analysed using parametric survival regression models using a
Weibull distribution. Owing to the paucity of events for the ﬁrst two deﬁnitions of failure, models with
only treatment effect covariates were ﬁtted. Additionally, for the models of the ﬁnal deﬁnition of failure,
adjustments for minimisation covariates and surgeon were run. For the ﬁnal deﬁnition of failure, events
were generated using a mixture of interval and non-interval censored data, the impact of which was
explored by rerunning models using interval-censored regression. Proportional hazards were assumed for
all models and participants were censored at time of death or 10 years if they had not experienced an
event. The proportions of participants experiencing speciﬁc types of reoperation over the 10-year trial
follow-up period were compared using exact logistic regression (owing to the small number of events).
All estimates of treatment effects are presented as hazard ratios or odds ratios and 95% CIs. Analyses
were implemented using streg, intreg and exlogistic in Stata 12.1.
All analyses assumed no interaction between patellar resurfacing and the other interventions: that is
patellar resurfacing had no effect on the treatment effects for any other comparison. As no previous
factorial trials have been conducted for knee replacement, there is a shortage of data on which to base
assumptions about interactions. However, we are aware of no clinical or mechanical reason why any
interaction between patellar resurfacing and other comparisons would be expected and, therefore,
assumed no interaction. The partial factorial design provided an opportunity to conduct preliminary
analyses to explore whether there is any interaction between patellar resurfacing and the other
comparisons, which was conducted in sensitivity analyses by including an interaction term between
interventions at each time point. This analysis included only those that were randomised to more than7
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8one comparison. Results are plotted as a difference in differences through time to aid interpretation.
Post-hoc subgroup analysis on age at time of operation (< 70 vs. ≥ 70 years) and patellofemoral groove
shape (domed vs. anatomical) were conducted in a similar fashion to the partial factorial element by
allowing an interaction between subgroup and allocation at each time point.Avoidance of bias, including blindingAs described above, the randomisation process was concealed and an intention-to-treat approach used in
all primary analyses. Surgeons undertaking the procedures were not ‘blind’ to the allocation for obvious
reasons. The primary outcome measure was based on participant-completed questionnaires. Only
participants who wished to know which type of prosthesis they had received were told this information.
In principle, it is possible that this knowledge might have inﬂuenced responses to questionnaires, but any
such effect would be likely to dissipate over such a long period of follow-up.Health economic evaluation
Study question for economic evaluation
We aimed to assess the cost-effectiveness of the following types of knee prosthesis, in line with the
comparisons addressed by the trial:
l patellar resurfacing versus no patellar resurfacing
l mobile versus ﬁxed bearing
l all-polyethylene versus metal-backed tibial component
l unicompartmental versus TKR.
Following UK guidelines for economic evaluation,47 the KAT economic evaluation was conducted from the
costing perspective of the UK NHS and from the health perspective of the patients undergoing knee
replacement. The analysis, therefore, excluded costs incurred by other sectors of the economy, such as lost
productivity, informal care, participants’ out-of-pocket expenses or home/residential/rehabilitation care.
As KAT was a pragmatic trial involving long-term follow-up of elderly participants, data collection was
streamlined further to reduce the questionnaire burden on participants and maximise response rates to
annual questionnaires. In particular, the amount of costing data collected from annual questionnaires was
limited to the main NHS costs directly attributable to knee replacement.Framework for economic evaluation
Cost–utility analysis (CUA) was used to evaluate cost-effectiveness in order to capture any differences in
quality of life between randomised comparisons. The primary end point therefore comprised the cost per
quality-adjusted life-year (QALY) gained. CUA was used regardless of whether functional status or quality
of life differed between randomised comparisons, as our primary interest is in the joint distribution of cost
and effect differences, and also because KAT was not powered to demonstrate equivalence, and thus
assuming no difference in outcomes could give misleading conclusions and bias estimates of decision
uncertainty.48,49
The base-case analysis comprised a within-trial economic evaluation using only data from KAT. Results
were not extrapolated beyond the end of the trial, as the within-trial period was already substantial (up to
12 years). Attrition and administrative censoring (i.e. data from time points not yet reached as a result of
staggered recruitment times) were dealt with using multiple imputation and inverse probability weighting
(IPW), as described below. The economic evaluation included all participants formally included in the trial
with the exception of 34 participants who died before surgery and 66 participants who were randomised
to the total versus unicompartmental knee replacement comparison or withdrew from the trial prior toNIHR Journals Library www.journalslibrary.nihr.ac.uk
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evaluation includes all annual questionnaires received by 8 June 2012. Additional data on hospital
readmissions were obtained from HES up to 31 March 2011 (for participants living in England) and from
ISD up to 31 December 2010 (for participants living in Scotland).
The base-case economic evaluation took a 10-year time horizon and, therefore, included all data on quality
of life and costs and readmissions that occurred within 10 years of primary TKR or before administrative
censoring (if sooner). However, alternative time horizons are presented in the sensitivity analyses. Costs and
QALYs accrued beyond year 1 were discounted to present values at 3.5% per annum.50Collection of resource-use data and unit costs
Quantities of knee-related resources used in the primary admission and subsequent follow-up were collected
prospectively for each trial participant. Data collection focused on resources associated with the study knee
and excluded resource use from unrelated causes to simplify data collection and reduce the length of
participant questionnaires. Focusing on resource use directly related to the study knee and the complications
of knee surgery also avoids the risk of catastrophic episodes involving high health-care resource use unrelated
to treatment (e.g. renal failure, cancer or extended psychiatric admissions) swamping the main effect of
treatment on costs and, therefore, reduces uncertainty around incremental costs and cost-effectiveness.51
Data on quantities of NHS resources related to the study knee were identiﬁed from the surgeon’s form
(see Appendix 1), the hospital care form (see Appendix 1) and annual questionnaires (see Appendix 1)
completed by participants, with additional data on hospitalisations being collected from HES and ISD
(Table 1). Questionnaires focused on the main cost drivers (see Table 1), which were identiﬁed following
discussions with clinicians and from evidence from previous publications. In line with clinical analyses,
readmissions to hospital that were related to the study knee or that were considered (by clinical
adjudication) relevant to the primary TKR procedure [e.g. readmissions for myocardial infarction, DVT or
pulmonary emboli (PE) within 3 months of TKR] were included in the analysis, but all other readmissions
(including readmissions for thromboemboli that occurred after revision procedures on the study knee) were
excluded from the analysis. The assumptions used to estimate resource use and costs from questionnaire
responses are listed in Box 1.
Mobility aids and medications used to manage pain and arthritis in non-hospitalised participants were
excluded from the analysis to simplify questionnaires and reduce the burden on participants. Mobility aids
are unlikely to comprise a large proportion of 5- or 10-year total costs; furthermore, they will often be
funded from outside the NHS perspective taken in this analysis, and the need for mobility aids will
also be affected by comorbid conditions. Similarly, pharmaceuticals are likely to account for only a small
proportion of total costs: recent evidence suggests that analgesics and arthritis medication accounts for
only around 2–3% of total health-care spending in participants who have undergone joint replacement.62
Additionally, the following resources were assumed to be included in other unit costs and not considered
separately to avoid double counting:
l Drugs (e.g. antibiotics, anaesthetics, anticoagulants) and non-surgical treatments (e.g. urinary catheters)
administered during knee-related hospital admission: assumed to be covered by the cost of a bed-day.
l Cement, time in recovery room, intraoperative complications and blood products transfused while in
theatre: assumed to be included in the cost of theatre time and not accounted for separately to avoid
double counting.
l Surgical instruments used in primary knee replacement: assumed to be supplied at no cost by
prosthesis manufacturers.
l Diagnostic tests or postoperative complications other than imaging for DVT/PE, transfusion and
admission to high-dependency unit: assumed to be covered by the cost of a bed-day/outpatient
consultation and any associated increases in length of stay.9
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ABLE 1 Health-care resources included in the economic evaluation and unit costs in 2010/11 pounds sterling
Resource included
in economic
evaluation
Source of data on
resource-use quantities
Unit
cost
(£) Reference for unit cost
Minute of theatre
time
Primary TKR: HCF
Readmissions and return
to theatre: EO estimates
(based on surgery
classiﬁcation identiﬁed from
hospital/HES/ISD records)
16.87 Mean cost/minute across all orthopaedic operating
theatres in Scottish NHS hospitals,52 inﬂated from
2010–11 values to 2011–12 values using HCHS pay
and prices inﬂation index.53 Includes cost of staff,
premedication/anaesthesia and recovery room. The
cost of theatre time is also assumed to cover the cost
of cement and blood transfusions delivered during
the surgery. Although exact data on the duration of
the primary TKR operation (from entry to anaesthesia
room to leaving operating theatre) were available
from the HCF, participant-level data on subsequent
surgery (either during readmissions or later in the
primary hospital admission) were not available. One
of three orthopaedic surgeons estimated the typical
duration of each type of surgery performed in the
trial (and each combination of surgery types
conducted in the same readmission) and this duration
was applied to all participants undergoing that
surgery type; the initial estimates were validated by
one of the three surgeons to ensure consistency
Hospital bed-day Primary: HCF
Readmissions:
HES/ISD, RF
328.73 Weighted average cost per excess bed-day for
elective inpatient admissions for all procedures to the
knee except those for trauma or for children,54
inﬂated from 2009–10 values to 2011–12 values
using HCHS pay and prices inﬂation index.53,55 As the
majority of admissions included in the analysis were
for orthopaedics, the cost of orthopaedic bed-days
was applied regardless of whether the reason for
admission was non-orthopaedic (e.g. for PE). The
length of stay calculated for each participant included
time in hospital before the primary TKR procedure:
even if this occurred before randomisation
Day-case stay in
hospital
PAF, HES/ISD, RF 216.00 Owing to a lack of data on the hotel costs for
participants who are admitted and discharged on the
same day, such participants were assumed to accrue
a cost mid-way between the cost of a bed-day
(£328.73)54 and the cost of an orthopaedic
outpatient consultation (£103.27).54 National average
costs of day-case procedures cannot be used here, as
they include theatre costs and components, which
are costed separately
Knee components SF and RF Various See text for details
Loan of instruments
for revision surgery
N/A 500 Mean cost of hiring instruments for revision surgery
for component manufacturers, which was applied to
all one-stage revisions and the second stage of
two-stage revisions. The average cost is based on a
typical loan charge and is applied to 50% of
procedures to allow for the fact that loan charges are
waived for high-volume centres
Unit of whole blood HCFa 119.00 National price charged per unit of whole blood in
2012–13,56 deﬂated from 2012–13 to 2011–12
values using HCHS pay and prices inﬂation index57
Transfusion HCFa 95.72 Cost of transfusion estimated by a previous economic
evaluation, excluding the cost of blood and overnight
stay,58 inﬂated from 2004–5 values to 2011–12
values using HCHS pay and prices inﬂation index53,55
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ABLE 1 Health-care resources included in the economic evaluation and unit costs in 2010/11 pounds sterling
ontinued )
Resource included
in economic
evaluation
Source of data on
resource-use quantities
Unit
cost
(£) Reference for unit cost
CT HCF, RF 121.07 Based on the cost of CT (to diagnose PE), one area,
pre and post contrast (RA10Z), averaged across
outpatient, direct access and other,54 inﬂated from
2009–10 values to 2011–12 values using HCHS pay
and prices inﬂation index.53,55 The cost of CT was
applied to all participants for whom PE was recorded
as a postoperative complication or for whom CT or
VQ scan or tests/imaging for PE were recorded in free
text ﬁelds
Leg ultrasound HCF, RF 56.50 Based on the cost of an ultrasound scan (to diagnose
DVT or haematoma) taking < 20 minutes (RA23Z),
averaged across outpatient, direct access and other,54
inﬂated from 2009–10 values to 2011–12 values
using HCHS pay and prices inﬂation index.53,55
The cost of a leg ultrasound was applied to all
participants for whom DVT was recorded as a
postoperative complication or for whom ultrasound,
venogram or tests/imaging for DVT were recorded in
free text ﬁelds
Spell in
high-dependency/
critical care unit
HCF, RFa 992.70 Incremental cost of 24 hours spent in high-dependency
unit: average cost of a bed-day in critical care unit
(£1321.44; service codes XC01Z–XC07Z),59 minus cost
per bed-day in an orthopaedic ward (£328.73)59
Outpatient
consultation
PAF 103.27 Weighted average across orthopaedic outpatient
consultations (service code 110N),54 inﬂated from
2009–10 values to 2011–12 values using HCHS pay
and prices inﬂation index53,55
Physiotherapy
consultation
PAF 43.33 Weighted average of consultations with hospital
physiotherapists and community physiotherapists60
(inﬂated from 2010–11 values to 2011–12 values
using HCHS pay and prices inﬂation index53),
assuming that 50% of participants would see a
hospital rather than community physiotherapist.61
The cost of NHS physiotherapy consultations was
applied in all cases, as the proportion of consultations
that were paid privately is not known
GP consultation PAF 37.59 Unit cost per surgery consultation lasting 11.7 minutes,
including direct care staff costs and qualiﬁcation
costs,60 inﬂated from 2010–11 values to 2011–12
values using HCHS pay and prices inﬂation index53
CT, computed tomography; EO, expert opinion – typical operation time estimated by one of three orthopaedic surgeons
based at one specialist orthopaedic centre; HCF, hospital care form (see Appendix 1); HCHS, hospital and community
hospital services; N/A, not applicable; PAF, participant annual form (or 3-month form), completed by participant
at 3 months and annually thereafter (see Appendix 1); RF, readmission form (see Appendix 2); SF, surgeon’s form
(see Appendix 1); VQ, ventilation/perfusion.
a Resource use was only included in costing analyses in cases in which this type of resource was explicitly mentioned on
the hospital care form.
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OX 1 List of assumptions used in costing analyses
Costing analyses: component
l 30% ﬁxed discount on all knee components.a
l Participants were assumed to not have received components other than patellas, femurs, tibial trays and
tibial inserts unless component stickers or descriptions were attached to the form, although all ‘other’
components (e.g. stem extensions, augments, rods or blocks) recorded were also included in the analysis.
l Participants were assumed to use no more than one component of each of the four main types (patella,
tibial insert, tibial tray and femur) per operation. Duplicate codes (e.g. for a second femur) were excluded
from the analysis and assumed to be erroneous; in particular, duplicate codes may have been attached to
participants’ notes or hospital forms in error, relate to the other knee (in a bilateral operation) or have
been ordered but returned to the manufacturer unused.
l All primary TKR procedures were assumed to require a tibial tray and femoral component (even if no
corresponding component codes were included on the hospital form). Participants allocated to patellar
resurfacing who received the allocated procedure were also assumed to have received a patella. All
participants were assumed to require a tibial insert unless the tibial tray recorded was all polyethylene.
l All late patellar resurfacing and patella revision procedures were assumed to require a patella. All
exchange of tibial insert procedures (whether conducted during or after the primary hospital stay) were
assumed to require a tibial insert. Other components were assumed to be required during readmissions if
readmission forms indicated that that component had been revised, or if codes and/or descriptions were
recorded on the hospital form.
l First-stage revisions were assumed to require no knee components unless codes for cement spacer
moulds were indicated on the readmission form or hospital notes.
l The cost of instruments for primary TKR was excluded from the analysis, as these are generally provided
free of charge by component manufacturers. However, loan charges of £250 per operation were added to
the cost of all one-stage revisions of the tibial and/or femur and all second-stage revisions. Although most
high-volume centres will either own instruments for revision surgery or have them provided free of charge
by manufacturers, smaller centres, which are assumed to account for 50% of revision procedures, will incur
loan charges of around £500 per operation, giving an average cost of £250 (50% times £500) per revision.
Costing analyses: readmissions and ambulatory consultations
l The type of knee prosthesis used is assumed to have no effect on consumption of non-knee-related
health-care resources, personal and social care services, mobility aids or medication.
l We assumed that annual questionnaires and HES/ISD provide complete data on all hospital readmissions
up to the last questionnaire that participants return, or until the cut-off date for HES or ISD (if later).a
l All knee-related physiotherapy consultations were assumed to be funded by the NHS, with 50%
occurring in hospital and the remainder in the community.
l The reporting periods of the 3-month questionnaire and the 1-year questionnaire overlap: the 3-month
questionnaire asks participants to give the number of GP/physiotherapy/outpatient consultations they
have attended ‘since leaving the hospital’, whereas the 1-year questionnaire asks for consultation
numbers ‘in the last year’. The number of consultations occurring in year 1 was, therefore, assumed to
equal whichever was largest out of the number reported in the 1-year questionnaire and the number
reported in the 3-month questionnaire. This ensures that consultation numbers during year 1 are always
based on a 12-month period and allows for the potential discrepancies that could arise from participants
answering the 1-year questionnaire > 1 year after hospital discharge, thereby missing the period of most
intensive follow-up. Participants who did not return the 1-year questionnaire were assumed to have
missing data on ambulatory consultations in year 1, even if the 3-month questionnaire was returned.
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lImplausible or logically inconsistent data values recorded on questionnaires (e.g. participant weight
< 10 kg) were treated as missing and imputed using multiple imputation (see Methods for imputing
missing data).
Quality-adjusted life-year calculations
l EQ-5D utility was measured at baseline, 3 months, 1 year and annually thereafter. QALY calculations
assumed that all quality-of-life measurements were taken at the scheduled time points: that is, 1-year
EQ-5D utility was always measured exactly 12 months after the primary operation. This assumption
simpliﬁes QALY calculations and ensures that the initial increase in quality of life is always applied over
the ﬁrst 3 months after TKR, even if the EQ-5D questionnaire was completed much later.
l Quality of life was assumed to change linearly between baseline and 3 months, between 3 and
12 months and between annual questionnaires. For example, the number of QALYs accrued during year
2 was assumed to be the average of utility at year 1 and that at year 2. Similarly, utility at the time of
death was estimated by linearly interpolating between participants’ last observed utility and the utility
imputed in place of the following annual questionnaire using multiple imputation (see Methods for
imputing missing data).
Mortality
l For participants who died during the study, the date of death was obtained from routine monitoring by
the NHS Information Centre, supplemented, when necessary, by contact with the participant’s GP or
details supplied by relatives on annual questionnaires sent out before quarterly ONS updates were
received. In the very few cases in which the exact date of death was not known, death was assumed to
have occurred half-way between the last date the participant was known to be alive (e.g. the date when
they returned their last annual questionnaire) and the ﬁrst date when they were known to be dead
(e.g. when a questionnaire was returned by relatives).
l EQ-5D utility and the number of GP, physiotherapy and orthopaedic outpatient consultations were
imputed for participants’ last year of life using multiple imputation (see Appendix 3). Dummy variables
indicating the year of death (relative to randomisation) were included in multiple imputation to allow for
the effect of proximity to death on quality of life and resource use.
l To allow for the fact that participants who die during year y do not accrue a full year of resource use or
QALYs, we multiplied the number of ambulatory consultations imputed for a complete year by the
fraction of the year lived during year y. This adjustment implicitly assumes that ambulatory consultations
related to the knee are evenly distributed across the last year of life. No adjustment was made for
numbers of readmissions, as these are assumed to be complete up until the time of censoring or death.
Analysis
l The effect of each randomised comparison is assumed to be additive: that is the type of tibial component
used is assumed to have no effect on the cost or QALY gain from patellar resurfacing (and vice versa).a
l Discounting for time preference was based on the number of whole years that had elapsed since the
primary TKR operation date. Ambulatory consultations reported in the year y questionnaire were assumed
to have occurred in that year even if the questionnaire was completed early or late. Readmissions were
considered to have occurred in year y if the admission date was less than y years after the primary
operation date (regardless of when the participant was discharged). To ensure consistency with the
clinical analysis, the second stage of two-stage revisions was assumed to always occur in the same year as
the primary stage.
a Assumption relaxed or varied in sensitivity analyses.
l
BOX 1 List of assumptions used in costing analyses (continued)
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14Unit cost data were collected from routinely available sources (see Table 1).52,56,58,60 The index year for
pricing was 2011/12 and prices from earlier (or later) years were inﬂated (or deﬂated) to 2011/12 values
using the hospital and community hospital services (HCHS) pay and prices index.53,55
Stickers giving the product codes for the knee prosthesis components used in primary knee replacement
and revisions were attached to the surgeon’s form to indicate which brand and model was used in that
operation. For all readmissions identiﬁed from participant questionnaires or HES/ISD that were deemed
potentially related to knee surgery, the hospital was asked to provide a copy of participants’ notes
and/or complete the readmission form (see Appendix 2) including codes for all components used. Each
component used was then valued using list prices obtained from manufacturers. List prices from 2008
were used for primary procedures when available and inﬂated to 2011/12 values. However, when such
prices were not available (e.g. for components that have since been discontinued), list prices payable at the
time of the KAT operations (1999–2002) were inﬂated to 2011/12 values using the HCHS pay and prices
inﬂation index;53,55 when the price of discontinued components at the time of operation was unavailable,
prices were based on comparable components available today. Prices for revision components were
obtained between 2008 and 2012 and inﬂated/deﬂated based on HCHS when necessary. The pay and
prices index appears to be appropriate for knee replacement components, as those components for which
list prices were available for 2001 and 2008 increased in price by 38.9% over that period (cf. 36.2%
HCHS inﬂation).53
In practice, the prices hospitals pay for devices are substantially lower than list prices, as each hospital
negotiates discounts with their supplier(s). Although actual discounts vary between hospitals and are
commercially sensitive, we applied a ﬁxed discount of 30% on all components in the base-case analysis;
this discount was varied in sensitivity analyses.Calculation of quality-adjusted life-years
Participants completed the three-level EQ-5D and SF-12 questionnaires preoperatively, 3 months after the
primary TKR and annually thereafter as part of the participant annual form (see Appendix 1). In the
base-case analysis, QALY calculations were based on EQ-5D utilities as prespeciﬁed in the trial protocol.
EQ-5D is recommended47 and widely used,63 enabling the cost-effectiveness of trial interventions to be
compared with other economic evaluations. EQ-5D health-state preference values were calculated using
the UK N3 tariff, which is based on time trade-off valuations from 3395 members of the UK general
public.64 The number of QALYs that each participant accrued following TKR was calculated as the area
under the utility curve, with linear interpolation between utility measurements (see Box 1).Methods for imputing missing data
As the calculation of costs and QALYs requires summation of cost and utility data across numerous
resource-use items and time points, missing data are a greater problem for economic evaluation than for
clinical end points. Speciﬁcally within KAT, around 7% (12,102/173,404) of data points prior to
administrative censoring were missing across the 77 variables included in the analysis, with 63%
(1414/2252) of participants having missing data for at least one resource-use item or quality-of-life
measurement, in addition to 884 participants (38%) who were administratively censored before the
10-year follow-up. A complete case analysis excluding all such participants would therefore have been
highly inefﬁcient. Furthermore, complete case analysis would also have been prone to bias,65 as some
missing data were not missing completely at random: for example, length of stay for revision procedures
can be missing only for participants who underwent revisions and utility cannot be missing for participants
known to have died in previous years. [The assumption that data are missing completely at random means
that the probability of data being missing does not depend on either the values of observed data or the
values of missing or unobserved data. Whereas complete case analysis assumes that data are missing
completely at random, multiple imputation techniques assume that data are missing at random, i.e. that
the probability that data are missing may depend on observed covariates included in the imputation
model, but not on unobserved data.] Mean imputation and multiple imputation were used to ensureNIHR Journals Library www.journalslibrary.nihr.ac.uk
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adjust for administrative censoring.Mean imputation
Mean imputation was used for those variables that were not major cost drivers, had low levels of
missingness and had limited data on which to base multiple imputation models (see Appendix 3). In
particular, only 32 participants (1.4%) were transfused during their primary admission, 7 of whom had
missing data on the number of units transfused; similarly, of the 324 readmissions, only 40 readmissions
had missing component codes and 4 were missing length of stay. Imputing these variables using multiple
imputation would have increased the complexity of the analysis and is unlikely to have provided stable
estimates: particularly for components used in participants’ second or subsequent readmission, for which
very few data are available. For these variables, we therefore calculated the mean price or number of units
across all participants who used such a component and applied this conditional mean to those with
missing data. By assuming that all participants with missing data incurred exactly the same component
cost, this method slightly underestimates the uncertainty around the mean, although this is unlikely to
have affected the results signiﬁcantly, as these resources are not major cost drivers.Multiple imputation
Multiple imputation was used to impute all other missing data and propagate the uncertainty around
imputed values through the analysis. Multiple imputation predicts missing values by iteratively estimating
regression models on observed and imputed data.66 This enabled missing data on speciﬁc resource items
or EQ-5D utility measurements to be imputed based on participants’ baseline characteristics and treatment
allocation, other utility measurements and the quantities of other resources that they required, allowing for
the correlations observed between these variables for other participants. Multiple imputation was
conducted using the imputation using chained equations (ice) command (version 1.3.0) within Stata
12.0.67–69 Default options within ice were used unless otherwise stated, which included running 10 cycles
or iterations. Imputation was performed on the entire trial data set (excluding postrandomisation
exclusions and participants randomised to total vs. unicompartmental knee replacement); imputation was
run simultaneously on all three randomised comparisons in order to maximise the amount of data available
to impute missing data and to ensure that all analyses used the same imputation model.
In line with current recommendations,66 treatment indicators, demographic variables and cost components
without missing data were included in the imputation function in addition to those variables with missing
data to avoid bias and produce more accurate imputed values. Appendix 3 gives the full list of variables
included in multiple imputation and the imputation models used. Treatment allocation was coded using
six dummies (patellar resurfacing, no patellar resurfacing, all polyethylene, metal-backed, mobile bearing
and ﬁxed bearing), which were equal to one if the participant was randomised to that treatment arm and
zero if they were randomised to the other arm in that comparison or not included in that randomised
comparison. This coding matched the way in which the partial factorial design was analysed. Conditional
imputation was used to allow for mortality, ensuring that only participants alive at the start of that year
were included in models to impute missing EQ-5D utilities and consultation counts. Year 11 data were
included in the imputation model to improve predictions of utilities and resource use in earlier years and to
facilitate sensitivity analyses using a longer time horizon. However, as year 12 data were available for only
78 living participants, year 12 variables were omitted from multiple imputation analyses to simplify the
imputation function.
It is generally recommended that the number of imputations run is at least equal to the percentage of
participants with missing data for at least one variable.66 After conditional mean imputation was applied,
63% (1414/2252) of participants included in the analysis had some items of missing data before
administrative censoring or 10 years (whichever was earlier). We therefore generated 100 imputed data
sets to ensure that subsequent analyses give a reliable and replicable estimate of the posterior distribution
around missing values. All analyses were repeated for each imputed data set and results combined using
Rubin’s rule.6615
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16Multiple imputation was used to impute data for participants lost to follow-up or who declined further
follow-up70 as well as data from non-returned questionnaires or item non-response, as such data may not
be missing completely at random, with dropouts potentially accruing higher costs and/or worse quality of
life. Utilities and resource use after administrative censoring were imputed using multiple imputation to
facilitate imputation of early observations; however, data imputed after administrative censoring were not
used in the base-case analysis.Adjustment for administrative censoring
Readmissions were identiﬁed from the participant annual form and from monitoring of routine admissions
data via HES in England and ISD in Scotland. Readmission data from HES were available up to 31 March
2011 for participants living in England and data from ISD (for participants living in Scotland) were available
up to 31 December 2010. It was assumed that HES, ISD and the participant annual form provided data on
all readmissions related to the study knee that occurred before administrative censoring, including those in
participants’ last year of life and of participants who declined further follow-up or could not be contacted.
This assumption is likely to be reasonable, as all participants consented to collection of readmission data
from HES and/or ISD. Analysis of data up to year 5 suggested that HES/ISD picked up 82% of readmissions
identiﬁed from participants’ annual forms, whereas participants’ forms identiﬁed 85% of readmissions
identiﬁed through HES/ISD.71
However, no data are available for any participant after administrative censoring. Participants were
considered to be administratively censored from the year when their last annual questionnaire was received
or from the last annual follow-up point when both routine mortality data and HES/ISD data on readmissions
were available (if this date was later than the participant’s last questionnaire). Participants who died during
the period for which HES and ISD data were available were considered not administratively censored. For
example, a participant undergoing TKR on 1 December 2001 who completed annual questionnaires every
year before the database was closed on 8 June 2012 would be censored at 10 years (the time the last
annual questionnaire was completed, which is later than the latest available HES data, which ran up to
31 March 2011) and would contribute 10 years of complete data to the analysis. However, a participant with
the same operation date who did not return questionnaires in years 9 and 10 would be considered to have
been censored at 9 years (the last annual follow-up that occurred during the period up to 31 March 2011 for
which HES data were available); missing data on quality of life and ambulatory care for this participant in
year 9 would be imputed using multiple imputation.
Although all participants consented to routine data on mortality being obtained from the ONS at the time
of randomisation, in June 2006, it became necessary to obtain additional consent for all participants in
Scotland to conduct routine mortality monitoring through the NHS Information Centre. Of the 527
Scottish participants alive on 8 June 2006, 74 declined consent or were already lost to follow-up. Excluding
18 participants for whom death dates were available from other sources (e.g. annual questionnaires
returned by relatives) and 20 participants who returned questionnaires in the last year for which HES/ISD
data were available, 36 participants have unknown vital status. These participants were considered to have
been administratively censored at the time when they last returned a questionnaire or had a recorded
admission, or at their last annual follow-up before 8 June 2006 (whichever was later).
Although administrative censoring is likely to be non-informative and the average follow-up time did not
differ signiﬁcantly between randomised comparisons, small differences in follow-up time could affect
estimates of cumulative costs and QALYs. In line with current guidelines,72 we therefore adjusted for
censoring using IPW,73,74 using the methods described below. The effect of adjusting for administrative
censoring was evaluated in sensitivity analyses, which took a 9-year time horizon (using uncensored data
for 93% of participants), took a within-trial time horizon (using all data available for each participant and
making no adjustment for administrative censoring) or used multiple imputation estimates of utility and
resource use after administrative censoring.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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for uncertainty
Although KAT is partially factorial, each randomised comparison was analysed separately, in line with
clinical analyses. As a result, each comparison was assumed to address independent questions about
separable aspects of knee replacement. In line with the clinical analysis (see Statistical analyses of clinical
end points) and the study protocol (see Appendix 1), it was also assumed that there was no interaction
between the different comparisons and that treatment effects were additive. The analysis, therefore,
assumed that the cost-effectiveness of patellar resurfacing compared with no resurfacing was not affected
by whether the tibial component was mobile versus ﬁxed, or all polyethylene versus metal-backed, and
that the decision about whether or not to resurface the patella was not affected by decisions about tibial
component design. Interactions were not assessed in the base-case analysis, as the study is not powered to
detect interactions and 85% of participants were randomised to only one comparison. However, a
secondary regression analysis investigated interactions between randomised comparisons for the two
subsets of participants randomised to two comparisons.
Following imputation of missing data on resource use, component prices and utilities, QALYs were
calculated as the area under the utility proﬁle and quantities of each type of resource were multiplied by
unit costs to give the total QALYs and costs accrued by each trial participant in each of the 100 imputed
data sets. Costs and QALYs accrued beyond year 1 were discounted at a rate of 3.5% per annum.50
Imbalances in baseline utility have been shown to introduce substantial bias into unadjusted economic
evaluations, as baseline utility is directly included in QALY calculations and normally strongly predicts
on-treatment utility.75 We therefore adjusted for differences in baseline utility by estimating the number
of QALYs accrued in each year using ordinary least squares (OLS) regression, controlling for baseline
utility and treatment allocation and generating predictions for each study arm based on the mean baseline
utility across both arms.
Total costs, resource use and QALYs across the 10-year time horizon were calculated using IPW73,74 to
allow for administrative censoring and differences in follow-up time among participants. To implement
IPW, OLS regression estimates of the average costs and QALYs accrued in each study arm in each year
across uncensored participants were multiplied by the number of participants who were alive and not
administratively censored at that time point. Dates of censoring for each participant were identiﬁed as
described above. Total costs and QALYs were divided by the Kaplan–Meier estimate of the probability of
being administratively censored by that time point and then divided by the number of participants included
in the analysis. Weighted costs and QALYs were summed across all time periods to give total costs.
Uncertainty around resource use, costs, QALYs and incremental cost-effectiveness ratios (ICERs) was
quantiﬁed using bootstrapping. Bootstrapping was conducted separately for each randomised comparison
(excluding participants not randomised to that comparison) and bootstrapping on each comparison was
repeated for each of the 100 imputed data sets. For imputed data set m, bootstrapping76 was used to
sample participants with replacement from the trial data set; OLS regression was used to predict resource
use, costs and QALYs in each year on that bootstrap replicate and the results of such regression analyses
were combined in IPW with Kaplan–Meier estimates of the probability of being censored at each year
in that bootstrap replicate. This procedure was repeated on 100 bootstrap replicates drawn (with
replacement) from each of the 100 imputed data sets. The standard errors (SEs) around IPW estimates of
total costs and QALYs for each imputed data set were calculated as the standard deviation across the
100 bootstrap replicates; results were combined across all imputed data sets using Rubin’s rule to calculate
SEs, CIs and p-values around resource use, costs and QALYs.66
Results are presented as mean ± SE for each group and mean ± 95% CI for between-group differences,
with costs in pounds sterling at 2011 prices. The empirical distributions of 10,000 bootstrap estimates of
incremental costs and QALYs for each comparison were plotted as scatter graphs on the cost-effectiveness
plane. The net beneﬁt method77,78 was also used to estimate cost-effectiveness acceptability curves,79,8017
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18which plotted the probability that each type of prosthesis reﬁnement was cost-effective compared with its
comparator against the ceiling ratio. The ceiling ratio represents the amount the NHS is assumed to be
willing or able to pay per QALY gained. As the distributions of costs and QALYs for all three comparisons
span all four quadrants of the cost-effectiveness plane, the 95% CIs around the ICERs are not deﬁned and
range from dominant to dominated. As a result, no 95% CIs are shown for ICERs.
Conclusions were based on the assumption that the NHS is willing to pay £20,000 per QALY gained,
based on published social value judgements.81 Prosthesis reﬁnements generating more QALYs than their
comparator were inferred to be cost-effective compared with their comparator if they cost < £20,000 per
QALY gained, whereas less effective reﬁnements were inferred to be cost-effective if they saved > £20,000
per QALY forgone compared with their comparator. We assumed that the NHS has symmetrical
preferences with respect to losses and gains, as savings from one intervention will fund the cost of others
within the largely ﬁxed NHS budget and to ensure that conclusions are not affected by which treatment is
designated the comparator.Sensitivity and subgroup analyses
In total, 18 sensitivity analyses were conducted to relax the assumptions used in the base-case analysis and
explore the effect of using alternative methodologies:
l Complete case analysis: excluding all participants with missing data on any component of QALYs or
resource use before death or administrative censoring. To ensure complete data on costs and QALYs in
participants’ last year of life, EQ-5D utility at time of death was assumed to be equal to participants’
last observed EQ-5D utility measurement and the number of ambulatory consultations attended in
participants’ last year of life was assumed to be equal to the number of consultations attended in the
previous year, multiplied by the fraction of the year for which the participant was alive.
l Per-protocol analysis: excluding all participants who did not receive the procedure to which they were
randomly allocated, or for whom it was unclear whether they had received the allocated procedure.
l Length of stay reduced by 46% for all primary KAT procedures to reﬂect the fact that mean length of
stay for TKR is now 5.3 days,82 compared with 10.0 days among KAT participants.
l 0% price discount applied to component prices (such that all component prices are based on list prices).
l 50% price discount applied to component prices.
l Varying cost per bed-day by ± 50% to reﬂect uncertainty around costs.
l Varying cost per minute of theatre time by ± 50% to reﬂect uncertainty around costs and the
possibility of double-counting of knee components, which were (to a small degree) included in the cost
of theatre time by aggregation of costs over all orthopaedic procedures.
l Alternative discount rates allowing for time preference [0% and 5% for both costs and QALYs and
using differential discounting (0% for QALYs and 3.5% for costs)].
l No adjustment for baseline utilities.
l Within-trial time horizon: including all data collected before administrative censoring and making no
adjustment for administrative censoring.
l 8-year time horizon.
l 9-year time horizon.
l 11-year time horizon.
l Using multiple imputation to adjust for administrative censoring, rather than IPW. This analysis used
the multiple imputation estimates of utilities and resource use after administrative censoring that were
excluded from the base-case analysis. For simplicity, this analysis assumed that no participants were
readmitted after administrative censoring. Mean imputation was used to impute dates of death for
participants who were administratively censored before year 10, assuming that the interval between
censoring and death equalled their remaining life expectancy at the time of censoring (obtained from
Government Actuary’s Department estimates for age, sex and country of residence).83
l Participants receiving a femoral component with a patellofemoral joint that is shaped to accommodate
an anatomic patella (conducted only for the patella comparison).NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18190 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 19l Participants receiving a femoral component with a patellofemoral joint that is shaped to accommodate
a domed patella (conducted only for the patella comparison).
All sensitivity analyses were based on 10,000 bootstrap replicates. Complete case analysis and per-protocol
analyses were based on separate runs of bootstrapping, whereas all other sensitivity analyses were
estimated from the raw data generated in the base-case bootstrapping analysis.
The partial factorial design permitted participants recruited to the patellar resurfacing versus no resurfacing
comparison to also be randomised to either mobile versus ﬁxed bearing or all-polyethylene versus
metal-backed tibial components. In total, 338 participants were randomised in more than one comparison,
193 of whom were in the mobile versus ﬁxed bearing comparison and 145 in the all-polyethylene versus
metal-backed comparison. Although the base-case analysis assumed no interactions between randomised
comparisons, interactions were evaluated in sensitivity analyses run on the subset of participants who were
randomised to more than one comparison to evaluate whether interactions exist and (if so) what impact
this has on the study conclusions. Linear regression was used to estimate the magnitude and statistical
signiﬁcance of interactions between patellar resurfacing and mobile versus ﬁxed bearing and (separately)
between patellar resurfacing and all-polyethylene versus metal-backed tibial components. OLS regression
was used to predict the total annual cost and total annual QALYs as a function of the main effects for
each comparison and an interaction term. For example, the explanatory variables within the analysis of
mobile versus ﬁxed bearing comprised a dummy indicating whether or not participants were randomised
to patellar resurfacing, a dummy indicating whether or not participants were randomised to mobile
bearing and an interaction term (the product of the other two dummies). Baseline EQ-5D utility was
included as an additional predictor of annual QALYs. Regression analyses were repeated on 100 bootstrap
replicates on each of the 100 imputed data sets, and predicted annual QALYs and annual costs for each
treatment arm were adjusted for censoring using IPW and summed to give total costs and total QALYs
over the ﬁrst 10 years after TKR. As a secondary evaluation of interactions, subgroup analyses were
conducted to estimate the costs and QALYs for each comparison on the subset of participants randomised
to patellar resurfacing and on the subset randomised no patellar resurfacing. Both sets of analyses should
be interpreted with caution, as they are based on small participant numbers.
Six post-hoc subgroup analyses were also conducted to explore whether or not differences between
randomised comparisons varied between participant subgroups:
l participants < 70 years of age
l participants aged ≥ 70 years
l participants also randomised to patellar resurfacing (conducted only for the metal-backed and mobile
bearing comparisons)
l participants also randomised to have no patellar resurfacing (conducted only for the metal-backed and
mobile bearing comparisons).
Although no subgroups other than randomised patella allocation were prespeciﬁed in the protocol, there
are strong a priori reasons to expect costs and/or outcomes of the KAT comparisons to differ by age and
patellofemoral joint shape. In particular, age is currently an important factor taken into account in
surgeons’ decisions about which component type to use, as it predicts whether or not participants are
likely to out-live their prosthesis. In particular, all-polyethylene tibial components are often used on cost
grounds in older participants, who are unlikely to out-live the prosthesis. In the absence of prior data to
inform the cut-off, the sample was divided into two approximately equal halves. Similarly, the shape of the
patella button (anatomical or domed) may affect the cost and/or efﬁcacy of patellar resurfacing. As patella
buttons are usually matched to the patellofemoral groove in the femoral component (which is used
regardless of whether the participant had patellar resurfacing), we therefore subgrouped by groove shape
in the patella comparison.19
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20Organisational set-up
Funding for the trial
The trial was funded by the National Institute for Health Research (NIHR) HTA programme (project number
95/10/01). Additional industry funding for research support in clinical centres was provided by the
following: Howmedica Osteonics (Newbury, UK); Zimmer (Swindon, UK); J&J DePuy (Leeds, UK); Corin
Medical (Cirencester, UK); Smith & Nephew Healthcare Ltd (Cambridge, UK); Biomet Merck Ltd (Bridgend,
UK); and Wright Cremascoli (Woking, UK).The project management group
The trial was overseen by a project management group (see Appendix 4 for membership). This group met
at variable intervals, typically 4-monthly, usually by teleconference, through the course of the study.The data monitoring committee
Accumulating trial data were periodically reviewed by a data monitoring committee, independent of the
trial organisers (see Appendix 4 for membership). The committee had three members: a statistician with
experience of monitoring accumulating RCT data (who also acted as chairperson); an orthopaedic surgeon
who was not involved in the trial; and a clinician with experience of RCTs.
The committee met four times between February 2002 and March 2005 at approximately yearly intervals,
as decided by the committee. The committee’s terms of reference were guided by the Peto approach to
data monitoring in RCTs (see protocol in Appendix 1). Using this to recommend a change in the protocol
(such as stopping recruitment in one or all elements) requires both (1) proof beyond reasonable doubt that
for all or some types of participants one particular type of prosthesis is clearly indicated or contraindicated
(often taken as three SEs difference in the primary outcome) and (2) evidence that might reasonably be
expected to inﬂuence materially the care of people who require knee replacement by clinicians who know
the results of this and comparable trials. On each occasion, the committee recommended continuation of
the trial with no change of protocol. All other people, including the project management group, clinical
collaborators and trial staff (except those who supplied the conﬁdential analyses), remained ignorant of
the interim results considered by the committee. The committee stood down once the initial trial results up
to 2 years after surgery were analysed.Participating centres
In total, 116 surgeons in 34 centres in the UK participated in KAT (Table 2).
Numbers recruited to each comparison
From July 1999 to January 2003, 4070 potentially eligible participants were identiﬁed and 2374 (58%)
gave their consent and were randomised (Figure 2). The main reasons for non-randomisation were the
participant’s refusal to take part in the trial (546; 32%); the surgeon not wanting the participant to be
randomised (462; 27%); a missed opportunity to recruit a scheduled participant (351; 21%); cancellation or
deferral of the surgery or non-attendance on the part of the participant (84; 5%); the surgeon undertaking
the procedure not being registered to participate in the trial (38; 2%); unavailability of necessary equipment
(24; 1%); and unknown reasons (45; 3%). Subsequently, 22 participants were found to have been
randomised in error: 14 were randomised twice, 3 were not eligible, 3 were treated by surgeons who
were not registered to participate in the comparison and 2 were excluded for other reasons. This left
2352 participants formally in the trial: 1715 were included in the comparison assessing the patellar
resurfacing; 539 in the comparison assessing the mobile bearing; 409 in the comparison assessing the
metal backing; and 34 in the comparison assessing total versus unicompartmental knee replacement.
There were 345 participants randomised in more than one comparison (see Figure 1). Separate CONSORT
diagrams are presented for each comparison in the individual comparison chapters (see Chapters 3–6).NIHR Journals Library www.journalslibrary.nihr.ac.uk
ABLE 2 Participating centres
Centre
Patellar
resurfacing
Mobile
bearing
All
polyethylene Unicompartmental
Participants
recruited
Aberdeen Yes No No No 130
Barnstaple Yes No No No 85
Basildon Yes Yes No No 68
Birmingham No Yes No No 19
Bournemouth Yes No No Yes 122
Bury Yes No No No 24
Chester Yes No Yes No 122
Dundee Yes Yes No No 146
Exeter Yes No No No 198
Glasgow Yes Yes No No 63
Gloucester Yes No No No 19
Grimsby Yes No Yes No 21
Hairmyres Yes No No No 60
Halifax No Yes No No 72
Hartlepool Yes No Yes No 40
High Wycombe Yes No No No 8
Hull Yes No No No 36
Huntington Yes No No No 6
Leeds (Leeds General
Inﬁrmary)
No No Yes No 69
Leeds (St James’s
University Hospital)
No No Yes No 94
Liverpool No Yes Yes No 18
Macclesﬁeld Yes No No Yes 19
Middlesbrough Yes Yes No Yes 41
Oxford Yes Yes No Yes 198
Perth Yes No No No 56
Redditch Yes Yes No No 46
Scunthorpe Yes Yes No No 69
Sidcup Yes No No No 52
Stracathro Yes Yes Yes No 140
Swansea Yes Yes No No 41
Swindon Yes No No No 73
Whiston No Yes No No 28
Wirral No No Yes No 87
Worcester Yes Yes No Yes 82
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resurfacingDescription of the groups at trial entryOf the 2352 participants randomised, 1715 were recruited to the comparison assessing patellar resurfacing.
The two randomised groups were well matched at baseline (Table 3). In both groups the mean age was
70 years. In the patellar resurfacing group, 45% were male and in the non-resurfacing 44%. In both
groups the mean body mass index (BMI) was 30 kg/m2, and 96% of both groups had osteoarthritis.
Participants were also well matched on the American Society of Anesthesiologists (ASA) classiﬁcation
system and previous knee surgery.
Surgical management
In total, 116 surgeons in 34 centres in the UK participated in KAT, 99 (85%) of whom recruited
participants to the patellar resurfacing comparison. Of the 1715 randomised in this comparison, 1420
(83%) received the allocated procedure; 42 were subsequently withdrawn and received no surgery;
2 participants died prior to surgery; 8 received a unicompartmental replacement, which was not evaluated
within this comparison; and for 21 the procedure received was unknown (Figure 3). The remainder, for
various reasons, either had the patellar resurfaced when they were allocated to non-resurfacing (11%,
93 of 854) or, conversely, did not have a resurfacing when allocated to resurfacing (15%, 129 of 861).
The most common reasons for non-compliance were clinical decision at time of operation or logistical
constraint such as prostheses being unavailable at time of operation.
In-hospital care and short-term complications
Information on intra- and postoperative complications was returned for 1634 (99%) operations.
Intraoperative complications were observed in only a small percentage of the participants (2.1%; 35 of
1634), and the operative procedure caused problems in few participants (0.9%; 15 of 1634). Overall, there
were no differences between the randomised groups in these respects. Postoperative complications were
reported in 15.1% (248) of 1638 participants; however, speciﬁc problems, such as wound infection,
septicaemia, DVT or PE, cerebrovascular accident, and myocardial infarction, were rare (Table 4). Overall,
2.0% (33) of 1638 participants had additional knee surgery.
Four had knee dislocations. One participant allocated to be treated with both patellar resurfacing and a
ﬁxed-bearing prosthesis, but who actually received a mobile-bearing prosthesis, required closed reduction
of the joint because of dislocation of the rotating insert 4 days after the initial operation. The participant
had another dislocation 2 weeks later and was readmitted for revision of the spacer and femoral
component. One participant, allocated to the patellar resurfacing group but who crossed over
to the no-resurfacing group, had a subluxation of the bearing and required a reoperation for replacement
of the platform insert. The remaining two participants who had dislocations (one allocated to both
the no-patellar-resurfacing group and the mobile bearing group and the other allocated to the
no-patellar-resurfacing group only) required manipulation under anaesthesia. Six participants died in the
intermediate postoperative period: two died from a PE; one from a myocardial infarction; one from
ischemic heart disease; one from pneumonia; and one from a cerebrovascular accident. Overall, 94.7%
(1551) of 1638 participants were discharged directly to their home. The median length of hospital stay
was 9 days. There were no differences between the randomised groups with regard to any of the
above factors.23
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TABLE 3 Description of groups at trial entry for patella comparison
Characteristic
Patellar resurfacing
(n = 861)
No patellar resurfacing
(n = 854)
Age (years) (mean, SD) 70 8 70 8
Female 474 55.1 481 56.3
BMI (kg/m2) (mean, SD) 29.5 5.5 29.8 5.2
ASA classiﬁcation
Completely ﬁt and healthy 153 17.8 143 16.7
Some illness but has no affect on normal activity 500 58.1 497 57.7
Symptomatic illness present but minimal restriction 144 16.7 136 15.8
Symptomatic illness causing severe restriction 5 0.6 5 0.6
Missing 59 6.9 73 8.5
Primary type of knee arthritis
Osteoarthritis 800 92.9 789 92.4
Rheumatoid 29 3.4 37 4.3
Both 2 0.2 1 0.1
Missing 30 3.5 27 3.1
Extent of knee arthritis affecting mobility
One knee 225 26.1 229 26.8
Both knees 366 42.5 342 40.0
General 270 31.4 283 33.1
n = 831 n = 820
Other conditions affecting mobility 101 12.2 127 15.5
Medical 61 7.3 66 8.0
Locomotor/musculoskeletal 55 6.6 78 9.5
n = 829 n = 824
Previous knee surgery 281 33.9 268 32.5
Ipsilateral osteotomy 11 1.3 13 1.6
Ipsilateral patellectomy 0 0.0 0 0.0
Contralateral previous knee replacement 112 13.5 94 11.4
Other previous knee surgery 167 20.1 172 20.9
Arthroscopy 146 17.6 150 18.2
Other related surgery 26 3.1 23 2.8
ASA, American Society of Anesthesiologists; SD, standard deviation.
Cell contents are n and per cent unless otherwise stated.
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Participants randomised
(n = 1715)
Allocated to patellar
resurfacing
(n = 861)
Allocated to no patellar
resurfacing
(n = 854)
Baseline status
Response
Non-response
n = 813
n = 48
n = 813
n = 41
Treatment received 
Received allocated intervention
Did not receive allocated
intervention
Reasons:
Death before surgery
Withdrawn from surgery
Crossover to other KAT
intervention
Received unicompartmental
knee
Unclear
n = 696
n = 165
n = 1
n = 19
n = 129
n = 3
n = 13
n = 724
n = 130
n = 1
n = 23
n = 93
n = 5
n = 8
Ten-year follow-up status
Response
Deceased
Non-response
Declined further follow-up
Lost to follow-up
Not yet reached 10 years
Death before surgery
Withdrawn before surgery
n = 459
n = 229
n = 79
n = 59
n = 4
n = 11
n = 1
n = 19
n = 432
n = 228
n = 84
n = 69
n = 4
n = 13
n = 1
n = 23
Included in primary outcome
analysis
Yes
No
Reasons:
Death before surgery
Withdrawn before surgery
Death before 3-month follow-up
No postsurgery primary outcome
n = 816
n = 45
n = 1
n = 19
n = 6
n = 19
n = 798
n = 56
n = 1
n = 23
n = 9
n = 23
Included in economic
evaluation
Yes
No
Reasons:
Death before surgery
Withdrawn before surgery
n = 841
n = 20
n = 1
n = 19
n = 830
n = 24
n = 1
n = 23
FIGURE 3 CONSORT diagram for patella comparison.
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TABLE 4 In-hospital care and short-term complications for patella comparison
Variable
Patellar resurfacing
(n = 825)
No patellar resurfacing
(n = 813)
Any postoperative complications 127 15.4 121 14.9
Knee dislocation 2 0.2 2 0.2
Proven wound infection 10 1.2 9 1.1
Septicaemia 1 0.1 1 0.1
Treated DVT or PE 21 2.5 22 2.7
Conﬁrmed cerebrovascular accident 1 0.1 0 0.0
Conﬁrmed myocardial infarction 6 0.7 2 0.2
Other serious complication 94 11.4 91 11.2
Medical complications 54 6.5 44 5.4
Surgical complications 12 1.5 18 2.2
Fall 0 0.0 2 0.2
Suspicion of infection 7 0.8 9 1.1
Conﬁrmed infection 1 0.1 1 0.1
Skin complications 8 1.0 13 1.6
Stiffness 6 0.7 4 0.5
Suspected thrombolytic complications 6 0.7 1 0.1
Urinary complications 20 2.4 14 1.7
Any additional perioperative knee surgery 14 1.7 19 2.3
Manipulation under anaesthetic 2 0.2 8 1.0
Wound problem 1 0.1 2 0.2
Stiffness 0 0.0 2 0.2
Suspicion of infection 8 1.0 7 0.9
Conﬁrmed infection 0 0.0 0 0.0
Prosthetic complication 1 0.1 0 0.0
Other 2 0.1 0 0.0
n = 830 n = 809
Status at discharge
Alive 826 99.5 807 99.8
Dead 4 0.5 2 0.2
n = 830 n = 809
Discharged to home 795 95.8 756 93.4
n = 834 n = 815
Days in hospital
Median, IQR 9 7–11 9 7–11
Mean, SD 10.2 5.7 9.84 4.5
IQR, interquartile range; SD, standard deviation.
Denominator for percentages is the number of responses for that variable. Cell contents are n and per cent unless
otherwise stated.
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DOI: 10.3310/hta18190 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 19Response rates at each follow-up point for patella comparisonTable 5 describes the response rate; the response rate to questionnaires sent was high in both groups
over the whole follow-up period, ranging from 84% to 97%. The proportion of participants sent a
questionnaire dropped over the life of the trial, as one would expect given a cohort of this nature, owing
to death, loss to follow-up and patients declining further follow-up. At 10 years the response rate was
approximately 70% of the cohort who were still living.
Outcomes after a median of 10 years post operationOxford Knee Score
There was no evidence of a between-group difference in OKS at baseline or any stage thereafter (Table 6).
The mean OKS in both patellar resurfacing and non-resurfacing groups was 18 preoperatively. It increased
to 35 at 1 year and thereafter remained about the same, although it did decrease slightly in the long term
(Figure 4). The estimated adjusted difference in OKS between the two groups was 0.45 (95% CI –0.66 to
1.56) at 10 years (see Table 6). The marginal estimate over the whole 10-year follow-up was 0.61 (95% CI
–0.23 to 1.44; p = 0.153), a difference in favour of the patellar resurfacing intervention, which reﬂects
slightly, but consistently, higher values in favour of patellar resurfacing over the whole 10-year follow-up
(Figure 5). Sensitivity analysis imputing the last value before revision gave practically identical results; the
marginal estimate was 0.73 (95% CI –0.12 to 1.58; p = 0.09).
The distribution of the OKS at 10 years in the two groups is shown in Figure 6. The distributions are very
similar, and in particular there are few participants with a poor outcome in either group. Question 12 of
the OKS enquires about symptoms relating to stair descent. This item showed a similar pattern to the OKS,
that is a small but consistent difference in favour of patellar resurfacing over the whole 10-year follow-up
(Figure 7).
Subgroup analysis
There were two post-hoc subgroup analyses proposed for the primary outcome in this comparison: the
shape of the groove in the femoral component (anatomical vs. domed) and age (< 70 vs. ≥ 70 years).
The shape of the groove is described as either anatomical or domed, depending on whether it is designed
to articulate with an anatomically shaped or domed-shaped patella button.
All prostheses were classiﬁed as anatomical or domed. Of the 1614 participants included in the analysis of
the primary outcome, OKS, 48 (3%) could not be classiﬁed given the information recorded. The subgroup
analysis was run three times: ﬁrst excluding the unknowns, and then again reclassifying these 48 as
anatomical, and then domed. The breakdown of shape was the same in each arm of the trial:
29% anatomical, 68% domed and 3% unclassiﬁed. Figure 8 is a plot of the interaction term (or the
difference in differences) at each time point for the anatomical shape by patellar resurfacing interaction.
The estimates are about zero with 95% CIs fairly wide throughout, reﬂecting no evidence of a shape
effect modiﬁcation on the primary outcome, where a positive difference would indicate that resurfacing
was more favourable if the prostheses were anatomical.
Figure 9 plots the difference in favourable effect for patellar resurfacing for those aged < 70 years,
compared with those ≥ 70 years. A positive difference in differences suggests a higher relative beneﬁt for
resurfacing in the younger age group. After an early peak favouring patellar resurfacing in the younger
subgroup, the difference in differences settles around zero and indicates no evidence for a treatment
modiﬁcation on the primary outcome OKS by age.
EuroQol 5D
There was no evidence of a between-group difference in EQ-5D at baseline or at any stage thereafter
(Table 7). The mean EQ-5D utility was about 0.40 preoperatively. It increased to about 0.74 at 1 year and
thereafter steadily decreased to about 0.66 at 10 years (Figure 10). At 10 years, the difference in EQ-5D27
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TABLE 6 Descriptive statistics and estimated treatment effects at each follow-up time point for OKS for
patella comparison
Time point
Patellar resurfacing No patellar resurfacing
Diff. 95% CI p-valuen Mean SD n Mean SD
Baseline 793 18.5 7.4 798 18.1 7.7
3 months 661 31.2 9.6 679 30.5 9.4 0.78 –0.20 to 1.77 0.12
1 year 635 34.7 9.4 645 34.5 10.2 0.31 –0.69 to 1.30 0.55
2 years 556 35.6 9.8 589 35.2 10.2 0.51 –0.51 to 1.53 0.33
3 years 609 35.5 10.1 602 34.7 10.4 0.83 –0.18 to 1.84 0.11
4 years 610 34.9 10.7 616 34.3 10.6 0.84 –0.17 to 1.84 0.10
5 years 594 35.0 10.6 570 34.6 10.2 0.75 –0.27 to 1.77 0.15
6 years 550 35.1 10.5 534 34.9 10.3 0.28 –0.76 to 1.31 0.60
7 years 530 34.6 11.0 504 34.2 10.5 0.70 –0.35 to 1.74 0.19
8 years 495 34.0 11.0 487 34.0 10.5 0.36 –0.70 to 1.41 0.51
9 years 461 34.2 10.9 431 33.8 10.4 0.79 –0.29 to 1.88 0.15
10 years 418 33.6 11.3 380 33.5 10.8 0.45 –0.66 to 1.56 0.43
Diff., the estimated difference between treatments at that time point adjusted for minimisation covariates and surgeon – a
positive difference favours patellar resurfacing; n, the number of responses; SD, standard deviation.
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FIGURE 4 Mean (SD) OKS by group at each follow-up time point for patella comparison. PR, patellar resurfacing.
DOI: 10.3310/hta18190 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 19
29
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Murray et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
05
10
15
20
25
Pe
rc
en
ta
g
e 
o
f 
p
ar
ti
ci
p
an
ts
0 8 16 24 32 40 48
OKS at 10 years
PR
No PR
FIGURE 6 Histogram of OKS at 10 years by treatment group for patella comparison. PR, patellar resurfacing.
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FIGURE 7 Estimated treatment effect on OKS question 12, stairs descent (95% CI), at each follow-up time point
for patella comparison. Treatment effect is the estimated difference between treatments at that time point
adjusted for minimisation covariates and surgeon; a positive difference favours patellar resurfacing.
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FIGURE 5 Estimated treatment effect on OKS (95% CI) at each follow-up time point for patella comparison.
Treatment effect is the estimated difference between treatments at that time point adjusted for minimisation
covariates and surgeon; a positive difference favours patellar resurfacing.
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IGURE 9 Interaction term (solid line) at each follow-up time point for OKS age < 70 years old by patellar
esurfacing. Dotted lines represent 95% CIs.
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esurfacing. Dotted lines represent 95% CIs.
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TABLE 7 Descriptive statistics and estimated treatment effects at each follow-up time point for EQ-5D utility for
patella comparison
Time point
Patellar resurfacing No patellar resurfacing
Diff. 95% CI p-valuen Mean SD n Mean SD
Baseline 791 0.404 0.301 807 0.389 0.309
3 months 737 0.703 0.232 739 0.687 0.240 0.004 –0.021 to 0.029 0.75
1 year 734 0.744 0.231 725 0.732 0.253 0.003 –0.022 to 0.029 0.81
2 years 693 0.743 0.244 689 0.724 0.268 0.014 –0.011 to 0.040 0.28
3 years 679 0.733 0.254 667 0.706 0.278 0.025 –0.001 to 0.051 0.055
4 years 661 0.717 0.266 647 0.688 0.290 0.024 –0.002 to 0.050 0.070
5 years 641 0.718 0.257 611 0.701 0.266 0.016 –0.011 to 0.043 0.24
6 years 589 0.705 0.266 572 0.686 0.279 0.010 –0.017 to 0.037 0.48
7 years 573 0.695 0.284 550 0.677 0.286 0.015 –0.013 to 0.042 0.29
8 years 532 0.669 0.289 512 0.672 0.294 –0.012 –0.040 to 0.016 0.41
9 years 490 0.667 0.296 475 0.659 0.283 0.002 –0.026 to 0.031 0.87
10 years 443 0.665 0.287 424 0.647 0.302 0.012 –0.018 to 0.042 0.42
Diff., the estimated difference between treatments at that time point adjusted for minimisation covariates and surgeon – a
positive difference favours patellar resurfacing; n, the number of responses; SD, standard deviation.
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FIGURE 10 Mean (SD) EQ-5D utility by group at each follow-up time point for patella comparison.
PR, patellar resurfacing.
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32was 0.012 (95% CI –0.018 to 0.042) (see Table 7). The marginal estimate over the whole 10-year
follow-up was 0.011 (95% CI –0.008 to 0.030; p = 0.27) in favour of the patellar resurfacing
intervention (Figure 11).
Short Form 12
There was no evidence of a between-group difference in SF-12 at baseline or at any stage thereafter.
SF-12 physical component score (PCS) was 31 for both groups preoperatively (Table 8). It increased to 41
at 1 year and thereafter slowly decreased to 37 for both groups at 10 years (Figure 12). The marginal
estimate over the whole 10-year follow-up was 0.40 (95% CI –0.78 to 1.57; p = 0.51) in favour of the
patellar resurfacing intervention (Figure 13).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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FIGURE 11 Estimated treatment effect on EQ-5D utility (95% CI) at each follow-up time point for patella
comparison. Treatment effect is the estimated difference between treatments at that time point adjusted for
minimisation covariates and surgeon; a positive difference favours patellar resurfacing.
ABLE 8 Descriptive statistics and estimated treatment effects at each follow-up time point for SF-12 PCS for
atella comparison
Time point
Patellar resurfacing No patellar resurfacing
Diff. 95% CI p-valuen Mean SD n Mean SD
Baseline 780 31.1 8.0 792 31.3 8.5
3 months 719 39.4 9.4 708 38.7 9.1 0.55 –0.47 to 1.56 0.29
1 year 725 40.8 10.5 708 40.7 10.4 0.08 –0.94 to 1.09 0.88
2 years 694 40.7 11.0 675 40.8 10.4 0.02 –1.02 to 1.05 0.98
3 years 659 40.8 11.1 651 39.8 10.9 1.00 –0.05 to 2.04 0.06
4 years 652 39.7 11.4 641 39.2 10.9 0.78 –0.26 to 1.83 0.14
5 years 622 39.6 11.0 612 39.4 11.5 0.47 –0.59 to 1.53 0.39
6 years 578 39.1 11.1 554 38.7 11.4 0.52 –0.57 to 1.60 0.35
7 years 559 38.6 11.6 532 38.5 11.5 0.49 –0.61 to 1.59 0.38
8 years 518 37.6 11.2 501 38.1 11.6 –0.33 –1.45 to 0.79 0.56
9 years 478 37.6 11.3 459 37.9 11.4 0.00 –1.14 to 1.15 1.0
10 years 440 37.5 11.5 416 37.3 11.1 0.40 –0.78 to 1.57 0.51
Diff., the estimated difference between treatments at that time point adjusted for minimisation covariates and surgeon – a
positive difference favours patellar resurfacing; n, the number of responses; SD, standard deviation.
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FIGURE 12 Mean (SD) SF-12 PCS by group at each follow-up time point for patella comparison.
PR, patellar resurfacing.
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FIGURE 13 Estimated treatment effect on SF-12 PCS (95% CI) at each follow-up time point for patella comparison.
Treatment effect is the estimated difference between treatments at that time point adjusted for minimisation
covariates and surgeon; a positive difference favours patellar resurfacing.
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34The mean SF-12 mental component score (MCS) was about 50 for both groups preoperatively. It increased
to about 52 at 1 year and then decreased slowly to 49 at 10 years (Figure 14 and Table 9). The marginal
estimate over the whole 10-year follow-up was 0.56 (95% CI –0.16 to 1.23; p = 0.13) in favour of the
patellar resurfacing intervention (Figure 15).0 1 2 3 4 5
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IGURE 14 Mean (SD) SF-12 MCS by group at each follow-up time point for patella comparison.
R, patellar resurfacing.
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TABLE 9 Descriptive statistics and estimated treatment effects at each follow-up time-point for SF-12 MCS for
patella comparison
Time point
Patellar resurfacing No-patellar resurfacing
Diff. 95% CI p-valuen Mean SD n Mean SD
Baseline 780 50.7 11.4 792 49.7 11.2
3 months 719 51.2 10.6 708 51.1 11.0 –0.42 –1.41 to 0.56 0.40
1 year 725 52.3 10.2 708 51.5 11.1 0.39 –0.59 to 1.37 0.44
2 years 694 51.6 9.9 675 50.9 11.1 0.20 –0.80 to 1.20 0.70
3 years 659 51.0 9.9 651 50.3 11.3 0.30 –0.71 to 1.31 0.57
4 years 652 51.2 10.2 641 50.1 11.2 0.68 –0.34 to 1.69 0.19
5 years 622 50.8 10.4 612 50.1 10.5 0.69 –0.35 to 1.72 0.19
6 years 578 50.8 10.4 554 50.3 10.5 0.45 –0.61 to 1.51 0.41
7 years 559 50.7 10.5 532 49.9 10.7 0.84 –0.23 to 1.92 0.12
8 years 518 50.2 10.6 501 49.1 10.6 0.91 –0.19 to 2.02 0.10
9 years 478 49.7 10.9 459 48.8 10.7 0.59 –0.55 to 1.72 0.31
10 years 440 49.2 11.0 416 48.9 11.0 –0.04 –1.22 to 1.13 0.94
Diff., the estimated difference between treatments at that time point adjusted for minimisation covariates and surgeon – a
positive difference favours patellar resurfacing; n, the number of responses; SD, standard deviation.
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FIGURE 15 Estimated treatment effect on SF-12 MCS (95% CI) at each follow-up time point for patella comparison.
Treatment effect is the estimated difference between treatments at that time point adjusted for minimisation
covariates and surgeon; a positive difference favours patellar resurfacing.
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During the ﬁrst 10 postoperative years, 15% (122/841) of the resurfaced group and 15% (128/830) of the
non-resurfaced group required readmission and/or further intervention (Table 10; odds ratio 0.93, 95% CI
0.71 to 1.23, p = 0.63); 7% (58/841) of the resurfaced group and 8% (67/830) of the non-resurfaced group
required further minor or intermediate operations (odds ratio 0.85, 95% CI 0.53 to 1.32, p = 0.39); 2%
(15/841) of the resurfaced group and 2% (16/830) of the non-resurfaced group required patellar-related
operations (odds ratio 0.93, 95% CI 0.46 to 1.90, p = 0.85); and 3% (26/841) of the resurfaced group and
5% (39/830) of the non-resurfaced group required other further major operations (odds ratio 0.65, 95% CI
0.39 to 1.10, p = 0.11). The reasons for further surgery included infection, pain, stiffness, loosening and
instability. There was no statistically signiﬁcant difference in the proportion of participants requiring further
surgery in the resurfaced or non-resurfaced groups for any of the different levels of secondary intervention.
The majority of the readmissions and reoperations were in the ﬁrst 5 years (81%). Late patellar resurfacing35
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ABLE 10 Readmissions up to a median of 10 years postoperatively for patella comparison
Readmission type
Patellar resurfacing
(N = 841)
No patellar resurfacing
(N = 830)
n % n %
Total number of procedures requiring readmission 179 209
No. of participants requiring at least one
readmission
122 15 128 15
Minor/intermediate operations
Total number of operations 72 87
At least one minor operation 58 7 67 8
Multiple minor operations 13 2 16 2
Number requiring at least one of
Wound closure 1 < 1
Debridement/exploration/washout 15 2 17 2
MUA 18 2 24
Arthrolysis and quadriceplasty 1 < 1
Arthroscopy EUA/biopsy 6 1 11 1
Aspiration 18 2 19 2
Bone removal 2 < 1 1 < 1
Drain abscess 1 < 1
Cement block exchange 1 < 1
Exchange of polyethylene insert 5 < 1 5 1
Removal screws plates 1 < 1
Patella-related operations
Any patella-related operation 15 2 16 2
Number requiring at least one of
Late patellar resurfacing 9 1 16 2
Patella fracture 2 < 1
Patella revision 2 < 1
Patella realignment 1 < 1
Removal of patella button 1 < 1
Major operations
Any major operation 26 3 39 5
Multiple major operations 4 < 1 6 1
Number requiring at least one of
Above-knee amputation 2 < 1
Two-stage revision 9 1 15 2
One-stage revision 19 2 25 3
EUA, examination under anaesthetic; MUA, manipulation under anaesthetic.
PATELLAR RESURFACING VERSUS NO PATELLAR RESURFACING
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DOI: 10.3310/hta18190 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 19was carried out on 1.9% (16/830) of the non-resurfaced group and 1.1% (9/841) of the resurfaced group
(odds ratio 0.55, 95% CI 0.24 to 1.26, p = 0.16). The reason why some resurfaced group participants had
a late resurfacing was that, although they were allocated to resurfacing, they did not have resurfacing at
the original operation. For reasons stated previously, 129 of the 861 (15.0%) participants allocated to
resurfacing crossed over clinically and did not have the patellar resurfaced at the primary procedure. Of these
129 participants, 9 (7%) had subsequent late resurfacing of the patella. Conversely, 761 of the 854 allocated
to the non-resurfaced group did not have a resurfacing at the primary operation; 16 of these 761 participants
(2.1%) had late patellar resurfacing. All the ‘late’ patellar resurfacing procedures took place in the ﬁrst
5 years. The reasons for these, when recorded, were either ‘pain’ or ‘pain and/or stiffness’. During the second
5 years, there were six patella-related reoperations. They were all in the patella resurfaced group and they
were all the result of complications of the patellar resurfacing: two were for patella fracture, two were patella
revisions, one was the removal of a patella button and one was patella realignment for patella dislocation.
Time-to-event analyses showed that there was no evidence of a difference between the randomised groups
on time to any major reoperation or patella-related operation (hazard ratio 0.75; 95% CI 0.50 to 1.14;
p = 0.18; Figure 16); time to any reoperation (hazard ratio 0.87; 95% CI 0.65 to 1.17; p = 0.35; Figure 17);
or time to any reoperation or OKS dropping to below baseline levels beyond 1 year (hazard ratio 0.94;
95% CI 0.78 to 1.12; p = 0.47; Figure 18).
The OKS for those participants who had late resurfacing is shown in Figure 19. Prior to the resurfacing, the
OKS was found to deteriorate. In the year before the late resurfacing, the mean OKS was 15.9 (standard830
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38deviation 8.9). After the procedure, OKS improved again, averaging 21.3 (standard deviation 8.9) during
the second postoperative year. This was higher than before the late resurfacing, but the OKS for these
patients remained considerably lower than the mean OKS for the whole trial group.
Cost comparison
The average primary TKR procedure took just over 2 hours (including time in the anaesthetic room and
operating theatre, but excluding recovery), with patellar resurfacing non-signiﬁcantly increasing operation
time by an average of 3 minutes (p = 0.21; Table 11). The mean length of stay was 10 days in both arms,
which reﬂects typical practice at the time when the KAT procedures were conducted, but is substantially
longer than today’s average of 5.3 days.82 Peri-/postoperative complications (p = 0.77) and further surgery
(p = 0.60) were equally rare in both groups.
On average, each patella component cost £116 (assuming a 30% discount off list prices). However,
deviations from the allocated procedure reduced the incremental cost of patella components with patellar
resurfacing versus no resurfacing to £84 per participant, which was, as expected, statistically signiﬁcant
(p < 0.001). There was no statistically signiﬁcant difference in use or cost of tibial (p = 0.46) or other
components (p = 0.93) (see Table 11).
The total cost of the inpatient stay and procedure for primary TKR was just over £7000 per participant.
Although this appears to be substantially higher than the average cost of Healthcare Resource Groups (HRGs)NIHR Journals Library www.journalslibrary.nihr.ac.uk
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40HB21A-C in 2010–11 (£6080),84 the cost in KAT would have been < £5000 if KAT participants had had similar
lengths of stay to today’s patients. This would suggest that today’s patients have either longer operation times
or more expensive brands of knee components than were used in KAT. As a result of the increased cost of
patella components and non-signiﬁcant trends in other cost components, the total cost of the inpatient stay
was £202 higher for participants randomised to patellar resurfacing (p = 0.029) (see Table 11).
However, as discussed previously, participants randomised to no patellar resurfacing were non-signiﬁcantly
more likely to be readmitted for causes related to their knee replacement: for every 100 participants
randomised to no patellar resurfacing, there were three additional readmissions (p = 0.32). Furthermore, the
readmissions experienced by participants randomised to no patellar resurfacing were more costly: an average of
£4815 per readmission, versus £4061 per readmission in the patellar resurfacing arm (p = 0.23). As a result,
readmissions cost an average of £864 per participant for participants allocated to patellar resurfacing, versus
£1181 for the no patellar resurfacing arm: suggesting a saving of £317 per participant allocated to patellar
resurfacing (p = 0.15). As discussed previously, the number of readmissions is highest in the ﬁrst year after TKR
(with 0.115 readmissions per participant in the patellar resurfacing group and 0.127 for no patellar resurfacing)
and decreases rapidly thereafter (Figure 20). The ﬁrst year also accounted for the majority of the difference
between patellar resurfacing and no resurfacing, although the incidence continued to be slightly higher until
year 5, but was negligible thereafter.
The number and cost of ambulatory consultations were similar in the two groups and decreased over
time (see Figure 20). The average participant had 1.6 orthopaedic outpatient visits, 4.8 physiotherapy
consultations and 1.1 GP consultations about their knee during the ﬁrst year after TKR, which declined to
around 0.1 orthopaedic outpatient visits, 0.2 physiotherapy and 0.2 GP consultations per year during years
4–10. Overall, the cost of ambulatory care was £11 higher in the patellar resurfacing group, although no
differences were statistically signiﬁcant (minimum p = 0.57; see Table 11).
Including readmissions and ambulatory consultations, the total cost of follow-up was £1573 per patient
in the patellar resurfacing group and £1878 per participant in the no resurfacing group (see Table 11).
Readmissions accounted for 55% of the total follow-up cost in the patellar resurfacing group and 63%
of that in the no patellar resurfacing group. Although the difference in follow-up cost was not statistically
signiﬁcant (p = 0.21), its magnitude more than offsets the added cost of patella components. Overall,1
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FIGURE 20 Illustration of cost breakdown by year after discharge from hospital for patella comparison. Error bars
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DOI: 10.3310/hta18190 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 19the total cost accrued by the patellar resurfacing group within 10 years of TKR was £104 (95% CI –£423
to £630) lower than that in the no patellar resurfacing group (p = 0.70).Within-trial cost-effectiveness results
Base-case analysis
The total cost accrued in each year of the trial generally decreased over time, reﬂecting mortality, the
decreasing probability of readmission and the falling intensity of outpatient follow-up, although some
oscillations were observed in later years due to variations in the small number of readmissions each year
(Table 12, see Figure 20). In the ﬁrst year, participants randomised to patellar resurfacing accrued
non-signiﬁcantly higher costs as a result of the added cost of patella components (p = 0.67). However,
costs were markedly, but not signiﬁcantly, lower in the patellar resurfacing group in years 2 (p = 0.42),
3 (p = 0.10) and 4 (p = 0.26) and similar thereafter.
As discussed above, participants had a very poor quality of life at baseline, with a mean baseline utility
of around 0.4. Following TKR, utility rose in both groups to around 0.69 at 3 months and 0.74 at 1 year.
Quality of life was higher in the patellar resurfacing group at all time points, although differences did not
reach statistical signiﬁcance (all p > 0.05).
From EQ-5D utilities, QALYs were calculated by taking the area under the EQ-5D curve, with multiple
imputation of missing data and adjustments for mortality, time preference censoring and the small
imbalance in baseline EQ-5D utility. This suggested that the average participant experienced around
0.7 QALYs during each of the ﬁrst 3 years after TKR (see Table 12). However, as the QALY metric also allows
for mortality (assigning participants a utility of zero after death) and the QALYs in Table 12 are discounted to
allow for the fact that society places a lower value on beneﬁts accrued in the future, the numbers of QALYs
observed beyond year 2 decreased substantially more quickly than the mean EQ-5D utility.
The patellar resurfacing group had higher EQ-5D utility (see Table 7) and accrued more QALYs (see Table 12)
than the no resurfacing group in every year. In many cases, the difference in QALYs accrued in a given year
was larger than the difference in EQ-5D utility, and QALY differences (unlike those for EQ-5D utility) reached
statistical signiﬁcance in years 3 and 4. The larger QALY differences appear to be partly the result of multiple
imputation of missing utility values and partly the result of a non-signiﬁcant difference in mortality, as mean
survival was around 21 days longer for participants randomised to patellar resurfacing (p = 0.60). Across
the ﬁrst 10 years after TKR, the average participant randomised to patellar resurfacing accrued 5.30 QALYs:
0.19 more than the no patellar resurfacing group (p = 0.08).
At a 10-year time horizon, the patellar resurfacing group, therefore, accrued more QALYs and lower costs
than the group allocated to no patellar resurfacing. Patellar resurfacing can, therefore, be said to dominate
no patellar resurfacing, being more effective and less costly.
However, differences in neither costs (p = 0.70) nor QALYs (p = 0.08) reached the conventional level of
statistical signiﬁcance. Plotting incremental costs and incremental QALYs on the cost-effectiveness plane
(Figure 21) demonstrates that there is a 63% probability that patellar resurfacing dominates no resurfacing,
a 34% probability that it is more costly and more effective and only a 4% probability that it is less effective.
Although there is no signiﬁcant difference in either costs or QALYs individually, the joint distribution of
costs and QALYs shows that we can be reasonably conﬁdent that patellar resurfacing is either dominant or
produces health gains that are large compared with its incremental cost. In most NHS decision-making,
treatments are considered cost-effective if they cost no more than a ‘ceiling ratio’ of around £20,000 per
QALY gained.81 The distribution of costs and QALYs observed here shows that we can be > 95% conﬁdent
that patellar resurfacing is good value for money if the NHS is willing and able to pay at least £7250 per
QALY gained (Figure 22), suggesting that patellar resurfacing is very good value for money.41
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However, as with all economic evaluations, our analysis required a number of assumptions and choices
among a number of alternative methodologies. We, therefore, conducted sensitivity analyses to assess the
impact of using different methods or assumptions.
These analyses demonstrate that the results are extremely robust, with patellar resurfacing dominating no
resurfacing and having a > 95% probability of being cost-effective at a ceiling ratio of £20,000 per QALY
gained in every analysis except for the complete case analysis (Table 13). In particular, the analysis is robust
to changes in the time horizon and the discount rates used to adjust for time preference, as the majority
of differences in costs and QALYs are in the ﬁrst few years after primary TKR (which are given higher
weight). Changes in costing methodology also have relatively little impact because the conclusion
is driven by the comparatively large difference in QALYs and readmissions. It is particularly notable that
changing the discount applied to component list prices has no effect on the conclusions and that the
46% reduction in length of stay since KAT operations were completed has little effect on incremental
costs, as length of stay is similar in the two groups. Changing the methods used to deal with censoring
and imbalance in baseline utility also had minimal impact.
By contrast, the complete case analysis found patellar resurfacing to be substantially more costly and only
slightly more effective than no resurfacing, costing £49,160 per QALY gained. As treatments that cost
< £20,000 per QALY gained are normally considered cost-effective in NHS decision-making,81 the complete
case analysis would suggest that patellar resurfacing is poor value for money. However, by excluding all43
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DOI: 10.3310/hta18190 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 19participants who had missing data on any variable collected before the participant was administratively
censored (including data from up to 14 questionnaires completed over 10 years), the complete case
analysis excludes more than half of the sample, substantially reducing statistical power. Furthermore,
complete case analyses are prone to bias, as they do not include all randomised participants and assume
that data are missing completely at random.65 Bias is particularly likely here, as participants cannot have
missing data on costs or QALYs after they have died or been administratively censored. Furthermore only
participants who receive a patella can have missing data on the cost of a patella and only participants who
are readmitted can have missing data on component costs or length of stay during subsequent
hospitalisations. Consequently, the results of this analysis should be interpreted with caution.Subgroup analysis
As surgeons often consider participants’ age and their likelihood of out-living their knee prosthesis in
decisions around component design, a post-hoc subgroup analysis estimated outcomes for subgroups
divided by age (see Table 13). Younger participants (< 70 years old at the time of TKR) accrued higher total
costs and more QALYs within 10 years of TKR than those aged ≥ 70 years, presumably because of their
longer life expectancy. For younger participants, the estimated cost savings and QALY gains from patellar
resurfacing were greater than those of the base case, although the ﬁnding that patellar resurfacing
dominated no resurfacing was the same. By contrast, older participants randomised to patellar resurfacing
accrued higher costs than those randomised to no resurfacing and the QALY gains from resurfacing were
also lower than in the base case; as a result, patellar resurfacing cost £1629 per QALY gained in
participants aged ≥ 70 years, but remained cost-effective.
As discussed above, patella components may be either a domed shape or an anatomical shape, with
corresponding changes to the shape of the trochlear groove within the femoral component. It is generally
assumed that a non-resurfaced patella would perform better with an anatomical trochlea, rather than one
designed for a domed patella button. Subgrouping participants by the shape of the groove within the
femoral component suggested that the effectiveness of patellar resurfacing is slightly better among
participants with a femoral groove shaped for an anatomical patella than among those with grooves
shaped for domed patellas, while patellar resurfacing was also less costly than no resurfacing in the group
with anatomical patellas, but more costly in those with domed patellas. However, patellar resurfacing
remained very good value for money in both groups. Costs were also higher among participants with
anatomical patellofemoral grooves than among those with dome-shaped grooves.DiscussionIn this study, which is the largest RCT of patellar resurfacing, there was no signiﬁcant difference in clinical
outcome between patellar resurfacing or not up to 10 years post operation. We therefore conclude that
there is no clinical advantage for patellar resurfacing. However, there are non-signiﬁcant trends towards
increased effectiveness with patellar resurfacing owing to improved outcomes, as well as decreased costs
owing to fewer reoperations. Taken together, these ﬁndings mean that we can be 96% conﬁdent that
patellar resurfacing is cost-effective compared with no resurfacing.
The study indicates that up to 10 years post operation, functional status and quality of life are not
signiﬁcantly inﬂuenced by patellar resurfacing. The 95% CI of the difference in OKS between patellar
resurfacing and no resurfacing was –0.66 to 1.56 (see Table 6). A clinically important difference on the
OKS scale is thought to be between three and ﬁve points, whereas a two-point difference is of possible
clinical signiﬁcance. This study was adequately powered to detect a clinically important difference, even
taking into account the participants who did not receive their allocated procedure. Therefore, if there was
a difference in OKS too small to be detected by this study, it would also be too small to be of clinical
signiﬁcance. There may, however, be a difference that the OKS is not sensitive enough to identify. If there
was, it would probably relate to activities, such as descending stairs, that stress the patellofemoral joint.
Question 12 of the OKS enquires about symptoms relating to stair descent. There is no signiﬁcant47
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48difference between patellar resurfacing and not, even with this question. Our ﬁndings that there are no
differences in outcome are similar to those from meta-analyses of other RCTs,85,86 and our estimated CIs
rule out a two-point difference on the OKS.
The proportion of participants undergoing patella-related reoperations was similar in the resurfaced (2%)
and non-resurfaced (2%) groups. This contradicts the meta-analyses of previous RCTs, which tended to
show an increased patella-related reoperation rate in the non-resurfaced group.85 There were, however,
different patterns of patella-related reoperations in the two groups. Late patellar resurfacing, which tended
to be carried out in the ﬁrst 5 years, was more commonly carried out in the non-resurfaced group (2%)
than in the resurfaced group (1%). In contrast, operations for complications related to patellar resurfacing
which were carried out in the second 5 years were carried out only in the resurfaced group (1%). This
observation, in part, explains the difference between our conclusion and those of the meta-analyses. The
follow-up of the studies in the meta-analyses tended to be shorter than that of KAT. During the ﬁrst
5 years of our study, there was a non-signiﬁcant trend towards an increased rate of patella-related
reoperation, as in the meta-analyses. This, however, disappeared in the 10-year analysis.
In large-scale, multicentre, pragmatic surgical RCTs such as KAT non-adherence to allocated procedure is
inevitable. Analysis of reoperation rates was by intention to treat to avoid selection bias that per-protocol
or as-treated analyses are prone to. On an intention-to-treat basis, there was no evidence of a difference
between the two groups in the rate of patella-related reoperations. It is useful in this instance, however, to
consider the procedure received, as clearly late resurfacing is possible only if the patella is not resurfaced in
the ﬁrst place. There were 853 conﬁrmed participants who did not receive a patella-resurfacing index
operation (see Figure 3) and, of these, 25 (3%) had a late resurfacing. In those that received patellar
resurfacing, the incidence of patella-related reoperation was 6/789 (0.8%), which all occurred after
5 years.
There are two further reasons for the difference in the conclusions of our study and the meta-analyses.
First, the authors did not abstract the correct data from the KAT 2-year report (which was included in the
meta-analysis) and, furthermore, the remaining included studies in the meta-analyses tended to be small,
single-centre studies. We would argue that evidence from KAT is more relevant, as it offers a pragmatic
assessment of the treatment policy and would reﬂect what would happen in practice if there were a
national guideline recommending patellar resurfacing. It is also important to consider the evidence
according to the operation received. There was a very high incidence (7%) of late patellar resurfacing in
the small (16%) subgroup of participants who were randomised to patellar resurfacing but did not have a
resurfacing at the initial operation. The incidence of late resurfacing in this subgroup is three times higher
than that in the other participants who did not have resurfacing. There are various possible reasons for this
observation: perhaps these participants or their surgeons may have been aware that they had not had
their allocated patellar resurfacing and, therefore, may have been more likely to request or be advised to
have patellar resurfacing if they had a degree of residual anterior pain, as they were more likely to be
suspicious that the failure to resurface the patella was the cause of the ongoing pain. Alternatively,
participants with very severe damage to the patella may not have had resurfacing because of technical
difﬁculties, but, because of the severe damage, if they had ongoing pain, a surgeon might have felt a late
resurfacing would help.
Traditionally, patellar resurfacing has been done with a dome-shaped replacement. To match this, the
cross-section of the trochlea has been circular. This cross-sectional shape is very different from the
cross-sectional shape of the normal patella, and is possibly a cause of poor results following knee
replacement without resurfacing. To improve the results of knee replacement without resurfacing, knee
replacements with an anatomically shaped trochlea were introduced. These designs can be used with an
anatomically shaped patella button. It was expected that the shape of the trochlea would inﬂuence the
results of the study, with non-resurfaced patellas performing better with trochleas designed to work with
anatomical, rather than domed, patellas. The study, however, found that the shape of the trochlea had noNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18190 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 19inﬂuence on the relative merits of patellar resurfacing or not. It therefore does not seem to matter whether
a knee replacement is designed to have an anatomical or a dome-shaped patella.
There has been some debate as to the merits of late resurfacing.87–89 This study provides evidence to
suggest that participants who undergo this procedure have a slowly reducing functional score in the years
prior to late resurfacing and that after surgery their functional scores do improve by about ﬁve OKS points
(from approximately 16 to 21). However, after their late resurfacing, their scores were nearer the mean
preoperative score (18) than the mean postoperative score (35) of the other participants in the trial. It is,
therefore, not clear whether participants are actually receiving some real but small beneﬁt from the late
resurfacing or whether the small improvement in score occurring after the late resurfacing and the
drop in score preceding this is a manifestation of random variations in score. Furthermore, it is clear that
participants who have late resurfacing do have a problem with their knee but that this problem is, largely at
least, not related to their lack of resurfacing, and that exploration of the knee and resurfacing does not
solve it. Evidence from KAT does not support the use of late resurfacing. If, despite this, patients are offered
late resurfacing, they should be advised that this procedure is likely to, at best, provide marginal beneﬁt.
The occurrence of late resurfacing is usually considered to be a manifestation of some patients who have
not initially had resurfacing having a very poor outcome and, therefore, an argument for resurfacing. We
found that there was no difference in the distribution of postoperative scores in the resurfaced and
non-resurfaced groups; in particular, there was not a higher incidence of participants with very poor
outcomes in the non-resurfaced group (see Figure 6). We therefore have to conclude that the likely reason
why late resurfacing is carried out is not because there are worse results with no resurfacing, but rather
because, if a participant has problems after TKR and there is a simple operation such as a late resurfacing
that might help and that can be done, then a surgeon will do it. This may also be part of the explanation
why there is a trend towards more readmissions, minor/intermediate and major reoperations and higher
postoperative costs in the non-resurfaced group. For a patient with a poor outcome from a TKR, a surgeon
may be more likely to explore a knee to resurface the patella, if this has not already been done, and once
the knee is exposed a surgeon may be more likely to ﬁnd a problem and attempt to rectify it. Furthermore,
if there are more operations, there are more likely to be complications of the operations and more
ambulatory consultations will be needed. Therefore, if a surgeon is to pursue a policy of not resurfacing the
patella, he or she should also have a policy not to reoperate on the knee unless a deﬁnite problem, other
than a non-resurfaced patella, is identiﬁed. In other words, when assessing a patient who is having trouble
following knee replacement, he or she should ignore whether or not the patella has been resurfaced. If late
patellar resurfacing were not undertaken, the health gains and cost-savings associated with conducting
patellar resurfacing during primary TKR would be substantially smaller or potentially non-existent.
In the second 5 years, the only patella-related reoperations were in the resurfaced group. These were all
related to complications of the patellar resurfacing, which occurred only in the second 5 years. There were
two patellar resurfacing revisions, two reoperations for patella fracture, one realignment and one removal
of button. Operations for patella complications tend to be more major undertakings than late resurfacings
and have more complications. In addition, as is the case with late patellar resurfacing, they tend not to
have a good outcome. As late resurfacing tended to occur in the ﬁrst 5 years and complications with
the resurfacing occurred in the second 5 years, there is a concern that with time the incidence of
complications with resurfacing will continue to increase, such that in the long-term there will be more
patella-related reoperations in the resurfaced group than in the non-resurfaced.
The economic evaluation suggested that the cost of the primary inpatient stay was about £200 higher
(p = 0.03) for the resurfaced group than for the non-resurfaced group. This was partly because the
implants were about £100 cheaper (p < 0.001) with no resurfacing and partly because other costs were
lower. Therefore, as far as the hospital is concerned, not resurfacing the patella results in an appreciable
cost saving. However, KAT provides strong evidence that this is a false economy, as over 10 years we can
be 96% conﬁdent that patellar resurfacing is good value for money at a £20,000/QALY ceiling ratio,
saving £100 and gaining 0.2 QALYs per participant treated. For every 100 participants who undergo49
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50patellar resurfacing, we would expect to avoid three knee-related readmissions; the savings associated with
avoiding these readmissions more than offsets the additional costs of patella components. These results
were robust to changes in assumptions and methods, with no sensitivity analysis, other than a complete
case analysis, which has inherent biases,65 changing the conclusion that patellar resurfacing dominates no
resurfacing. In particular, the ﬁnding that varying the cost of bed-days, theatre time and discounts from
component list prices does not change the conclusions suggests that the conclusions would apply to a
wide range of hospitals across the UK. Furthermore, the ﬁnding that the conclusions would remain the
same if the length of stay were reduced to the level seen in 2010–11 suggests that the ﬁndings from
participants randomised in 1999–2003 are likely to still be valid today. However, as discussed above, the
cost-effectiveness of patellar resurfacing may be less favourable if it were compared with a policy of
avoiding all resurfacing (whether early or late). As late patellar resurfacing may affect readmissions and
ambulatory consultations and quality of life for some time either side of the resurfacing procedure, it is
difﬁcult to evaluate this scenario without modelling work.
A subgroup analysis indicated that patellar resurfacing was more cost-effective in participants < 70 years
old at the time of operation, although it remained good value for money in both groups. A second
subgroup analysis found no appreciable difference in cost-effectiveness depending on whether the femoral
component was designed for an anatomical or domed patella replacement.ConclusionsIn conclusion, at 10 years there is no clear clinical beneﬁt to resurfacing the patella. It provides no
functional advantage and results in a similar reoperation rate to that observed in patients who have not
had patellar resurfacing, and, in particular, it is not associated with a lower rate of patella-related
reoperations. These ﬁndings are different from those of previous studies, which have tended to show a
higher patella-related reoperation rate with not resurfacing, primarily as resurfacing at the initial operation
prevents late resurfacing. The difference appears to be because our study has a longer follow-up and is
pragmatic in design. Therefore, our conclusions are likely to be more relevant to recommendations about
general clinical practice. Furthermore, we have found that the outcome of patellar resurfacing is not
inﬂuenced by whether the femoral component is patella friendly or not, and that late patellar resurfacing
has little, if any, beneﬁt.
The health economic analysis did, however, strongly suggest that resurfacing the patella is cost-effective,
because it is associated with lower costs and better outcomes over the 10-year period. Although the
differences in costs and QALYs were not statistically signiﬁcant when considered individually, when taken
together they are signiﬁcant and are indicative of a real advantage for resurfacing. Secondary analysis
indicates that patellar resurfacing is more cost-effective in participants aged < 70 than in older patients,
although it remains good value for money in both age groups. The health economic analysis therefore
provides evidence to support the routine use of resurfacing.
There are two caveats. First, we have found that the number of reoperations for patella complications
increases with time. There is, therefore, a concern that in the resurfaced group in the long term the
incidence of reoperation will increase more in the resurfaced than in the non-resurfaced group. Further
follow-up is required to see if this happens. Second, if surgeons who do not resurface the patella also had
a policy to ignore the patella and not to do late resurfacing in participants with a poor outcome, the QALY
gains and cost savings associated with patellar resurfacing would decrease.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18190 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 19Chapter 4 Mobile bearing versus ﬁxed bearingDescription of the groups at trial entryOf the 2352 participants recruited, 539 were randomised within the comparison of mobile versus ﬁxed
bearings. The two randomised groups were well matched at baseline (Table 14). In both groups, the mean
age was 69 years. In the mobile bearing group, 39% were male and in the ﬁxed group 41%. In both
groups, the mean BMI was approximately 30 kg/m2 and 93% of both groups had osteoarthritis.
Participants were also well matched on ASA grade and previous knee surgery.
Surgical management
Of the 116 surgeons in 34 centres in the UK who participated in KAT, 24 (21%) recruited participants to
the mobile versus ﬁxed bearings comparison. Of the 539 randomised in this comparison, 469 (87%)
received the allocated procedure (Figure 23); 22 were subsequently withdrawn and received no surgery;
4 received a unicompartmental replacement; and for 2 the procedure received was unknown. Of the
263 participants allocated to ﬁxed bearings, 10 (4%) received the mobile bearing intervention, and in the
mobile bearing group 32/276 (12%) received the ﬁxed bearing intervention. The main reasons reported
for crossover to the other allocation were communication errors relating to allocation, clinical decision after
randomisation and components not being available for the allocated procedure.
In-hospital care and short-term complications
Postoperative complications were reported in 11.3% (61) of the 539 participants; however, speciﬁc
problems, such as wound infection, septicaemia, DVT or PE, cerebrovascular accident and myocardial
infarction, were rare (Table 15). Overall, 2.0% (11) of 539 participants had additional knee surgery. Two
participants had dislocations, one in each group. There were two deaths, one in each group: one from
respiratory arrest and the other from DVT and PE. The median length of stay was 8 days in each group
and most participants were discharged to their own home. There were no differences between the
randomised groups with regard to any of the above factors.
Response rates at each follow-up point
Table 16 describes the response rate; the response rate to questionnaires sent was high in both groups
over the whole follow-up period, ranging from 80% to 98%. The proportion of participants sent a
questionnaire dropped over the life of the trial, as one would expect given a cohort of this nature, owing
to death, loss to follow-up and participants declining further follow-up. At 10 years, the response rate was
approximately 55% of the cohort who were still living.
Outcomes after a median of 10 years post operationOxford Knee Score
There was no evidence of a between-group difference in OKS at baseline or at any stage thereafter
(Table 17). The mean OKS in both mobile bearing and ﬁxed bearing groups was approximately 17 at
baseline. It increased to approximately 33 at 1 year and thereafter remained about the same, although it
did decrease slightly in the long term (Figure 24). The difference in OKS between the two groups was
small, 0.28 (95% CI –1.86 to 2.43) at 10 years (see Table 17). The marginal estimate over the whole
10-year follow-up was 0.29 (95% CI –1.17 to 1.75; p = 0.70) in favour of the mobile bearing intervention
(Figure 25). Sensitivity analysis imputing the last value before revision gave practically identical results;
the marginal estimate was 0.34 (95% CI –0.16 to 1.85; p = 0.65).51
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Murray et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
TABLE 14 Description of groups at trial entry for mobile vs. ﬁxed bearing
Characteristic
Mobile bearing
(n = 276)
Fixed bearing
(n = 263)
Age (years) (mean, SD) 69 8 69 9
Female 169 61.0 155 58.9
BMI (kg/m2) (mean, SD) 29.5 5.3 30.3 6.0
ASA
Completely ﬁt and healthy 36 13.0 43 16.3
Some illness but has no effect on normal activity 155 56.2 149 56.7
Symptomatic illness present but minimal restriction 63 22.8 52 19.8
Symptomatic illness causing severe restriction 1 0.4 3 1.1
Missing 21 7.6 16 6.1
Primary type of knee arthritis
Osteoarthritis 243 88.0 234 89.0
Rheumatoid 18 6.5 15 5.7
Both 0 – 1 0.4
Missing 15 5.4 4.9
Extent of knee arthritis affecting mobility
One knee 65 23.5 64 24.3
Both knees 99 35.7 96 36.5
General 113 40.8 103 39.2
n = 264 n = 244
Other conditions affecting mobility 48 18.2 50 20.5
Medical 19 7.2 23 9.4
Locomotor/musculoskeletal 38 14.4 32 13.1
n = 264 n = 248
Previous knee surgery 95 36.0 93 37.5
Ipsilateral osteotomy 5 1.9 5 2.0
Ipsilateral patellectomy 1 0.4 0 0.0
Contralateral previous knee replacement 25 9.5 27 10.9
Other previous knee surgery 67 25.4 65 26.2
Arthroscopy 58 22.0 58 23.4
Other related surgery 12 4.5 7 2.8
SD, standard deviation.
Cell contents are n and per cent unless otherwise stated.
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Participants randomised
(n = 539)
Allocated to mobile
bearing
(n = 276)
Allocated to fixed
bearing
(n = 263)
Baseline status
Response
Non-response
n = 264
n = 12
n = 252
n = 11
Treatment received 
Received allocated intervention
Did not receive allocated
intervention
Reasons:
Death before surgery
Withdrawn from surgery
Crossover to other KAT
intervention
Received unicompartmental
knee
Unclear
n = 226
n = 50
n = 0
n = 14
n = 32
n = 2
n = 2
n = 243
n = 20
n = 0
n = 8
n = 10
n = 2
n = 0
Ten-year follow-up status
Response
Deceased
Non-response
Declined further follow-up
Lost to follow-up
Not yet reached 10 years
Death before surgery
Withdrawn before surgery
n = 102
n = 70
n = 25
n = 16
n = 0
n = 49
n = 0
n = 14
n = 124
n = 55
n = 21
n = 16
n = 0
n = 38
n = 0
n = 8
Included in primary outcome
analysis
Yes
No
Reasons:
Death before surgery
Withdrawn before surgery
Death before 3-month follow-up
No postsurgery primary outcome
n = 250
n = 22
n = 0
n = 14
n = 2
n = 10
n = 249
n = 14
n = 0
n = 8
n = 1
n = 5
Included in economic
evaluation
Yes
No
Reasons:
Death before surgery
Withdrawn before surgery
n = 262
n = 14
n = 0
n = 14
n = 255
n = 8
n = 0
n = 8
FIGURE 23 CONSORT diagram for mobile vs. ﬁxed bearing.
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TABLE 15 In-hospital care and short-term complications for mobile vs. ﬁxed bearing
Variable Mobile bearing (n = 259) Fixed bearing (n = 249)
Any postoperative complications 34 13.1 27 10.8
Knee dislocation 1 0.4 1 0.4
Proven wound infection 2 0.8 3 1.2
Septicaemia 0 0.0 1 0.4
Treated DVT or PE 3 1.2 6 2.4
Conﬁrmed cerebrovascular accident 0 0.0 0 0.0
Conﬁrmed myocardial infarction 1 0.4 1 0.4
Other serious complication 27 10.4 19 7.6
Medical complications 10 3.9 8 3.2
Surgical complications 6 2.3 6 2.4
Fall 0 0.0 1 0.4
Suspicion of infection 2 0.8 1 0.4
Conﬁrmed infection 0 0.0 0 0.0
Skin complications 2 0.8 1 0.4
Stiffness 2 0.8 1 0.4
Suspected thrombolytic complications 1 0.4 0 0.0
Urinary complications 4 1.5 5 2.0
Any further perioperative knee surgery 5 1.9 6 2.4
Manipulation under anaesthetic 2 0.8 3 1.2
Wound problem 2 0.8 1 0.4
Stiffness 0 0.0 0 0.0
Musculoskeletal ligamentous (including
imbalance)
0 0.0 0 0.0
Patella complication 0 0.0 0 0.0
Suspicion of infection 1 0.4 1 0.4
Conﬁrmed infection 0 0.0 0 0.0
Prosthetic complication 0 0.0 0 0.0
n = 258 n = 250
Status at discharge
Alive 257 99.6 249 99.6
Dead 1 0.4 1 0.4
Discharged to home 246 95.3 243 97.2
n = 256 n = 247
Days in hospital
Median (IQR) 8 7–11 8 7–11
Mean (SD) 9.76 6.5 9.94 4.9
IQR, interquartile range; SD, standard deviation.
Cell contents are n and per cent unless otherwise stated.
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TABLE 17 Descriptive statistics and estimated treatment effects at each follow-up time point for OKS for mobile vs.
ﬁxed bearing
Time point
Mobile bearing Fixed bearing
Diff. 95% CI p-valuen Mean SD n Mean SD
Baseline 257 17.2 7.6 243 16.5 7.4
3 months 193 30.4 9.8 196 29.4 9.6 0.38 –1.41 to 2.18 0.68
1 year 187 33.4 10.5 200 32.6 10.7 0.66 –1.14 to 2.46 0.47
2 years 185 33.6 10.5 176 32.8 10.4 –0.13 –1.96 to 1.70 0.89
3 years 192 34.3 10.1 191 32.7 11.2 0.76 –1.05 to 2.57 0.41
4 years 173 33.4 10.3 192 32.4 11.1 0.59 –1.24 to 2.42 0.53
5 years 169 33.2 10.7 181 33.6 10.0 –0.41 –2.26 to 1.43 0.66
6 years 169 33.3 10.0 165 32.6 10.7 0.51 –1.36 to 2.38 0.59
7 years 156 32.3 10.5 165 33.2 10.2 –1.17 –3.05 to 0.72 0.23
8 years 147 32.5 11.0 160 31.4 10.8 0.68 –1.23 to 2.58 0.49
9 years 135 32.0 11.1 156 31.2 11.0 0.95 –0.98 to 2.88 0.33
10 years 86 31.1 11.4 114 31.2 11.2 0.28 –1.86 to 2.43 0.78
Diff., the estimated difference between treatments at that time point adjusted for minimisation covariates and surgeon – a
positive difference favours mobile bearings; n, the number of responses; SD, standard deviation.
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FIGURE 24 Mean (SD) OKS by group at each follow-up time point for mobile vs. ﬁxed bearing.
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FIGURE 25 Estimated treatment effect on OKS (95% CI) at each follow-up time point for mobile vs. ﬁxed bearing.
Treatment effect is the estimated difference between treatments at that time point adjusted for minimisation
covariates and surgeon; a positive difference favours mobile bearing.
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DOI: 10.3310/hta18190 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 19Figure 26 explores the potential for interaction in those allocated to two interventions by plotting
difference in OKS between mobile and ﬁxed bearings among those allocated to patellar resurfacing
compared with those allocated to no patellar resurfacing. A positive difference in differences suggests a
higher relative beneﬁt for mobile bearings in the patellar resurfacing group. The graph indicates that there
may be a potential interaction, suggesting patellar resurfacing when using a mobile bearing may be
beneﬁcial. However, there is considerable uncertainty around these estimates as a result of the reduced
sample size in the partial factorial aspect of the trial.
EuroQol 5D
There was no evidence of a between-group difference in EQ-5D at baseline or at any stage thereafter
(Table 18). The mean EQ-5D utility was approximately 0.32 at baseline. It increased to approximately 0.70
at 1 year and thereafter steadily decreased to about 0.67 at 10 years (Figure 27). At 10 years the
difference in EQ-5D was 0.041 (95% CI –0.021 to 0.104) (see Table 18). The marginal estimate over the1 2 3 4 5 6 7 8 9 10
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FIGURE 26 Interaction term (solid line) at each follow-up time point for OKS for patellar resurfacing by mobile
bearing. Dotted lines represent 95% CIs.
TABLE 18 Descriptive statistics and estimated treatment effects at each follow-up time point for EQ-5D utility for
mobile vs. ﬁxed bearing
Time point
Mobile bearing Fixed bearing
Diff. 95% CI p-valuen Mean SD n Mean SD
Baseline 253 0.320 0.316 241 0.336 0.309
3 months 225 0.664 0.274 223 0.664 0.240 0.012 –0.038 to 0.062 0.63
1 year 221 0.716 0.286 227 0.689 0.290 0.035 –0.015 to 0.085 0.17
2 years 211 0.710 0.285 209 0.675 0.267 0.036 –0.015 to 0.086 0.17
3 years 206 0.710 0.263 204 0.658 0.313 0.030 –0.021 to 0.081 0.26
4 years 195 0.681 0.304 192 0.657 0.300 0.009 –0.043 to 0.061 0.73
5 years 194 0.680 0.290 187 0.692 0.267 –0.024 –0.076 to 0.029 0.37
6 years 184 0.668 0.289 177 0.672 0.297 –0.003 –0.056 to 0.050 0.92
7 years 175 0.669 0.293 172 0.638 0.302 0.020 –0.034 to 0.073 0.47
8 years 162 0.662 0.310 169 0.641 0.299 0.010 –0.045 to 0.064 0.72
9 years 150 0.639 0.292 160 0.615 0.325 0.038 –0.018 to 0.093 0.18
10 years 98 0.653 0.302 120 0.604 0.310 0.041 –0.021 to 0.104 0.19
Diff., the estimated difference between treatments at that time point adjusted for minimisation covariates and surgeon – a
positive difference favours mobile bearings; n, the number of responses; SD, standard deviation.
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58whole 10-year follow-up was 0.018 (95% CI –0.020 to 0.056; p = 0.36) in favour of the mobile bearing
intervention (Figure 28).
Short Form 12
There was no evidence of a between-group difference in SF-12 measured either at baseline or at any stage
thereafter. Mean SF-12 PCS was approximately 31 for both groups at baseline (Table 19). It increased to
approximately 39 at 1 year and thereafter slowly decreased to approximately 36 for both groups at
10 years (Figure 29). The difference in score at 10 years was –0.15 (95% CI –2.37 to 2.07) (see Table 19).
The marginal estimate over the whole 10-year follow-up was 0.19 (95% CI –1.26 to 1.64; p = 0.79)
(Figure 30).
The mean SF-12 MCS was 48 for both groups preoperatively (Table 20). It increased to about 50 at 1 year
and then decreased slowly to 48 at 10 years (Figure 31). The difference in score at 10 years was –0.91
(95 %CI –3.31 to 1.48). The marginal estimate over the whole 10-year follow-up was –0.18
(95% CI –1.41 to 1.26; p = 0.91) (Figure 32).
Clinical outcomes
During the ﬁrst 10 postoperative years, 16% (41/262) of the mobile bearing group and 18% (45/255) of
the ﬁxed bearing group required readmission and/or further intervention (odds ratio 0.84; 95% CI 0.52 to
1.34; p = 0.47; Table 21); 8% (22/262) of the mobile bearing group and 6% (16/255) of the ﬁxed bearing
group required further minor or intermediate operations (odds ratio 1.36; 95% CI 0.69 to 2.68; p = 0.37);1 2 3 4 5 6 7 8 9 10
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IGURE 28 Estimated treatment effect on EQ-5D utility (95% CI) at each follow-up time point for mobile
s. ﬁxed bearing. Treatment effect is the estimated difference between treatments at that time point adjusted for
inimisation covariates and surgeon; a positive difference favours mobile bearings.
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IGURE 27 Mean (SD) EQ-5D utility by group at each follow-up time point for mobile vs. ﬁxed bearing.F
v
m
FNIHR Journals Library www.journalslibrary.nihr.ac.uk
ABLE 19 Descriptive statistics and estimated treatment effects at each follow-up time point for SF-12 PCS for
obile vs. ﬁxed bearing
Time point
Mobile bearing Fixed bearing
Diff. 95% CI p-valuen Mean SD n Mean SD
Baseline 251 31.0 8.1 237 30.4 7.9
3 months 213 38.5 9.5 215 38.1 9.7 –0.20 –2.02 to 1.63 0.83
1 year 218 40.4 10.6 225 38.7 10.8 1.08 –0.73 to 2.89 0.24
2 years 212 40.4 11.4 200 38.7 10.6 1.01 –0.84 to 2.86 0.29
3 years 208 39.1 11.0 203 37.9 10.8 0.36 –1.49 to 2.21 0.70
4 years 194 38.5 11.1 198 38.5 11.7 –0.32 –2.19 to 1.56 0.74
5 years 190 38.2 12.1 189 38.6 10.9 –0.80 –2.69 to 1.09 0.41
6 years 182 37.9 11.6 179 37.4 11.4 0.21 –1.70 to 2.13 0.83
7 years 171 38.4 11.2 171 37.1 11.5 0.41 –1.53 to 2.35 0.68
8 years 155 38.1 11.4 162 37.2 11.4 0.29 –1.69 to 2.28 0.77
9 years 149 36.5 11.3 162 35.8 11.3 –0.12 –2.11 to 1.87 0.91
10 years 97 36.6 11.8 118 35.9 11.4 –0.15 –2.37 to 2.07 0.89
Diff., the estimated difference between treatments at that time point adjusted for minimisation covariates and surgeon – a
positive difference favours mobile bearings; n, the number of responses; SD, standard deviation.
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FIGURE 29 Mean (SD) SF-12 PCS by group at each follow-up time point for mobile vs. ﬁxed bearing.
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FIGURE 30 Estimated treatment effect on SF-12 PCS (95% CI) at each follow-up time point for mobile vs. ﬁxed
bearing. Treatment effect is the estimated difference between treatments at that time point adjusted for
minimisation covariates and surgeon; a positive difference favours patellar resurfacing.
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TABLE 20 Descriptive statistics and estimated treatment effects at each follow-up time point for SF-12 MCS for
mobile vs. ﬁxed bearing
Time point
Mobile bearing Fixed bearing
Diff. 95% CI p-valuen Mean SD n Mean SD
Baseline 251 48.1 12.0 237 48.6 11.9
3 months 213 48.2 11.8 215 49.5 11.0 –0.81 –2.68 to 1.06 0.40
1 year 218 50.6 11.2 225 50.1 12.1 0.14 –1.72 to 1.99 0.89
2 years 212 49.8 10.8 200 50.8 11.3 –0.59 –2.49 to 1.32 0.55
3 years 208 49.8 10.5 203 48.3 11.7 1.21 –0.69 to 3.12 0.21
4 years 194 49.7 10.9 198 49.5 11.5 0.18 –1.76 to 2.12 0.85
5 years 190 49.5 10.2 189 50.1 10.8 –0.46 –2.42 to 1.50 0.65
6 years 182 49.0 10.8 179 49.0 11.3 0.09 –1.90 to 2.08 0.93
7 years 171 49.0 11.0 171 49.4 10.3 –0.74 –2.77 to 1.28 0.47
8 years 155 48.2 12.2 162 48.9 10.9 –0.73 –2.81 to 1.35 0.49
9 years 149 49.7 10.8 162 48.1 11.2 1.53 –0.56 to 3.63 0.15
10 years 97 47.5 11.4 118 48.9 10.5 –0.91 –3.31 to 1.48 0.45
Diff., the estimated difference between treatments at that time point adjusted for minimisation covariates and surgeon – a
positive difference favours mobile bearings; n, the number of responses; SD, standard deviation.
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FIGURE 31 Mean (SD) SF-12 MCS by group at each follow-up time point for mobile vs. ﬁxed bearing.
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IGURE 32 Estimated treatment effect on SF-12 MCS (95% CI) at each follow-up time point for mobile vs. ﬁxed
earing. Treatment effect is the estimated difference between treatments at that time point adjusted for
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TABLE 21 Readmissions up to a median of 10 years postoperatively for mobile vs. ﬁxed bearing
Readmission type
Mobile bearing
(N = 262)
Fixed bearing
(N = 255)
n % n %
Total readmissions 57 63
No. of participants requiring at least one readmission 41 16 45 18
Minor/intermediate operations
Total number operations 26 15
Participants requiring
At least one minor operation 22 8 16 6
Multiple minor operations 3 1 3 1
Number requiring at least one of
Debridement/exploration/washout 4 2 1 < 1
Manipulation under anaesthetic 7 3 6 2
Arthroscopy EUA/biopsy 10 4 7 3
Late patellar resurfacing 2 1 4 2
Patella revision 1 < 1
Operations for instability
Total number of operations 6
Any operation for instability 5 2
Multiple operations for instability 1 < 1
Number requiring at least one of
Open relocation or exchange of bearing 3 1
Revision for instability 2 1
Revision for dislocation 1 < 1
Major operations
Total number operations 11 9
Any major operation 9 3 8 3
Multiple major operations 2 1 1 < 1
Number requiring at least one of
Two-stage revision 2 1 3 1
Revision pain/loosening 7 3 6 2
EUA, examination under anaesthetic.
DOI: 10.3310/hta18190 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 19and 3% (9/262) of the mobile bearing group and 3% (8/255) of the ﬁxed bearing group required other
further major operations (odds ratio 1.07; 95% CI 0.36 to 3.25; p = 1.00). There were six reoperations for
bearing dislocation or instability in the mobile bearing group in ﬁve participants (2%) compared with none
in the ﬁxed bearing group (p = 0.062). Time-to-event analyses showed that there was no evidence of a
difference between the randomised groups on time to any major reoperation or reoperation for instability
(hazard ratio 1.47; 95% CI 0.60 to 3.61; p = 0.39; Figure 33); time to any reoperation (hazard ratio 1.39;
95% CI 0.81 to 2.37; p = 0.23; Figure 34); or time to any reoperation or OKS dropping to below baseline
levels beyond 1 year (hazard ratio 0.93; 95% CI 0.67 to 1.29; p = 0.66; Figure 35).61
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FIGURE 34 Kaplan–Meier failure curves for time to any reoperation for mobile vs. ﬁxed bearing.
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FIGURE 33 Kaplan–Meier failure curves for time to ﬁrst major reoperation for mobile vs. ﬁxed bearing.
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FIGURE 35 Kaplan–Meier failure curves for time to any reoperation or OKS dropping below baseline score
for mobile vs. ﬁxed bearing.
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The participants randomised to mobile bearings had a similar mean operation time (p = 0.87) and length of
hospital stay (p = 0.79) to those in the ﬁxed bearing group, which were comparable to those seen among
participants randomised in the patellar resurfacing comparison (Table 22). There were also no signiﬁcant
differences in the cost or incidence of complications (minimum p = 0.64) or further surgery (minimum
p = 0.88) during the primary hospital stay.
However, mobile bearings signiﬁcantly increased the cost of tibial and femoral knee components.
Participants assigned to ﬁxed bearings used signiﬁcantly fewer tibial components (p < 0.001) than those in
the mobile bearing group, as all mobile bearings require a separate bearing, while ﬁxed bearings may be
all-polyethylene monoblocks. Additionally, participants assigned to mobile bearings tended to have more
expensive tibial trays (mean £712/tray for mobile vs. £682/tray for ﬁxed bearings) and inserts (mean £255/
insert for mobile vs. £196/insert for ﬁxed bearings). As a result, the total cost of tibial components was
£126 (95% CI £94 to £158; p < 0.001) higher for participants randomised to mobile rather than ﬁxed
bearings. Mobile bearings were also associated with more costly femoral components, increasing the cost
of femoral and other components by £155 (95% CI £119 to £191; p < 0.001) per participant. The total
cost of the primary hospital stay was therefore £239 higher for participants in the mobile bearing group
than for those in the ﬁxed bearing group, although between-participant variability in non-component costs
meant that this difference was not statistically signiﬁcant (p = 0.20) (see Table 22).
However, the increased cost of components during the primary hospital stay was partially offset by
non-signiﬁcant reductions in the cost of readmissions and ambulatory consultations during the 10 years
after TKR. Overall, participants randomised to ﬁxed bearings had 1.4 more GP (p = 0.71), physiotherapy
(p = 0.51) and orthopaedic consultations (p = 0.30) over the ﬁrst 10 years after TKR and had follow-up
costs that were £154 higher than those of participants randomised to mobile bearings (p = 0.74). The
difference in the number of orthopaedic outpatient, physiotherapy and GP consultations was highest in
year 1, whereas the difference in the cost of readmissions was greatest in years 2–4 (Figure 36). The total
cost in each year of the trial fell dramatically after the ﬁrst year, but oscillated in later years owing to
chance variations in the number of readmissions per year within the comparatively small sample. Costs
were particularly high in year 6, when there were three readmissions in the mobile bearing arm and two
in the ﬁxed bearing arm. Total costs were £207 higher in the mobile bearing group in year 1, between
£65 and £111 lower during years 2–4 and higher again in most subsequent years (see Table 23).
Total costs (including the primary hospital stay and 10 years’ outpatient follow-up) were therefore £85
(95% CI –£911 to £1081) higher in the group randomised to mobile bearings (p = 0.87).
Within-trial cost-effectiveness resultsBase-case analysis
Following the quality-of-life trends described above, the mobile bearing arm accrued non-signiﬁcantly
more QALYs during the ﬁrst 4 years after TKR (minimum p = 0.14). However, the mobile bearing
arm accrued fewer QALYs in most subsequent years (minimum p = 0.59; Table 23), despite life expectancy
being 9.29 years in the two groups (p = 0.98). Over the 10-year time horizon, the larger quality of
life increases observed in earlier years outweighed the quality of life decreases seen in later years and the
mobile bearing group therefore accrued 0.051 (95% CI –0.333 to 0.435) more QALYs than the ﬁxed
bearing group (p = 0.79).
Mobile bearings were therefore associated with non-signiﬁcantly higher costs (mean difference £85;
p = 0.87) and marginally more QALYs (mean difference 0.051; p = 0.79) over the 10-year time horizon.
The ICER for mobile bearings is therefore £1666 per QALY gained compared with ﬁxed bearings, although
there is substantial uncertainty around this point estimate. In NHS decision-making, treatments that
increase health and NHS costs are generally considered to be good value for money if they have an ICER63
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DOI: 10.3310/hta18190 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 19below £20,000 per QALY gained,81 making mobile bearings highly cost-effective based on their ICER point
estimate, although there remains substantial uncertainty around this ﬁgure.
However, there was substantial uncertainty around both incremental costs and incremental QALYs, with a
joint distribution spread across the four quadrants of the cost-effectiveness plane (Figure 37). There was a
32% probability that mobile bearings were more costly and more effective, a 29% probability that mobile
bearings dominated ﬁxed bearings (being less costly and more effective), a 27% probability that mobile
bearings were dominated and a 13% probability that they were less costly and less effective (south-west
quadrant). In particular, the uncertainty meant that the cost-effectiveness acceptability curve was very ﬂat,
with the probability of mobile bearings being cost-effective varying between 42% and 60% (Figure 38).
At a £20,000/QALY ceiling ratio, the probability of mobile bearings being cost-effective was 59%.
Sensitivity analyses
Sensitivity analyses suggested that the base-case conclusions were sensitive to the methods used to deal
with missing data and protocol violations (Table 24). The complete case analysis, based on 96 and
97 participants (excludes all participants with missing data on any resource-use variable or quality-of-life
measurement prior to death or administrative censoring), found mobile bearings to be substantially more
costly and marginally less effective than ﬁxed bearings. The per-protocol analysis also found mobile
bearings to be dominated by ﬁxed bearings (being more costly and less effective).
However, all other sensitivity analyses were consistent with the base-case ﬁnding that participants
randomised to mobile bearings accrued marginally higher QALYs than those randomised to ﬁxed bearings
and that there is a 51–65% probability that mobile bearings are cost-effective at a £20,000/QALY ceiling
ratio, although two analyses (increasing the discount of component prices and increasing the cost per
bed-day) found mobile bearings to dominate ﬁxed bearings. Time horizon had a marked effect on both
incremental costs and incremental QALYs because of the tendency for participants assigned to mobile
bearing to accrue fewer QALYs and higher costs in years 5–11. At an 8-year time horizon, the estimated
incremental QALYs were greater than those in the base-case analysis, whereas both lower incremental
costs and lower incremental QALYs were observed at an 11-year time horizon. This may suggest that
a longer follow-up could reverse the direction of differences in both costs and QALYs, making mobile
bearings less costly and less effective than ﬁxed bearings.65
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FIGURE 38 Cost-effectiveness acceptability curve for mobile vs. ﬁxed bearing.
DOI: 10.3310/hta18190 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 19Subgroup analyses
Subgroup analyses suggested that both the costs and beneﬁts of mobile bearings differ with age (see
Table 24). In particular, both the incremental costs and incremental health beneﬁts of mobile bearings
were markedly larger for participants aged < 70 years; although the cost-effectiveness ratio for this group
was similar to that of the total population, the probability that mobile bearings were cost-effective
compared with ﬁxed bearings rose to 86%, compared with 59% in the base-case analysis, despite the
smaller sample size. By contrast, mobile bearings were less costly but produced a smaller QALY gain than
ﬁxed bearings in older participants, saving £618 per QALY lost, which would not be considered good value
for money.Potential for interactions between mobile bearings and patellar resurfacing
Analysing the subset of 240 participants randomised to both the mobile bearing and patellar resurfacing
comparisons as a factorial trial, it was found that there were interactions that had a marked effect on
estimated incremental costs and QALYs. In particular, non-signiﬁcant qualitative interactions between the
two treatment allocation factors were observed for costs (p = 0.12), QALYs (p = 0.08) and net monetary
beneﬁts (p = 0.06), which means that the incremental effect of mobile bearings changes sign depending
on whether participants were allocated to patellar resurfacing or no resurfacing. [Net monetary beneﬁts
are a linear measure of cost-effectiveness that facilitates statistical analysis and comparison of multiple
groups. The total net monetary beneﬁt was calculated by multiplying the total number of QALYs accrued
in each treatment arm by the £20,000/QALY ceiling ratio and subtracting total costs.] In particular,67
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DOI: 10.3310/hta18190 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 19participants randomised to both mobile bearing and no patellar resurfacing accrued substantially higher
costs and substantially fewer QALYs than those allocated to the other three combinations of treatment
allocation. As a result of the interactions for QALYs and costs, mobile bearings dominated ﬁxed bearings in
participants who were also randomised to patellar resurfacing and had a 93% chance of being
cost-effective at the £20,000/QALY ceiling ratio, but were dominated by ﬁxed bearings, with a
17% chance of being cost-effective in participants randomised to no resurfacing.
As there is evidence that the incremental costs and beneﬁts of mobile bearings may depend on whether or
not participants are also randomised to patellar resurfacing, it is useful to also examine whether making
a joint decision about these two aspects of TKR (rather than independent decisions) would change the
conclusions. Treating the four combinations of treatment allocation as mutually exclusive strategies for TKR
suggests that ﬁxed bearings without patellar resurfacing dominate ﬁxed bearings with patellar resurfacing,
and mobile bearings without resurfacing are less costly and more effective than both of these alternatives.
However, the strategy with highest clinical effectiveness and cost-effectiveness comprises mobile bearing
with patellar resurfacing, which costs £1109 per QALY gained compared with ﬁxed bearing and no
patellar resurfacing. Taking account of interactions and evaluating the cost-effectiveness of mobile
bearings and patellar resurfacing simultaneously is, therefore, consistent with the conclusion of the
base-case analysis that both mobile bearings and patellar resurfacing are expected to be cost-effective.DiscussionThe mobile bearing component of KAT indicates that at 10 years post operation functional status, quality
of life, and reoperation and revision rates are not signiﬁcantly improved or made worse by the use of
a mobile bearing prosthesis. In addition, there is substantial uncertainty around the cost-effectiveness
of mobile bearings. This study therefore conﬁrms the ﬁndings of previous RCTs and systematic reviews,
showing that there is no real beneﬁt conferred by using mobile bearings in TKR.24–29
There was no signiﬁcant difference between the mobile and ﬁxed bearing designs for any
participant-reported outcome measure at any postoperative stage, which indicates that, at least up to
10 years, there is no difference in function or quality of life between the two designs. Furthermore, the
estimated CIs rule out the prespeciﬁed MCID on the primary outcome. The readmission rate was the same
for the two groups. There was also no statistically signiﬁcant difference in the rate of minor, intermediate
or major reoperations.
The main intended beneﬁt of mobile bearings is improved function and reduced wear and loosening.
These theoretical advantages would manifest as differences in participant-reported outcomes and
incidence of reoperation for aseptic loosening. As there are no differences in these outcome measures
at 10 years, these advantages are unconﬁrmed and remain theoretical. However, wear is a long-term
problem for which differences may appear after 10 years, so the follow-up should be continued. The
theoretical disadvantage of a mobile bearing (namely bearing instability) would manifest as reoperations
for instability or dislocation. There were six reoperations in ﬁve participants (2%) related to instability or
dislocation of the bearing in the mobile bearing group and none in the ﬁxed bearing group (p = 0.062).
This is, therefore, a real disadvantage of the mobile bearing. As the study has not demonstrated a deﬁnite
clinical advantage of mobile bearings, it provides a good reason not to use a mobile bearing.
The economic evaluation suggested that mobile bearings increased the cost of knee components by £277
per participant, which was partly offset by reductions in readmissions and ambulatory consultations in the
ﬁrst 4 years after primary TKR. Over the 10-year time horizon, mobile bearings cost an additional £85
(95% CI –£911 to £1081) per participant treated. Although the mobile bearing group had a better quality
of life in the ﬁrst few years after knee replacement, this trend was reversed in subsequent years, giving an
overall QALY difference of just 0.051 between mobile and ﬁxed bearings. Based on mean costs and
beneﬁts, we would expect mobile bearings to be good value for money, costing £1666 per QALY gained71
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72compared with ﬁxed bearings. However, as the QALY difference observed is extremely small and there
is substantial uncertainty around both costs and QALYs, we can be only 59% conﬁdent about this
conclusion. Sensitivity analyses demonstrated that this ﬁnding is sensitive to the methods used to deal
with missing data, protocol violations and time horizon, but not costing methodology. In the subgroup
of patients under the age of 70 years, the cost of the mobile bearings relative to the ﬁxed (£315;
95% CI –£749 to £1379) as well as the QALYs gained (0.317; 95% CI –0.212 to 0.845) increased,
and as a result the chance of mobile bearings being cost-effective at a £20,000/QALY ceiling ratio
increased to 86%.
Although mobile bearings were found to have greater expected net beneﬁts than ﬁxed bearings, which
could justify their adoption based on current information, more information is likely to be necessary to
conﬁrm this conclusion: particularly given the very small QALY gain and the substantial uncertainty around
both incremental QALYs and incremental costs. In particular, the mobile bearing group tended to accrue
fewer QALYs and greater costs in years 5–11, which suggests that longer follow-up may reverse the trends
observed, potentially making mobile bearings less costly and less effective over a longer time horizon.
Further follow-up is therefore needed to assess the long-term costs and beneﬁts of mobile bearings.
There was some evidence that patellar resurfacing affects the incremental costs and beneﬁts of mobile
bearings, although the interactions observed in the subset of participants randomised to both comparisons
were not statistically signiﬁcant. If the patella is resurfaced, then a mobile bearing appears to be more
cost-effective than a ﬁxed bearing. However, the numbers are small, the clinical explanation for an
interaction of this type is unclear and this analysis was one of several secondary or subgroup analyses.
Findings should therefore be interpreted cautiously and further study is needed to determine why the
interaction occurs before recommendations based on these interactions can be made.ConclusionThe study has shown no deﬁnitive advantage or disadvantage for mobile or ﬁxed bearings in terms of
postoperative functional status, quality of life, reoperation and revision rates or cost-effectiveness.
We therefore cannot make any strong conclusions about whether surgeons should or should not use
mobile bearings.
We did, however, identify two disadvantages of mobile bearings that would discourage surgeons from
using mobile bearings. First, there was an incidence of 2% of bearing instability in the mobile bearing
group and none in the ﬁxed bearing group. Second, there was a cost saving for the hospital associated
with the use of ﬁxed bearings.
Further follow-up of the patients would be useful: ﬁrst, to determine whether the theoretical advantage of
decreased wear and the observed trend towards lower QALYs beyond year 5 with mobile bearings in the
long term is real; second, to determine whether the trend towards mobile bearings having a greater
cost-effectiveness in patients < 70 years becomes signiﬁcant or if it disappears; and, third, to monitor the
potential interactions between patellar resurfacing and mobile bearings.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18190 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 19Chapter 5 All-polyethylene versus metal-backed
tibial componentsDescription of the groups at trial entryOf the 2352 participants in the trial, 409 were randomised within the comparison of metal-backed versus
all-polyethylene tibial components. The two randomised groups were well matched at baseline (Table 25).
In both groups the mean age was similar. In the metal-backed group, 49% were male compared with
46% in the all polyethylene group. In both groups, the mean BMI was about 29 kg/m2, and 95% of both
groups had osteoarthritis. Participants were also well matched on the ASA classiﬁcation and previous
knee surgery.
Surgical management
Of the 116 surgeons in 34 centres in the UK that participated in KAT, 17 (15%) recruited participants to
the metal-backed versus all polyethylene comparison. Of the 409 randomised in this comparison, 365
(89%) received the allocated procedure; seven participants were withdrawn before surgery; two received
a unicompartmental knee replacement; and in three cases it was unclear what surgery was received
(Figure 39). The remainder, for various reasons, either received a metal-backed tibia when they were
allocated an all-polyethylene tibia (15%, 31 of 207) or, conversely, received an all-polyethylene tibia when
allocated a metal-backed tibia (< 1.0%, 1 of 202). The most common reasons for non-compliance were
logistical constraints, such as prostheses being unavailable at the time of operation or clinical decision.
In-hospital care and short-term complications
Information on intra- and postoperative complications was returned for 398 (99%) operations.
Intraoperative complications were observed in only a small percentage of the participants (2.8%; 11 of
398), and the operative procedure caused problems in few participants (1.8%; 7 of 398). Overall, there
were no differences between the randomised groups in these respects. Postoperative complications were
reported in 16% (65) of the 398 participants for whom information was available; however, speciﬁc
problems, such as wound infection, septicaemia, DVT or PE, cerebrovascular accident and myocardial
infarction, were rare. Overall, 1.3% (5) of the 398 participants had additional knee surgery. One
participant died from a brain stem infarction in the intermediate postoperative period. Overall, 96% (382)
of the 398 participants were discharged directly to their home. The median length of hospital stay was
10 days (Table 26). There were no differences between the randomised groups with regard to any of the
above factors.
Response rates at each follow-up point
Table 27 describes the response rate; the response rate to questionnaires sent was high in both groups
over the whole follow-up period, ranging from 82% to 97%. The proportion of participants sent
a questionnaire dropped over the life of the trial, as one would expect given a cohort of this nature,
owing to death, loss to follow-up and patients declining further follow-up. At 10 years, the response rate
was approximately 60% of the cohort that were still living.73
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ABLE 25 Description of groups at trial entry for all-polyethylene vs. metal-backed components
Characteristic
All polyethylene
(n = 207)
Metal-backed
(n = 202)
Age (years) (mean, SD) 70 8 69 9
Female 111 53.6 103 51.0
BMI (kg/m2) (mean, SD) 28.7 4.6 28.7 4.6
ASA
Completely ﬁt and healthy 27 13.0 22 10.9
Some illness but has no effect on normal activity 127 61.4 127 62.9
Symptomatic illness present but minimal restriction 46 22.2 46 22.8
Symptomatic illness causing severe restriction 1 0.5 1 0.5
Missing 6 2.9 6 3.0
Primary type of knee arthritis
Osteoarthritis 193 93.2 189 95.0
Rheumatoid 9 4.3 10 5.0
Both 1 0.5 1 0.5
Missing 4 1.9 2 1.0
Extent of knee arthritis affecting mobility
One knee 46 22.2 49 24.3
Both knees 80 38.6 80 75
General 81 39.1 78 38.6
n = 199 n = 203
Other conditions affecting mobility 23 11.3 22 11.1
Medical 8 3.9 12 6.0
Locomotor/musculoskeletal 16 7.9 14 7.0
Previous knee surgery 73 36.0 76 38.2
Ipsilateral osteotomy 1 0.5 1 0.5
Ipsilateral patellectomy 0 0.0 1 0.5
Contralateral previous knee replacement 27 13.3 33 16.6
Other previous knee surgery 48 23.6 44 22.1
Arthroscopy 42 20.7 34 17.1
Other related surgery 8 3.9 12 6.0
SD, standard deviation.
Cell contents are n and per cent unless otherwise stated.
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Participants randomised
(n = 409)
Allocated to all
polyethylene
(n = 207)
Allocated to metal
backing
(n = 202)
Baseline status
Response
Non-response
n = 201
n = 6
n = 198
n = 4
Treatment received 
Received allocated intervention
Did not receive allocated
intervention
Reasons:
Death before surgery
Withdrawn from surgery
Crossover to other KAT
intervention
Received unicompartmental
knee
Unclear
n = 170
n = 37
n = 0
n = 4
n = 31
n = 1
n = 1
n = 195
n = 7
n = 0
n = 3
n = 1
n = 1
n = 2
Ten-year follow-up status
Response
Deceased
Non-response
Declined further follow-up
Lost to follow-up
Not yet reached 10 years
Death before surgery
Withdrawn before surgery
n = 85
n = 58
n = 19
n = 18
n = 0
n = 23
n = 0
n = 4
n = 91
n = 55
n = 16
n = 16
n = 0
n = 51
n = 0
n = 3
Included in primary outcome
analysis
Yes
No
Reasons:
Death before surgery
Withdrawn before surgery
Death before 3-month follow-up
No postsurgery primary outcome
n = 196
n = 11
n = 0
n = 4
n = 1
n = 6
n = 192
n = 10
n = 0
n = 3
n = 1
n = 6
Included in economic
evaluation
Yes
No
Reasons:
Death before surgery
Withdrawn before surgery
n = 203
n = 4
n = 0
n = 4
n = 199
n = 3
n = 0
n = 3
FIGURE 39 CONSORT diagram for all-polyethylene vs. metal-backed tibial components.
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ABLE 26 In-hospital care and short-term complications for all-polyethylene vs. metal-backed tibial components
Variable
All polyethylene
(n = 202)
Metal-backed
(n = 197)
Any postoperative complications 35 17.8 30 14.9
Knee dislocation 0 0.0 0 0.0
Proven wound infection 1 0.5 1 0.5
Septicaemia 0 0.0 0 0.0
Treated DVT or PE 5 2.5 3 1.5
Conﬁrmed cerebrovascular accident 0 0.0 0 0.0
Conﬁrmed myocardial infarction 1 0.5 1 0.5
Other serious complication 28 13.9 27 13.7
Medical complications 14 6.9 16 8.1
Surgical complications 0 0.0 3 1.5
Fall 0 0.0 1 0.5
Suspicion of infection 8 4.0 4 2.0
Conﬁrmed infection 0 0.0 0 0.0
Skin complications 2 1.0 2 1.0
Stiffness 2 1.0 1 0.5
Suspected thrombolytic complications 3 1.5 2 1.0
Urinary complications 3 1.5 2 1.0
n = 201 n = 196
Any further knee surgery before hospital discharge 4 2.0 1 0.5
Manipulation under anaesthetic 2 1.0 0 0.0
Wound problem 0 0.0 0 0.0
Stiffness 0 0.0 0 0.0
Musculoskeletal ligamentous (including imbalance) 0 0.0 0 0.0
Patella complication 0 0.0 0 0.0
Suspicion of infection 2 1.0 1 0.5
Conﬁrmed infection 0 0.0 0 0.0
Dislocation 0 0.0 0 0.0
Prosthetic complication 0 0.0 0 0.0
Unknown 0 0.0 0 0.0
Status at discharge
Alive 201 99.5 196 100.0
Dead 1 0.5 0 0.0
Discharged to home 192 95.0 190 96.9
Days in hospital
Median (IQR) 9 8 to 12 8 7 to 11
Mean (SD) 10.38 4.7 9.7 4.7
IQR, interquartile range; SD, standard deviation.
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78Outcomes after a median of 10 years post operationOxford Knee Score
There was no evidence of a between-group difference in OKS at baseline or at any stage thereafter
(Table 28). The mean OKS in both groups was about 17.5 preoperatively. It increased to about 33 at
1 year and thereafter remained about the same. The difference in OKS between the two groups was small
and was –1.19 (95% CI –3.48 to 1.11; p = 0.311) at 10 years (Figure 40, see Table 28). The marginal
estimate over the whole 10-year follow-up was –1.36 (95% CI –2.98 to 0.26; p = 0.10) in favour of the
metal-backed intervention (Figure 41). Sensitivity analysis imputing the last value before revision gave
practically identical results; the marginal estimate was –1.41 (95% CI –3.06 to 0.25; p = 0.10).
Figure 42 explores the potential for interaction in those allocated to two interventions by plotting the
difference in effect for all-polyethylene components for those allocated to patellar resurfacing comparedTABLE 28 Descriptive statistics and estimated treatment effects at each follow-up time point for OKS for
all-polyethylene vs. metal-backed tibial components
Time point
All polyethylene Metal-backed
Diff. 95% CI p-valuen Mean SD n Mean SD
Baseline 195 17.3 7.7 198 17.9 7.8
3 months 165 29.3 9.4 162 31.0 9.9 –1.95 –3.88 to –0.01 0.048
1 year 154 32.7 9.8 157 34.7 10.2 –1.55 –3.51 to 0.41 0.120
2 years 150 33.3 10.5 142 35.4 10.7 –1.21 –3.19 to 0.78 0.233
3 years 150 33.8 10.0 150 34.7 10.4 –0.80 –2.78 to 1.18 0.427
4 years 153 33.5 10.3 149 34.7 10.3 –1.65 –3.63 to 0.32 0.101
5 years 139 33.7 10.7 145 34.5 9.8 –1.37 –3.37 to 0.63 0.180
6 years 136 33.6 10.5 135 34.0 10.2 –0.94 –2.96 to 1.08 0.364
7 years 131 33.6 10.7 131 33.9 9.7 –1.13 –3.16 to 0.91 0.278
8 years 114 32.9 10.4 122 33.5 9.9 –1.52 –3.60 to 0.57 0.154
9 years 104 32.0 11.7 110 33.0 9.4 –1.55 –3.68 to 0.58 0.154
10 years 79 32.1 10.3 81 32.5 10.1 –1.19 –3.48 to 1.11 0.311
Diff., the estimated difference between treatments at that time point adjusted for minimisation covariates and surgeon – a
positive difference favours all-polyethylene components; n, the number of responses; SD, standard deviation.
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FIGURE 40 Mean (SD) OKS by group at each follow-up time point for all-polyethylene vs. metal-backed
tibial components.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
1 2 3 4 5 6 7 8 9 10
– 4
– 3
– 2
– 1
0
1
2
3
4
D
if
fe
re
n
ce
 in
 O
K
S
Estimated treatment
effect
Upper and lower
95% confidence
limits
Year
3
months
FIGURE 41 Estimated treatment effect on OKS (95% CI) at each follow-up time point for all-polyethylene vs.
metal-backed tibial components. Treatment effect is the estimated difference between treatments at that time
point adjusted for minimisation covariates and surgeon; a positive difference favours all-polyethylene components.
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FIGURE 42 Interaction term (solid line) at each follow-up time-point for OKS for patellar resurfacing by
all-polyethylene backing. Dotted lines represent 95% CIs.
DOI: 10.3310/hta18190 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 19with those allocated to no patellar resurfacing. A positive difference in differences suggests higher relative
beneﬁt for all-polyethylene backing in the patellar resurfacing group. The graph indicates that there may be
a potential interaction, suggesting that not resurfacing the patella, if using all polyethylene components,
might be beneﬁcial. However, there is considerable uncertainty around these estimates owing to the
reduced sample size in the partial factorial aspect of the trial and estimating CIs around interaction terms.
EuroQol 5D
There was a trend towards the metal-backed group having better EQ-5D scores than the all polyethylene
group (Figure 43). In 3 years (years 4, 5 and 9), the p-value was < 0.05 (Table 29, Figure 44). The marginal
estimate over the whole 10-year follow-up was –0.042 (95% CI –0.081 to –0.003; p = 0.033) in favour
of the metal-backed intervention (see Figure 44).
Short Form 12
There was a trend towards the metal-backed group having a signiﬁcantly better SF-12 PCS than the all
polyethylene group (Figure 45). In 3 years (3, 4 and 9) the p-value was < 0.05 (Table 30, Figure 46). The
marginal estimate over the whole 10-year follow-up was –1.63 (95% CI –3.19 to –0.069; p = 0.041) in
favour of the metal-backed intervention.
The SF-12 MCS was similar between the two groups at most time points (Table 31, Figure 47).
The marginal estimate over the whole 10-year follow-up was –0.22 (95% CI –1.73 to 1.29; p = 0.77),
a minimal difference between groups (Figure 48).79
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FIGURE 43 Mean (SD) EQ-5D utility by group at each follow-up time point for all-polyethylene vs. metal-backed
tibial components.
TABLE 29 Descriptive statistics and estimated treatment effects at each follow-up time point for
EQ-5D utility for all-polyethylene vs. metal-backed tibial components
Time point
All polyethylene Metal-backed
Diff. 95% CI p-valuen Mean SD n Mean SD
Baseline 196 0.357 0.319 196 0.402 0.314
3 months 179 0.644 0.239 182 0.682 0.251 –0.029 –0.080 to 0.022 0.27
1 year 178 0.690 0.237 176 0.720 0.265 –0.019 –0.071 to 0.032 0.47
2 years 174 0.690 0.272 163 0.719 0.262 –0.011 –0.063 to 0.041 0.68
3 years 163 0.675 0.257 165 0.730 0.246 –0.048 –0.101 to 0.005 0.074
4 years 159 0.673 0.262 163 0.738 0.238 –0.061 –0.114 to –0.008 0.024
5 years 153 0.638 0.300 149 0.717 0.240 –0.066 –0.120 to –0.012 0.017
6 years 146 0.648 0.284 145 0.680 0.278 –0.033 –0.087 to 0.022 0.24
7 years 139 0.650 0.299 135 0.697 0.248 –0.054 –0.109 to 0.002 0.059
8 years 122 0.622 0.295 130 0.678 0.249 –0.049 –0.106 to 0.008 0.093
9 years 113 0.593 0.313 116 0.692 0.232 –0.093 –0.152 to –0.034 0.002
10 years 83 0.625 0.302 88 0.650 0.239 –0.014 –0.079 to 0.050 0.661
Diff., the estimated difference between treatments at that time point adjusted for minimisation covariates and surgeon – a
positive difference favours all-polyethylene components; n, the number of responses; SD, standard deviation.
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80Clinical outcomes
There were 21/203 (10%) and 28/199 (14%) participants who were readmitted over the 10-year follow-up
period (Table 32) (odds ratio 0.72; 95% CI 0.39 to 1.31; p = 0.30). The reoperation rate for minor and
intermediate operations was very similar between the two groups (odds ratio 0.85; 95% CI 0.37 to 1.91;
p = 0.81), and the majority of these reoperations took place within the ﬁrst 5 years. Major reoperations
were slightly more common in the all polyethylene group, but were rare overall (odds ratio 2.32;
95% CI 0.52 to 14.16; p = 0.35). The majority of the major operations took place in the ﬁrst 5 years.
Time-to-failure analysis of time until the ﬁrst major reoperation estimated the hazard ratio as
2.30 (95% CI 0.60 to 8.90; p = 0.23; Figure 49), reﬂecting the higher number of reoperations in the all
polyethylene group, but the CI is wide owing to the low number of reoperations. For time to any
reoperation, the estimated hazard ratio was 0.85 (95% CI 0.44 to 1.68; p = 0.65; Figure 50). BroadeningNIHR Journals Library www.journalslibrary.nihr.ac.uk
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FIGURE 44 Estimated treatment effect on EQ-5D utility (95% CI) at each follow-up time point for all-polyethylene
vs. metal-backed tibial components. Treatment effect is the estimated difference between treatments at that time
point adjusted for minimisation covariates and surgeon; a positive difference favours all-polyethylene components.
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FIGURE 45 Mean (SD) SF-12 PCS by group at each follow-up time point for all-polyethylene vs. metal-backed
ibial components.
ABLE 30 Descriptive statistics and estimated treatment effects at each follow-up time point for SF-12 PCS for
ll-polyethylene vs. metal-backed tibial components
Time point
All polyethylene Metal-backed
Diff. 95% CI p-valuen Mean SD n Mean SD
Baseline 195 29.8 7.4 195 30.5 8.1
3 months 180 37.8 9.2 178 38.9 10.1 –0.79 –2.79 to 1.20 0.44
1 year 172 38.0 10.0 176 40.4 11.0 –1.81 –3.82 to 0.21 0.079
2 years 167 38.1 10.7 156 40.3 10.9 –1.63 –3.70 to 0.43 0.12
3 years 165 37.3 10.6 157 40.2 10.8 –2.68 –4.74 to –0.61 0.011
4 years 157 37.2 10.9 158 39.4 10.3 –2.11 –4.19 to –0.03 0.047
5 years 149 36.7 11.1 148 39.1 10.8 –1.93 –4.05 to 0.18 0.073
6 years 141 36.8 10.6 143 37.5 11.0 –0.28 –2.42 to 1.86 0.80
7 years 136 35.8 11.7 134 37.8 10.8 –2.02 –4.19 to 0.15 0.068
8 years 121 35.8 11.0 130 36.6 10.5 –0.45 –2.67 to 1.77 0.69
9 years 114 34.4 11.3 114 37.6 10.9 –2.78 –5.06 to –0.50 0.017
10 years 83 33.9 11.1 86 35.9 10.4 –1.46 –3.96 to 1.05 0.26
DOI: 10.3310/hta18190 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 19t
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aDiff., the estimated difference between treatments at that time point adjusted for minimisation covariates and surgeon – a
positive difference favours all-polyethylene components; n, the number of responses; SD, standard deviation.
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IGURE 46 Estimated treatment effect on SF-12 PCS (95% CI) at each follow-up time point for all-polyethylene vs.
etal-backed tibial components. Treatment effect is the estimated difference between treatments at that time
oint adjusted for minimisation covariates and surgeon; a positive difference favours all-polyethylene components.
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pTABLE 31 Descriptive statistics and estimated treatment effects at each follow-up time point for SF-12 MCS for
all-polyethylene vs. metal-backed tibial components
Time point
All polyethylene Metal-backed
Diff. 95% CI p-valuen Mean SD n Mean SD
Baseline 195 49.5 12.2 195 49.1 12.6
3 months 180 50.0 11.7 178 50.7 11.2 –1.14 –3.21 to 0.92 0.278
1 year 172 51.4 10.5 176 51.2 11.6 0.20 –1.89 to 2.29 0.853
2 years 167 51.0 10.2 156 51.4 10.2 –0.45 –2.59 to 1.70 0.683
3 years 165 50.4 10.2 157 50.1 10.3 0.12 –2.02 to 2.27 0.909
4 years 157 50.8 11.3 158 49.7 11.3 0.72 –1.44 to 2.88 0.515
5 years 149 49.1 11.4 148 49.4 11.9 –0.46 –2.66 to 1.75 0.685
6 years 141 49.2 11.7 143 50.4 10.8 –2.05 –4.28 to 0.19 0.073
7 years 136 50.5 11.5 134 49.7 11.0 0.04 –2.24 to 2.32 0.972
8 years 121 47.8 11.7 130 48.9 11.3 –1.46 –3.80 to 0.87 0.219
9 years 114 50.3 10.9 114 47.5 11.2 2.40 –0.01 to 4.81 0.051
10 years 83 49.9 12.0 86 48.1 10.7 0.24 –2.44 to 2.92 0.862
Diff., the estimated difference between treatments at that time point adjusted for minimisation covariates and surgeon – a
positive difference favours all-polyethylene components; n, the number of responses; SD, standard deviation.the deﬁnition of failure, to include any participant with an OKS after 1 year dropping below the baseline
reported OKS, resulted in a hazard ratio of 1.45 (95% CI 0.99 to 2.18; p = 0.056; Figure 51); participants
in the all polyethylene group were more likely to fail by this deﬁnition.
Cost comparison
The subset of participants for whom surgeons were in equipoise about whether to give an all-polyethylene
or metal-backed tibial component tended to have a shorter operation time than those randomised in
either of the other two comparisons (105 minutes for all polyethylene and 109 minutes for metal-backed,
vs. 120 minutes for other comparisons; Table 33). On average, operation time was 4.5 minutes shorter forNIHR Journals Library www.journalslibrary.nihr.ac.uk
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IGURE 47 Mean (SD) SF-12 MCS by group at each follow-up time point for all-polyethylene vs. metal-backed
ibial components.
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IGURE 48 Estimated treatment effect on SF-12 MCS (95% CI) at each follow-up time point for all-polyethylene vs.
etal-backed tibial components. Treatment effect is the estimated difference between treatments at that time
oint adjusted for minimisation covariates and surgeon; a positive difference favours all-polyethylene components.
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pparticipants randomised to receive all-polyethylene tibial components than for those in the metal-backed
group (p = 0.14).
Conversely, the average participant randomised to all-polyethylene tibias tended to stay 0.7 days longer
in hospital (p = 0.16). The cost of postoperative complications was similar in the two groups, although the
cost of further surgery to the knee during the hospital stay was more than twice as high in the group
randomised to all-polyethylene tibias.
All-polyethylene tibial components were 42% less expensive than metal-backed tibial components,
equating to a saving of £362 per participant (p < 0.001). This is primarily because for the all-polyethylene
tibias a single monoblock polyethylene component was required, whereas for the metal-backed tibias
a polyethylene bearing was required in addition to a metallic tibial component. However, there was no
signiﬁcant difference in the number or cost of patellas, femoral components or other components used
between the randomised groups (all p > 0.05).
Although the non-signiﬁcant increase in length of stay partially offset the savings from using cheaper tibial
components and reducing operation time, the overall cost of the inpatient stay was £208 (95% CI –£131
to £546) lower for the all polyethylene group than for those randomised to metal-backed tibial
components (p = 0.23).83
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ABLE 32 Readmissions up to a median of 10 years post operation for all-polyethylene vs. metal-backed
ibial components
Readmission type
All polyethylene
(N = 203)
Metal-backed
(N = 199)
n % n %
Total readmissions 33 34
No. of participants requiring at least one readmission 21 10 28 14
Minor/intermediate operations
Total number operations 20 19
Participants requiring
At least one minor operation 14 7 16 8
Multiple minor operations 4 2 2 1
Number requiring at least one of
Debridement/exploration/washout 1 < 1 1 < 1
MUA 5 2 8 4
Arthroscopy EUA/biopsy 6 3 7 3
Drain abscess 1 < 1
Exchange poly 2 1 1 < 1
Removal of patella button 1 < 1
Late patellar resurfacing 1 < 1
Patella revision 1 < 1
Major operations
Total number of operations 7 3
Participants requiring at least one major operation 7 3 3 1
Number requiring at least one of
Above-knee amputation 1 < 1 1 < 1
Revision for aseptic loosening 2 1 2 1
Revision for instability 1 < 1
Revision for pain 2 1
Revision for malalignment 1 < 1
EUA, examination under anaesthetic; MUA, manipulation under anaesthetic.
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84T
tHowever, the all polyethylene group tended to have higher levels of knee-related resource use during the
10 years after discharge from hospital. Although the number of readmissions was approximately the same
in each group (p = 0.94), those participants in the all polyethylene group who were readmitted tended
to have slightly more costly procedures (mean cost of readmission £4744, vs. £4292 in the metal-backed
group; p = 0.79). This is likely to reﬂect the higher number of one-stage revisions in the all polyethylene
group (see Table 32). As a result, the average cost of readmissions per participant was slightly higher in
the all polyethylene group (p = 0.87). This trend was most pronounced in year 2, although the cost of
readmissions was higher in the metal-backed group in year 1 and highly variable in subsequent years (see
Figure 52). All-polyethylene components were also associated with a 17% increase in orthopaedic
outpatient consultations (p = 0.18) and a 33% increase in physiotherapy consultations (p = 0.08). The trend
towards higher numbers of physiotherapy and outpatient visits in the all polyethylene group was observed
in every year except years 5 and 9 (see Figure 52).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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FIGURE 49 Kaplan–Meier failure curves for time to ﬁrst major reoperation for all-polyethylene vs. metal-backed
tibial components.
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FIGURE 50 Kaplan–Meier failure curves for time to any reoperation for all-polyethylene vs. metal-backed
tibial components.
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FIGURE 51 Kaplan–Meier failure curves for time to any reoperation or OKS dropping below baseline level at 1 year
or later for all-polyethylene vs. metal-backed tibial components.
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86The increased cost of readmissions and ambulatory follow-up offset nearly all of the savings from
all-polyethylene components that were observed in the primary hospital stay. As a result, the total cost
over the 10-year time horizon was almost identical in the two groups (£8225 for all polyethylene vs.
£8235 for metal-backed; p = 0.98).Within-trial cost-effectiveness results
Base-case analysis
As was the case for the mobile bearing comparison, total cost in years 3–12 was primarily driven by
readmissions and was low in the years in which no participants were admitted (Figure 52). Nonetheless,
incremental cost was higher in the all polyethylene group in all years other than year 1 (in which costs
were driven by the cost of the primary TKR procedure) and years 5 and 9 (in which the metal-backed
group had more readmissions and more outpatient consultations; Table 34).
However, QALYs showed a consistent trend over the ﬁrst 10 years after primary TKR, being consistently
(but not statistically signiﬁcantly) lower in the all polyethylene group than in those randomised to
metal-backed tibial components at every time point (minimum p = 0.06). The difference in QALYs tended
to increase over time, suggesting that the long-term beneﬁts of metal-backed components may be greater
than is observed with a 10-year time horizon. This trend appears to be a result of increasing differences
in quality of life, as life expectancy was actually around 36 days longer in the all polyethylene
group (p = 0.66).
Over the 10-year time horizon, the incremental cost of all-polyethylene tibial components compared with
metal-backed components was –£10 (95% CI –£872 to £851; p = 0.98), whereas the incremental QALY
gain was –0.293 (95% CI –0.706 to 0.119; p = 0.16). The evidence from KAT therefore suggests that
all-polyethylene tibial components are less costly and less effective than metal-backed components, with
the point estimate lying in the ‘south-west’ quadrant of the cost-effectiveness plane (Figure 53). In
principle, treatments that are cost-saving and less effective than their comparators could increase the
amount of health generated by NHS treatments, by freeing up resources that can be invested in other
treatments that generate greater health gains than those lost by using the less effective treatment. Based
on the £20,000 ceiling ratio typically used in NHS decision-making and assuming that the NHS has
symmetrical preferences for losses and gains, treatments that are less effective and less costly would be
considered good value for money if they saved at least £20,000 per QALY lost.
The base-case KAT results suggest that the NHS would save £10 and lose 0.293 QALYs for every
participant treated with all-polyethylene tibial components rather than metal-backed components, which
equates to an ICER of just £35 per QALY lost. This is substantially below the £20,000/QALY threshold,
suggesting that all-polyethylene components are poor value for money and should not be used in place of
metal-backed components, which cost just £35 per QALY gained compared with all polyethylene.
However, there is a modest amount of uncertainty around both incremental costs and incremental QALYs
(see Figure 53). In particular, there is an 8% chance that all-polyethylene tibial components are more
effective than metal-backed components and a 47% chance that they are more costly.
Taking account of the joint density of incremental costs and QALYs demonstrates that there is a 91%
probability that metal-backed tibial components are good value for money compared with all-polyethylene
components at a £20,000/QALY ceiling ratio (Figure 54).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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IGURE 52 Illustration of cost breakdown by year after discharge from hospital for all-polyethylene
s. metal-backed tibial components. Error bars show SEs around total cost.
ALL-POLYETHYLENE VERSUS METAL-BACKED TIBIAL COMPONENTSF
v88Sensitivity analyses
Sensitivity analyses suggested that the all polyethylene group accrued higher costs than the metal-backed
group in four scenarios (Table 35). First, as expected, increasing the discount on knee components, such
that hospitals pay only 50% (not 70%) of the list price, reduces costs in the metal-backed group more
than in the all polyethylene group. Second, increasing the cost per bed-day to £448/day (50% higher than
the national average excess bed-day cost in England and Wales) increases the cost in the all polyethylene
group more than in the metal-backed group because of the longer primary hospital stay and additional
readmissions. Third, if future costs and beneﬁts are not discounted to current values, costs increase
proportionately more in the all polyethylene group, as the additional costs accrued beyond year 1 are
given greater weight. Fourth, reducing the time horizon and excluding costs accrued in years 9 and
10 changes the conclusions owing to the readmission and outpatient/physiotherapy consultations that
occurred in the all metal-backed group in year 9. In other analyses, the magnitude of the cost savings
varied from £1 to £156.
As the imbalance in baseline utility was larger in this comparison than in those with greater participant
numbers, adjusting for baseline utility had the greatest effect on QALYs. However, no sensitivity analyses
changed the conclusion that the all polyethylene group accrued non-signiﬁcantly fewer QALYs than the
metal-backed group, although the incremental QALYs varied between –0.145 and –0.370. Similarly, the
point estimates in all analyses conﬁrmed the base-case ﬁnding that all polyethylene is poor value for
money, being dominated by metal-backed components or having a low cost-effectiveness ratio in the
south-west quadrant in all analyses. The probability that all-polyethylene tibial components represent
good value for money varied between 5% and 12%, but never reached conventional levels of
statistical signiﬁcance.Subgroup analyses
Examining how incremental costs and beneﬁts vary with age is of particular relevance for this comparison,
as all-polyethylene components are often given on cost grounds to older participants who are not
expected to outlive their knee prostheses. However, the results appear to suggest that this practice is
unjustiﬁed. Although in both arms participants aged ≥ 70 years had higher costs than younger
participants, the increase in costs with age was substantially larger for participants randomised to allNIHR Journals Library www.journalslibrary.nihr.ac.uk
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FIGURE 53 Stochastic cost-effectiveness results for all-polyethylene vs. metal-backed tibial components: scatter
graph on cost-effectiveness plane.
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FIGURE 54 Cost-effectiveness acceptability curve for all-polyethylene vs. metal-backed tibial components.
ALL-POLYETHYLENE VERSUS METAL-BACKED TIBIAL COMPONENTS
90polyethylene (see Table 35). As a result, the all polyethylene arm had non-signiﬁcantly higher costs than
the metal-backed arm in the older age group, and all-polyethylene components were therefore dominated
by metal-backed components. This analysis, therefore, suggests that all-polyethylene tibial components are
poor value for both age groups and may be more costly and particularly ineffective in older participants.Potential for interactions between metal backing and patellar resurfacing
We also examined whether there is evidence of an interaction between metal backing and patellar
resurfacing in the subgroup of 145 participants who were also randomised in the patella comparison.
Analysing the data for these participants as a factorial trial suggests that there are qualitative interactions
between metal backing and patellar resurfacing for costs (p = 0.577), QALYs (p = 0.047) and net monetary
beneﬁt (p = 0.060) that change the conclusions of the analysis, although the interaction for costs could
easily be explained by chance. These qualitative interactions mean that both costs and QALYs are
substantially higher in the group randomised to all-polyethylene tibial components and no patellar
resurfacing and the group randomised to metal-backed tibial components and patellar resurfacing (see
Table 35) than in the other two groups. As a result, all-polyethylene components appear to be poor value
for money in the patellar resurfacing group (saving £429 per QALY lost), but good value for money in
those participants randomised to no patellar resurfacing (costing £512 per QALY gained). However, the
results of this sensitivity analysis should be interpreted with great caution, as it is based on a small number
of participants and the large non-signiﬁcant interactions observed could easily have arisen by chance.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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ALL-POLYETHYLENE VERSUS METAL-BACKED TIBIAL COMPONENTS
94DiscussionIn this study we found improved outcome scores for metal-backed compared with all-polyethylene tibial
components and found metal backing to be cost-effective. The patterns of results for OKS, SF-12 and
EQ-5D were similar, all favouring metal backing and being statistically signiﬁcant for SF-12 and EQ-5D.
There was, however, no difference in complication, reoperation or revision rates. These ﬁndings are
different from those of previous RCTs and meta-analyses of the RCTs,32,34 in which no difference in
outcome was found. However, KAT is much larger than most previous RCTs and primarily assessed
patient-reported outcome measures. Previous studies, which did not include a formal assessment of costs
and cost-effectiveness, have concluded that all-polyethylene implants are more cost-effective, as the
implant costs less and as the outcome is the same.33,34 These studies, therefore, recommended that
all-polyethylene implants should be used, particularly in the elderly. However, 10-year data from KAT,
which is the only RCT with a full economic evaluation, does not support this conclusion and suggests that
metal-backed implants should be used – and particularly in the elderly.
Surgeons tend to prefer metal-backed tibial components because of their modularity, which makes the
surgery easier. In addition, the modularity should theoretically improve the functional outcome, as, after
cementing, the surgeon can select the appropriate thickness of polyethylene to achieve optimal ligament
tension, and the appropriate constraint to achieve optimal stability. The study does show a functional
beneﬁt from the metal-backed tibial components, although the marginal estimate of the beneﬁt of the
metal-backed component over the whole trial period was statistically signiﬁcant only for EQ-5D and
SF-12 PCSs and not for OKS. It is surprising that the difference was signiﬁcant for the generic scores rather
than the knee-speciﬁc score. Further investigation of this is required.
All-polyethylene tibial components should have fewer problems with wear and osteolysis than
metal-backed tibial components. This is because they have thicker polyethylene, which decreases articular
surface wear, and, as there is no modular junction, they can have no backside wear. The loading at the
bone–cement interface and within the cancellous bone will be different with the two component designs.
It is debatable which type of loading is best and, therefore, which will be associated with the lowest
loosening rate. It is therefore possible that there will be a difference in the revision rate between the two
designs, even though previous studies have not shown one.90,91 If there is a difference, it will be most
marked in the long term. At 10 years there is a slightly, but not signiﬁcantly, higher revision rate for the
all-polyethylene tibial component. Longer follow-up is required to determine if this difference in
revision rates increases.
The economic evaluation indicates that we can be 91% conﬁdent that all-polyethylene tibial components
are poor value for money. Although all-polyethylene components are cheaper than metal-backed
components initially, the cost savings are offset by non-signiﬁcant increases in the primary hospital stay
and the cost of readmissions, outpatient consultations and physiotherapy, such that estimated total costs
over the 10-year time horizon were just £10 lower in the all polyethylene group (p = 0.98). Participants
randomised to all-polyethylene tibial components also had a lower quality of life at all time points and
accrued 0.293 fewer QALYs than those randomised to metal-backed components (p = 0.16). As the
potential savings were insufﬁcient to warrant the observed reduction in health, all-polyethylene
components are expected to be poor value for money, with metal backing costing just £35 per QALY
gained compared with all-polyethylene. Our analysis assumes that decision-makers have symmetrical
preferences and that their willingness to accept QALY losses to realise savings is equal to their willingness
to pay for QALY gains. If decision-makers were averse to QALY losses and used a higher ceiling ratio
than £20,000 per QALY lost in the south-west quadrant, the probability that all-polyethylene tibial
components are poor value for money would be > 91%. Furthermore, subgroup analyses suggested
that all-polyethylene components are particularly ineffective and may increase total costs in participants
aged ≥ 70 years, suggesting that the use of all-polyethylene components as a less costly option in older
participants is inappropriate. Sensitivity analyses suggested that the conclusions are robust to changes
in the methods and assumptions used in the analysis.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18190 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 19There was some (non-signiﬁcant) evidence of an interaction between patellar resurfacing and metal
backing. In particular, subgroup analyses suggested that patients randomised to all polyethylene and no
resurfacing and metal backing with resurfacing accrued more QALYs than the other two combinations.
However, these observed interactions could be explained by chance and we are not aware of a good
clinical explanation for why they occur. Further investigation into the potential for clinical, kinematic
or statistical interactions between patellar resurfacing and metal backing is warranted.ConclusionIn this large 10-year pragmatic RCT, we have found that the functional results with a metal-backed tibial
component are better than with an all-polyethylene tibia. Although the complication, reoperation rates
and revision rates are similar, there is a concern that in the longer term there may be an increased revision
rate with the all-polyethylene tibia. The metal-backed tibia was also cost-effective compared with the
all-polyethylene tibia, with secondary analyses suggesting that metal backing is better (rather than worse)
value for money in participants aged ≥ 70 years. This study provides an evidence base supporting the
routine use of metal-backed tibias in all patients. The study does not support the previous general
recommendation that all-polyethylene tibias should be used to save money in the elderly;33,34 indeed,
it suggests that it not only is more costly in the elderly but also generates fewer QALYs.95
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knee replacementDescription of the groups at trial entryOf the 2374 participants randomised, 34 were recruited to the comparison assessing unicompartmental
knee replacement versus TKR.Description of data available for those recruitedA description of the group of participants recruited to this comparison is in Table 36.
Outcomes after a median of 10 years post operationOxford Knee Score
Table 37 and Figure 55 describe OKS over the 10-year follow-up period by allocated group.
EuroQol 5D
Table 38 and Figure 56 describe EQ-5D over the 10-year follow-up period by allocated group.
Short Form 12
Table 39 and Figure 57 describe the SF-12 PCS over the 10-year follow-up period by allocated group.
Table 40 and Figure 58 describe SF-12 MCS over the 10-year follow-up period by allocated group.
Discussion
Recruitment to this arm of the trial was very slow and was therefore terminated early. Prior to stopping,
34 patients had been recruited. As there has been only one other randomised trial of unicompartmental
knee replacement versus TKR, it was felt that the clinical scores should be described.92 No difference was
found, as would be expected with small numbers. Complications, reoperations and revisions were not
analysed, as it was felt the numbers were too small for this analysis to be of any value. The data from
KAT has therefore not contributed signiﬁcantly to the debate about whether unicompartmental knee
replacement should or should not routinely be used. The experience gained from KAT has, however,
been very useful in the planning of another randomised study of unicompartmental knee replacement
and TKR – TOPKAT (Total Or Partial Knee Arthroplasty Trial).93
During the planning and application for funding stages of KAT, unicompartmental replacements were
implanted through the standard approach used for TKR and many surgeons had equipoise about the
two types of replacement. We should, therefore, have been able to recruit, using the standard KAT
methodology, an appropriate number of patients for the trial. However, prior to starting the recruitment,
a new, minimally invasive technique for implanting unicompartmental replacement was introduced. This
has many advantages over the standard approach, including a faster recovery, lower morbidity and
improved function. As a result, many surgeons who would have recruited to the trial instead learnt the
minimally invasive technique. In addition, some surgeons lost their equipoise. As a result, the recruitment
rate was very much lower than predicted. The new trial, TOPKAT, was therefore designed differently from
KAT in that it has two options. Surgeons with equipoise are able to randomise in a standard fashion,
whereas surgeons who do not have equipoise can use an expertise-based randomisation. As most97
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TABLE 36 Description of groups at trial entry for unicompartmental knee replacement vs. TKR
Characteristic Unicompartmental (n = 18) TKR (n = 16)
Age (years) (mean, SD) 66 7 67 8
Female 10 56 9 56
BMI (kg/m2) (mean, SD) 29.8 3.7 28.7 5.0
ASA
Completely ﬁt and healthy 2 11 3 19
Some illness but has no affect on normal activity 13 72 8 5
Symptomatic illness present but minimal restriction 2 11 2 13
Symptomatic illness causing severe restriction 0 0
Missing 1 6 3 19
Primary type of knee arthritis
Osteoarthritis 18 100 15 94
Rheumatoid 1 6
Extent of knee arthritis affecting mobility
One knee 2 11 3 16
Both knees 10 56 6 38
General 6 33 7 44
n = 18 n = 16
Other conditions affecting mobility 1 6 2 13
Locomotor/musculoskeletal 1 6 2 13
n = 18 n = 16
Previous knee surgery 7 39 4 25
Ipsilateral osteotomy 1 6
Ipsilateral patellectomy
Contralateral previous knee replacement 4 22 2 13
Other previous knee surgery 3 17 2 13
Arthroscopy 2 11 1 6
Other related surgery 1 6
SD, standard deviation.
Cell contents are n and per cent unless otherwise stated.
UNICOMPARTMENTAL VERSUS TOTAL KNEE REPLACEMENT
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TABLE 37 Descriptive statistics and estimated treatment effects at each follow-up time point for OKS for
unicompartmental knee replacement vs. TKR
Time point
Unicompartmental TKR
n Mean SD n Mean SD
Baseline 18 21.7 8.0 15 18.1 7.5
3 months 13 30.7 10.1 12 32.8 8.1
1 year 13 34.1 12.8 13 33.8 9.8
2 years 12 38.3 7.3 13 35.2 10.7
3 years 17 37.5 7.5 14 33.4 10.5
4 years 14 36.6 9.3 14 33.9 9.9
5 years 14 36.0 11.0 15 36.9 10.5
6 years 14 35.1 10.9 15 36.9 10.3
7 years 13 35.0 8.3 14 33.8 9.6
8 years 14 34.2 8.9 12 34.9 10.6
9 years 14 32.0 9.3 11 35.7 8.3
10 years 13 31.2 9.7 10 34.1 11.3
n, the number of responses; SD, standard deviation.
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FIGURE 55 Mean (SD) OKS by group at each follow-up time point for unicompartmental knee replacement
vs. TKR.
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TABLE 38 Descriptive statistics and estimated treatment effects at each follow-up time point for EQ-5D for
unicompartmental knee replacement vs. TKR
Time point
Unicompartmental TKR
n Mean SD n Mean SD
Baseline 18 0.447 0.312 15 0.428 0.300
3 months 16 0.686 0.193 14 0.732 0.124
1 year 16 0.717 0.282 15 0.698 0.206
2 years 15 0.820 0.120 16 0.741 0.242
3 years 17 0.803 0.147 15 0.769 0.158
4 years 16 0.775 0.149 14 0.694 0.218
5 years 14 0.835 0.166 15 0.741 0.180
6 years 14 0.715 0.272 15 0.757 0.193
7 years 15 0.728 0.206 15 0.690 0.177
8 years 15 0.724 0.250 14 0.701 0.272
9 years 15 0.690 0.087 11 0.697 0.207
10 years 13 0.649 0.110 10 0.685 0.259
n, the number of responses; SD, standard deviation.
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FIGURE 56 Mean (SD) EQ-5D utility by group at each follow-up time point for unicompartmental knee replacement
vs. TKR.
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TABLE 39 Descriptive statistics and estimated treatment effects at each follow-up time point for SF-12 PCS for
unicompartmental knee replacement vs. TKR
Time point
Unicompartmental TKR
n Mean SD n Mean SD
Baseline 16 34.5 8.5 15 31.0 7.4
3 months 15 40.4 7.2 14 37.2 9.4
1 year 15 43.7 11.1 15 40.8 8.9
2 years 15 43.2 5.5 15 41.9 10.2
3 years 17 41.6 9.1 15 41.3 11.4
4 years 15 41.0 8.9 14 40.5 10.8
5 years 15 42.5 11.4 15 43.7 10.4
6 years 15 41.5 11.8 14 42.6 10.2
7 years 14 41.6 9.7 15 39.5 9.1
8 years 14 40.9 9.1 13 40.8 10.1
9 years 15 35.9 8.1 11 37.2 10.3
10 years 12 35.5 8.7 10 39.6 9.9
n, the number of responses; SD, standard deviation.
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FIGURE 57 Mean (SD) SF-12 PCS by group at each follow-up time point for unicompartmental knee replacement
vs. TKR.
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TABLE 40 Descriptive statistics and estimated treatment effects at each follow-up time point for the SF-12 MCS for
unicompartmental knee replacement vs. TKR
Time point
Unicompartmental TKR
n Mean SD n Mean SD
Baseline 16 49.4 11.9 15 48.7 9.9
3 months 15 50.0 10.5 14 54.1 10.2
1 year 15 51.1 8.7 15 53.1 10.1
2 years 15 52.6 7.7 15 51.1 10.9
3 years 17 51.7 10.7 15 52.3 9.9
4 years 15 52.3 10.8 14 48.4 11.1
5 years 15 47.6 9.8 15 46.4 10.1
6 years 15 48.5 8.5 14 48.9 9.9
7 years 14 47.6 10.4 15 49.1 9.5
8 years 14 47.6 9.4 13 51.4 11.5
9 years 15 48.0 10.9 11 51.8 11.7
10 years 12 46.3 6.1 10 48.9 8.2
n, the number of responses; SD, standard deviation.
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IGURE 58 Mean (SD) SF-12 MCS by group at each follow-up time point for unicompartmental knee replacement
s. TKR.
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vsurgeons have now learnt the minimally invasive technique, many more are now willing to be involved in
the standard randomisation arm. In the expertise-based option of the trial, patients who are appropriate
for the study are randomised and then either have a unicompartmental replacement implanted by a
surgeon who believes in unicompartmental replacement or a total replacement implanted by a surgeon
who believes in total replacement. The TOPKAT study, which has been funded by the NIHR HTA board,
ﬁnished its recruitment in September 2013 (HTA project reference number 08/14/08).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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future researchPatellar resurfacing versus no patellar resurfacingCurrently there is great variability in the use of resurfacing both in the NHS and world-wide. This is
primarily because some surgeons believe in resurfacing and some do not. In addition, a small proportion
of surgeons resurface the patella in some patients and not others. With some designs of knee
replacement, the trochlea is anatomically shaped. This design is considered patella-friendly and to perform
well without patella replacement. Previous studies have not clearly demonstrated whether or not it is
preferable to resurface the patella, or whether this depends on the design of the knee replacement, the
state of the patella or other patient factors.
In this pragmatic study, which is substantially larger than previous RCTs, we found no signiﬁcant difference
in clinical outcome, in terms of pain and function (assessed by OKS, EQ-5D or SF-12), complications,
readmission or reoperations between patients with and without patellar resurfacing (Table 41). There was
also no signiﬁcant difference in the incidence of patella-related reoperations. However, as there was a
non-signiﬁcant trend towards improved quality of life (0.187 QALYs per patient treated) and decreased
costs (£104 per patient treated) associated with resurfacing, patellar resurfacing was cost-effective. The
KAT results indicate a 96% probability that patellar resurfacing is cost-effective at a £20,000/QALY ceiling
ratio. Sensitivity analyses indicated that this conclusion was generally robust. Subgroup analyses also
suggested patellar resurfacing is more cost-effective in patients aged < 70 years, although it remains good
value for money in patients aged ≥ 70 years. The study, therefore, provides an evidence base supporting
routine resurfacing of the patella in all patients.
We did not ﬁnd evidence that the outcome of patellar resurfacing is inﬂuenced by whether the femoral
component had a trochlea designed to ﬁt an anatomical patella button or a domed patella button; the
trial ﬁndings therefore apply whether or not the femoral component is considered to be patella-friendly.
We also found that late patellar resurfacing had little or no beneﬁt, suggesting that, if a patient has not
had patellar resurfacing, late resurfacing should be avoided if possible.
Further research is needed: with increasing follow-up, there was an increasing number of reoperations for
complications of resurfacing and a decreasing number of late patellar resurfacing procedures. Some of the
complications resulting from resurfacing, such as patella fracture, require complex reconstructions and may
be associated with poor outcomes. The operations for patella complications are undertaken in patients
who have had resurfacing, whereas the late resurfacings are undertaken in patients who have not had
resurfacing. Therefore, there is a concern that after 10 years the rate of complications and reoperations in
the resurfaced patella group will increase more than in the non-resurfaced group. If there is a substantial
increase in the reoperation rate in the resurfaced group, particularly if it is associated with a worsening
clinical outcome resulting from resurfacing complications, our conclusion that the patella should routinely
be resurfaced would change. Follow-up to 15 and 20 years is required.
Late patellar resurfacing, overall, had little effect on outcome. However, this does not necessarily mean
that no patients improved after late resurfacing. Further research is required to understand the factors
associated with a good or poor outcome after late resurfacing. If guidelines that advised against late
resurfacing of the patella were made and adhered to, the beneﬁt of resurfacing might disappear.
We found some evidence of an interaction between patellar resurfacing and mobile bearings and
all-polyethylene tibias. This needs to be explored in more depth to determine if this is a real effect,
or just chance.103
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Murray et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
TABLE 41 Summary of ﬁndings from each chapter
Outcome
Patellar resurfacing vs. no
resurfacing Mobile vs. ﬁxed bearings
All-polyethylene vs.
metal-backed tibial
components
Functional (OKS) Small but consistent difference in
favour of patellar resurfacing;
95% CI suggests MCID unlikely;
treatment effect not modiﬁed by
patella shape
Similar between groups Consistent beneﬁt favouring
metal-backed, not statistically
signiﬁcant
Quality of life
(EQ-5D utility,
SF-12 PCS and
MCS)
Similar between groups Similar between groups Similar pattern to OKS but
statistically signiﬁcant
differences found
Reoperation Similar between groups Similar in both groups;
however, ﬁve participants
required reoperation for
instability or dislocation in the
mobile bearing group
Similar between groups
Incremental
QALYs (95% CI)
0.187 (–0.025 to 0.399; p = 0.08) 0.051 (–0.333 to 0.435;
p = 0.79)
–0.293 (–0.706 to 0.119;
p = 0.16)
Incremental costs
(95% CI) (£)
–104 (95% CI –630 to 423;
p = 0.70)
85 (–911 to 1081; p = 0.87) –10 (–872 to 851; p = 0.98)
Base-case cost-
effectiveness
result
Patellar resurfacing dominates no
resurfacing, with a 96% probability
of being cost-effective
Mobile bearings cost £1666
per QALY gained vs. ﬁxed
bearing, with a 59%
probability of being
cost-effective
All polyethylene saves £35 per
QALY lost vs. metal-backed,
with a 9% probability of being
cost-effective
Sensitivity analysis
results
Complete case ﬁnds resurfacing
not cost-effective
Complete case and
per-protocol analyses ﬁnd
mobile bearings dominated
Conclusions robust to changes
in methods other than
assumptions about interactions
Subgroup analysis
results
Cost-effective in both age
subgroups. Probability of being
cost-effective: 97% in participants
< 70 years, 74% in participants
≥ 70 years
Cost-effective in participants
< 70 years (86% probability),
but not ≥ 70 years
(24% probability)
All polyethylene is poor use of
resources in age subgroups.
Probability of being
cost-effective: 46% in
participants < 70 years, 5% in
participants ≥ 70 years
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104Mobile bearing versus ﬁxed bearingMobile bearings were introduced to minimise wear. They achieve this by having larger areas of contact
and thus lower contact stresses. However, their advantage of decreased wear may be nulliﬁed by them
having more articulating surfaces. Improved wear should result in a decrease in long-term failure rate.
Mobile bearings can also be used to alter the kinematics of the knee replacement. Improved kinematics
should result in an improved functional outcome. The main theoretical disadvantage is instability and
dislocation of the mobile bearing. In addition, mobile-bearing devices tend to be more expensive than
ﬁxed-bearing devices. Previous studies have shown no clear advantage or disadvantage of mobile bearings.
We found no deﬁnite advantage or disadvantage of mobile bearings in terms of postoperative functional
status, quality of life, reoperation and revision rates, or cost-effectiveness (see Table 41). We did, however,
identify two disadvantages of mobile bearings that could encourage surgeons to use ﬁxed-bearing devices.
First, there was a 2% incidence of instability or bearing dislocation in the mobile bearing group and none
in the ﬁxed bearing group. Second, although there was no signiﬁcant difference in overall costs in the
long term, there was a short-term saving for the hospital, as ﬁxed bearings are appreciably cheaper than
mobile bearings.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18190 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 19Further follow-up of the cohort would allow assessment of the long-term beneﬁts, risks and costs of
mobile bearings. The main theoretical advantage of mobile bearings is decreased wear. Wear can cause
failure of knee replacement either mechanically, if the bearing is worn through, or through loosening and
osteolysis. Both modes of failure require revision surgery. Failure due to wear tends to occur in the second
decade after knee replacement. Therefore, if decreased wear were a real as well as a theoretical
advantage of mobile bearings, it would probably be seen in the second decade. Follow-up of the patients
in KAT at least to 15 years would clarify this.
Within the health economic analysis, trends were observed which, if they persist in the long term, will
have important implications. The current evidence suggests that patients treated with mobile bearings are
expected to have marginally higher QALYs which are sufﬁcient to justify the small increased cost. There is,
however, substantial uncertainty around this ﬁnding. In particular, there is some evidence that the beneﬁts
of mobile bearings are short lived, with the group assigned to mobile bearings tending to have higher
costs and accrue fewer QALYs from the fourth year after TKR onwards. In the secondary analyses of the
subgroup of patients < 70 years, the ﬁndings were somewhat stronger than those in the cohort as a
whole. In particular, there was an estimated 86% probability that mobile bearings were cost-effective at
a £20,000/QALY ceiling ratio. If mobile-bearing knee replacements are cost-effective, they are likely to be
most cost-effective in the young active patients, as theoretically they should provide better function and
longevity. It may be, therefore, in the long term that mobile bearings are cost-effective in patients aged
< 70 years, whereas in patients aged ≥ 70 years ﬁxed bearings may dominate, generating more QALYs
and being less expensive. Again, longer term follow-up would help to determine if this is the case.All polyethylene versus metal-backedCurrently metal-backed tibial components are used for most knee replacements. Previous randomised trials
and meta-analyses of these trials found no difference in clinical outcome between the two types of tibial
component. As all-polyethylene components are substantially cheaper than metal-backed components, the
general recommendation within the orthopaedics community is that, in the elderly, all-polyethylene devices
should be used so as to save money.33,34 There have, however, not been any formal economic analyses to
support this recommendation.
We found that the functional results with a metal-backed tibia were better than those with an
all-polyethylene tibia (see Table 41). This difference was statistically signiﬁcant when the function was
assessed with the EQ-5D and SF-12, but not with the OKS. The complication and reoperation rates
were similar. There was a non-signiﬁcant trend towards a higher major reoperation rate with the
all-polyethylene tibia. The economic analysis indicated that the initial cost saving, resulting from the
all-polyethylene tibia being cheaper, was offset by higher subsequent costs such that overall the costs
of the two types of tibia were similar. However, as metal-backed components were found to be more
effective, there was a 91% probability that metal backing is cost-effective compared with all-polyethylene
components, costing £35 per QALY gained. Previous recommendations suggested that metal-backed tibias
would be less cost-effective than the all-polyethylene tibias in older people; however, we found the
opposite: metal-backed tibial components were more cost-effective in patients ≥ 70 years than in younger
patients, but were cost-effective in both age groups. This suggests that routinely using the metal-backed
tibia in all patients would be good value for money. Hence, we believe that the previous recommendation
that all-polyethylene tibias should be used to save money in the elderly is incorrect. Although initially they
save money for the hospital, overall they will cost the health service more and are less effective.105
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106Further follow-up would provide very useful clariﬁcation. Theoretically, one would expect differences in the
revision rates of all-polyethylene and metal-backed tibias in the long term. All-polyethylene designs are
likely to have fewer problems due to wear, as they tend to have thicker polyethylene and as there is no
possibility of backside wear between the polyethylene and the metal backing. In addition, the transmission
of load to the proximal tibia is different, so there may be a difference in loosening rates. Up to 10 years
we found a non-signiﬁcantly higher incidence of major reoperations in the all-polyethylene group. As the
incidence of revision tends to increase with time, longer follow-up would clarify whether or not this
is a real difference. There was also some conﬂicting evidence about the functional advantages of the
metal-backed tibia. Although the patterns of results were similar, the OKS did not demonstrate a
signiﬁcant advantage, whereas the EQ-5D and SF-12 did. Further follow-up would clarify this.Unicompartmental versus total knee replacementThe question of whether unicompartmental knee replacements should be widely used or not remains a
topical and controversial issue. Potentially, they could offer appreciable advantages compared with TKRs.
Unfortunately, because of inadequate recruitment, we were not able to address this subject. The
experience gained from KAT has, however, been very useful, as it provided the necessary background
information for planning of another study, TOPKAT, to address this issue. TOPKAT ﬁnished recruitment in
September 2013.General implications for clinical practice from the trial
as a wholeTaken together, the results of the randomisations provide evidence to support routine resurfacing of the
patella and the use of metal-backed tibial components, and suggest mobile bearings should be used with
caution and probably only in younger patients.
In each of the randomisations, some differences among the various arms were observed. For the functional
outcome scores, the differences tended to be relatively small. For reoperations and revisions, although the
relative differences were large, the absolute differences were small because the overall reoperation and
revision rates were low. For the health economic outcomes, the differences were clearer. Surgeons should
be aware of this when selecting implants and should adopt more expensive devices only when there is
evidence to support this.
If failure is deﬁned as a reoperation or OKS being less than it was preoperatively, then at 10 years the
cumulative failure rate is about 30%. This is a relatively large ﬁgure and patients should be warned about
this preoperatively. Further work is also needed to improve implant design and techniques. However, it
does not necessarily mean that 30% of patients end up with a poor result. This is partly because with time
the OKS may improve, and also because patients usually have a satisfactory outcome from reoperations or
revision surgery. At 10 years about 90% of patients have a better OKS than they did preoperatively.
Comparing the KAT population with data from the national Patient Reported Outcome Measures (PROMs)
data set, which covers around 85% of participants undergoing TKR in England in 2010–11, suggests that
KAT participants are typical of those undergoing TKR this decade. KAT participants had a mean baseline
OKS of 18.0 (cf. 19.0 in PROMs) and a baseline EQ-5D of 0.38 (cf. 0.41 in PROMs).91 Postoperative scores
seen in KAT at 12 months were also similar to those observed in the national PROMs data set at 6 months
(OKS 34.1 vs. 33.8 in PROMs; EQ-5D 0.73 vs. 0.70 in PROMs).91NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18190 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 19The length of stay observed for KAT procedures (mean 10 days; standard deviation 5 days) is typical of
that observed across England and Wales in 2000–3.94 However, the average length of stay has fallen
substantially in the past 10 years, such that the mean hospital stay for primary knee replacement is now
5.3 days.82 As a result of their longer length of stay, the average total cost of the inpatient stay for primary
TKR estimated in KAT (mean £7070; standard deviation £1873) is substantially higher than the current
national average in England and Wales (£6080, based on HRGs HB21A-C in 2010–11).84 However, if the
length of stay among KAT participants had been the same as that seen in recent years, the mean
estimated cost of KAT primary admissions would have been reduced to £5526 (standard deviation £1212):
£554 lower than the current national average. The reason for this difference is unclear. Differences in
costing methodology could be one explanation. In particular, our analysis used Scottish data on operating
theatre costs, because of a lack of available data on the cost of operating theatre time in England, and
based the cost of the inpatient stay on the cost per excess bed-day to avoid double counting. However,
the difference may also reﬂect changes in resource use over time, such as the higher cost of knee
replacement components now than in KAT, a greater usage of regional anaesthesia, or more
physiotherapy and other rehabilitation resources so as to achieve an early discharge.
Whereas the clinical results are likely to be applicable world-wide, the ﬁndings of economic evaluations are
generally more sensitive to changes in relative prices and clinical practice and are speciﬁc to a UK setting.
There may also be variations in clinical practice and procurement polices within the UK that could affect
cost-effectiveness. In particular, the discounts that hospitals receive off component list prices and the
loan charges incurred for instruments vary between hospitals, with low-volume centres typically incurring
higher costs. There are also substantial variations in component price among manufacturers, which may
increase variations among hospitals or surgeons who predominantly use components by one or two
manufacturers. Other variations in hospital care, such as variations in recovery room use, were also
observed. The indications and rates of revision surgery are also likely to vary among centres, although
such variations cannot easily be identiﬁed within a sample of this size. Other unit costs will also vary
geographically: particularly between Scotland and England and between London and provincial towns.
However, given that the economic results were primarily driven by the magnitude and direction of quality of
life differences and were insensitive to even substantial changes in the cost of components and hospital
care, the ﬁndings from KAT are likely to have wider relevance than other evaluations in which costs
comprise the major driver. Variation between centres also has equity implications. At present, a shortage of
data on the relative merits of different prostheses leads to marked variation among surgeons in the types
of prostheses used.
At present, surgeons also take account of several patient characteristics when deciding on the most
appropriate type of prosthesis, such as disease severity, deformity, diagnosis, age and activity. In particular,
more costly component designs, such as metal-backed components and mobile bearings, are predominantly
given to younger participants, who are more active and more likely to outlive their prostheses. In KAT,
secondary subgroup analyses suggested that patellar resurfacing, mobile bearings and all-polyethylene tibial
components were less cost-effective in participants aged ≥ 70 years than in younger participants. However,
patellar resurfacing and metal backing were nonetheless cost-effective for both age groups, suggesting that
allocation by age is not appropriate. However, subgroup analyses did suggest that mobile bearings were
dominated by ﬁxed bearings in older participants, but dominant in younger participants, suggesting that age
and activity may be an important consideration for this aspect of component design, although further
research is needed.
The results also have implications for hospital and commissioning budgets. Although economic results
suggest that patellar resurfacing and metal backing are cost-effective from an NHS perspective, both
aspects of prosthesis design increase costs during participants’ primary hospital stay, which are offset
by reductions in subsequent care and improvements in quality of life.107
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108General research implications from the trial as a wholeThe trial used a partial factorial design, which has been used in only a handful of trials to date, including
the Women’s Health Initiative92 and the UK prospective diabetes study.95 This study design enabled us to
address three distinct research questions in the same study, increasing our effective sample size by
recruiting some participants to two comparisons and avoiding the need to incur the ﬁxed costs of trial
administration and analysis for each comparison. These beneﬁts are of particular relevance to
orthopaedics, for which long follow-up time is essential and component designs raise a series of
inter-related research questions.
The partial factorial design also enabled an exploratory assessment of interactions between patellar
resurfacing and the other aspects of component design. Although the trial was extremely underpowered
for this analysis, this sensitivity analysis suggested substantial qualitative interactions among the
comparisons that could change the conclusions of the metal backing and patellar resurfacing comparisons.
Although the results of these sensitivity analyses could be explained by chance and should be interpreted
with caution, they nonetheless highlight an important area for future research. Although it may not be
feasible to conduct a fully factorial trial adequately powered to detect interactions, preliminary work to
explore the potential interaction between patellar resurfacing and metal backing or mobile bearings may
be warranted.
The partial factorial study design also introduces challenges for the trial-based economic evaluation. KAT
data are being used in ongoing research to explore the appropriate methodology for economic evaluation
of factorial design trials,96 which could help improve the quality of subsequent research. Orthopaedic
research also raises additional challenges for trial-based economic evaluation: particularly in relation to
valuing joint prostheses and operating theatre time and dealing with data collected over a 10-year
trial period.LimitationsThe study was designed about 15 years ago. Therefore, the questions that were considered to be
important then may not be relevant today. However, the questions are, in fact, still important particularly
as there are limited funds available for health care. The prostheses used in the study are no longer
commonly used today. However, as the questions were generic and as there have only been small changes
in prosthetic design, this makes no difference to the conclusions. Similarly, clinical practice has not
changed substantially, except that larger numbers of knee replacements are implanted and the inpatient
stay is shorter, so this should not affect the conclusions. Traditional randomised trials in orthopaedics have
had tight inclusion and exclusion criteria and have included surgeon-based outcome measures as well as
radiographs. KAT is very different as it is pragmatic in nature and is therefore better at guiding health
policy. A great strength of KAT is the detailed health economic analysis; however, the resource-use data
collection focused on the main drivers and excluded non-knee-related costs, pain medication and mobility
aids. In addition, we did not have accurate data on the discounts that hospitals receive. We therefore
assumed that there was a ﬂat rate of discount across all components, which may not be the case in
practice. The partial factorial design of the study means that we cannot easily allow for interactions
among treatment factors or have the power to accurately estimate or exclude such interactions.Analysis of the non-randomised dataThe comprehensive range of data on clinical characteristics, quality of life and resource use that have been
collected for KAT could be used to address additional research questions related to knee replacement.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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with baseline characteristics and to assess the evidence base underpinning the eligibility criteria for TKR
that had recently been introduced by a number of primary care trusts.97 This research demonstrated that,
although the costs and beneﬁts of TKR vary with OKS, TKR is highly cost-effective for participants of
grades 1–2 who had baseline OKS < 40 and for ASA grade 3 participants with OKS < 35. The study also
showed that the cost-effectiveness of TKR was independent of BMI and of disease in other joints. This
study was published in BMJ Open and presented at a number of national and international meetings.
EQ-5D and OKS data from KAT were also used alongside data from the national PROMs programme to
develop a mapping algorithm that can be used to estimate EQ-5D responses and utilities from patients’
responses to the OKS questionnaire,98 thereby facilitating future research assessing cost-effectiveness
on older data sets that include OKS but not EQ-5D. KAT data were also used to explore the potential
clustering effects of surgeon and/or centre in surgical trials and contributed to a database of intracluster
correlation coefﬁcients to aid in the design of future randomised surgical trials.99 There is also a
collaboration between KAT and COAST (another study funded by NIHR) in which KAT data are being
used to develop a predictive model of knee replacement outcome.Further researchThe three main priorities for further research are:
1. Continue follow-up of KAT patients up to a minimum of 15 years.
2. Additional detailed analysis of the 10-year KAT data set.
3. Further RCTs in joint replacement based on the experience gained from KAT. A good example of this is
TOPKAT, a study designed to determine whether total or partial knee replacement is better.
The analysis of the median 10-year follow-up data from KAT patients has gone a long way towards
providing a substantially ﬁrmer evidence base to guide answers to the questions addressed by the
randomisations within KAT. However, further follow-up to a minimum of 15 years and analysis of these
data should result in stronger conclusions, which should provide the basis for more detailed, stronger and
complete recommendations. There are two reasons for this. First, differences among the arms of the
various randomisations may appear or become more marked in the second decade post knee replacement,
and, second, the power of the study will increase with longer follow-up, which will allow more detailed
subgroup analysis. Failure due to many causes, such as component loosening, polyethylene wear and
osteolysis, tends to occur more frequently in the second decade than the ﬁrst. Therefore, any design
features, such as patellar resurfacing, mobile bearings and metal backing of the tibia, that inﬂuence these
failure mechanisms are likely to have a greater effect on revision rates in the second decade than the ﬁrst.
In the longer term, outcome scores following knee replacement tend to drop. Therefore, functional
differences among different designs of knee replacement may become more marked in the second
decade. With time there will be more reoperations and revisions, which will increase the power of the
study. For the standard analysis of the outcome scores, increased observations over time will not increase
power, although the power of the marginal beneﬁt calculation may increase with longer follow-up.
Similarly, as costs and QALYs accumulate over time, the power of the health economic analysis may
also increase if the follow-up is increased to 15 and 20 years.
Ongoing follow-up is particularly important for the patellar resurfacing randomisation, as we have found
that with increasing follow-up there were an increasing number of reoperations for complications of
resurfacing and a decreasing number of late patellar resurfacing procedures. We are therefore concerned
that after 15 years there may be an increasing number of problems with resurfacing the patella that may
change our ﬁndings, suggesting that the patella should not be resurfaced routinely. With the mobile
bearing randomisation, we found that after up to 10 years there was no deﬁnite difference between the
two arms. However, the main advantage of the mobile bearing, which is decreased wear, is most likely to
manifest in the second decade. Long-term follow-up could also explore the trend towards lower QALYs109
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110with mobile bearings beyond year 5 and explore the trend towards mobile bearings having a better
cost-effectiveness in younger people than in older people. Follow-up to 15 and 20 years should clarify
these issues. In the metal-backed versus all polyethylene randomisation, the 10-year results suggest a clear
health economic advantage for the metal-backed tibia. There was, however, no clear clinical difference. Up
to 10 years, we found a non-signiﬁcantly higher incidence of major reoperations in the all polyethylene
group. As the incidence of revision tends to increase with time, longer follow-up will clarify whether or not
this is a real difference. There was also some conﬂicting evidence about the functional advantages of the
metal-backed tibia. The OKS did not demonstrate a signiﬁcant advantage, whereas the EQ-5D and SF-12
did, although the patterns of results were very similar. Further follow-up would also clarify this.
We believe the median 10-year KAT data set is the best data set for knee replacement that exists.
It contains detailed data on patient demographics, surgical ﬁndings and management and implant
characteristics for a very large number of patients. It also contains data from annual follow-up about
clinical scores, complications, reoperations, costs and resource use. Further observational analysis of the
data set, which should ideally be extended to a minimum of 10 years, could be undertaken to describe the
natural history of knee replacement and to answer many of the key outstanding questions relating to TKR.
For example, KAT data could be used to identify patient, centre, surgical and implant factors associated
with a poor outcome, in terms of clinical score or reoperation rate, which would help surgeons improve
the results of knee replacements. It could be used to determine the optimum way to follow-up knee
replacement patients. It could be used to develop a detailed long-term health economic model of knee
replacement and thus to improve the cost-effectiveness of knee replacement. It could be used to explore
important observations made in the study such as that, when failure is deﬁned as reoperation or a worse
OKS than pre operation, the cumulative failure rate at 10 years is about 30% and that the various
outcome measures discriminate differently among knee replacement designs.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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152Further Information for General Practitioners
BACKGROUND
There is no doubt about the value of knee replacement surgery, with 20,000 knee replacements performed
annually in the UK, at an estimated cost of £70 million. However, a wide variety of prostheses are
currently being used, and uncertainty exists as to which are the best options, particularly for younger
and fitter patients whose potential benefit is greatest.
In particular, controversy still exists as to whether to mount the tibial bearing on a metal baseplate or
not, the benefit of patellar re-surfacing, and whether an element of axial rotation of the tibial bearing is
in the long term beneficial. The role of less expensive hemiarthroplasty designs particularly in the younger
age group also awaits proper scrutiny. Unless there is an unexpected radical breakthrough in biomaterials
research, there is a consensus that, for available materials, knee replacement design is unlikely to
change in broad terms in the foreseeable future, and certainly not in the next decade.
The planned study is therefore timely and will provide information which is important for clinicians,
patients and policy makers about the most appropriate forms of surgery.
AIMS
This study addresses questions about four developments in knee replacement surgery:
• Is a metal backing plate for the tibial component of the total knee replacement better than a single
high density polyethylene component?
• Is it better to resurface the patella as part of a knee replacement or not?
• Does a polythylene moving component (bearing) between the tibia and femur have a better outcome
than standard designs without a moving bearing?
• Is it better to replace a single component of the knee or to replace the whole knee joint?
The assessment of outcome for each of the comparisons is based on:
• Patient-assessed function and health status
• Reoperation rates
• The ‘worth’ of any additional cost to the NHS
BRIEF OUTLINE OF THE STUDY
Surgeons may opt to take part in any (or all) of the comparisons for which they have no clear preference
for one of the options. Individual patients will be entered into no more than two possible permutations,
however. Prior to admission to hospital, patients are sent information about the study, inviting them to
take part, and describing the possible options for their operation. If they agree to take part, they will be
randomised around the time they are admitted to hospital for their operation. During their hospital
admission, standard information will be collected on their operation and recovery, including short-term
complications and data relating to their hospital stay.
Three months and annually after their operation, participants will be sent postal questionnaires asking
about their general health, their knee function, and their use of the health service, including any re-
admissions and revision surgery. Follow-up will continue for up to eleven years after their operation, to
ensure that the long-term performance of the knee operation is properly assessed.
KAT Co-ordinating Office, Health Services Research Unit (FLEA), University of Aberdeen, Polwarth Building,
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I have:
• Discussed the study with:
• Been given the Information Sheet about the study
• Received satisfactory answers to questions
• Been given enough information about the study
I understand that:
• I am free to withdraw from the study at any time without having to give a reason
• If I withdraw, this will not affect my care
• My family doctor will be notified that I am taking part in the study
• My family doctor and the person I have nominated as my best contact may be approached
for additional information
• I will be sent questionnaires three months and each year after my operation
• Information from my hospital notes and NHS information to do with my knee replacement
may be collected
I agree to take part in the study
Please sign here:
Your name in block capitals:
Date:
I confirm that I have explained to the person named above, the nature and purpose of the
study and the procedures involved.
Signature of investigator:
Date:
Study Centre No Patient Study No
(For use by co-ordinating centre in Aberdeen)
KAT Co-ordinating Office, Health Services Research Unit (FLea), University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen
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170Study Centre No                                                                               Patient Study No
CONFIDENTIAL
KAT STUDY
PARTICIPANT THREE MONTH
QUESTIONNAIRE
We are going to ask you a few questions about your general health
followed by some specific questions about your knee.  We would
also like to know if you have needed to consult any medical services
over the past three months.
Even though you may have had both knees replaced, when
answering the following questions, please think only of your right
knee (not both knees).
This study is funded by the NHS Research and Development Health Technology
Assessment Programme
RIGHTNIHR Journals Library www.journalslibrary.nihr.ac.uk
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1. By placing a cross (X) in one box in each group below, please indicate which
statement best describes your own health state today.  Do not X more than
one box in each group.
Mobility
I have no problems in walking about
I have some problems in walking about
I am confined to bed
Self-Care
I have no problems with self care
I have some problems washing and dressing myself
I am unable to wash myself
Usual activities (e.g. work, study, housework, family or leisure activities)
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities
Pain / Discomfort
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
Anxiety / Depression
I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxious or depressed171
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The following questions ask for your views about your health, how you feel and how well
you are able to do your usual activities.
If you are unsure about how to answer any questions please give the best answer you can
and make any of your own comments if you like.  Do not spend too much time in answering
as your immediate response is likely to be the most accurate.
2. In general, would you say your health is (Please X one box)
Excellent Very Good Good Fair Poor
3. The following questions are about activities you might do during a typical day.
Does your health now limit you in these activities?  If so, how much?
(Please X one box on each line)
Yes, Yes, No, not
limited limited limited
a lot a little at all
Moderate activities, such as moving a table,
pushing a vacuum cleaner, bowling or playing golf
Climbing several flights of stairs
4. During the past 4 weeks, have you had any of the following problems with
your work or other regular daily activities as a result of your physical health?
(Please X one box on each line)
All Most Some A little None
of the of the of the of the of the
time time time time time
Accomplished less than you
would like
Were you limited in the kind of
work or other activities
Study Centre No                                                                               Patient Study NoNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta18190 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 195. During the past 4 weeks, have you had any of the following problems with your
work or other regular daily activities as a result of any emotional problems (such
as feeling depressed or anxious)? (Please X one box on each line)
All Most Some A little None
of the of the of the of the of the
time time time time time
Accomplished less than you
would like
Didn’t do work or other activities
as carefully as usual
6. During the past 4 weeks how much did pain interfere with your normal work
(including work both outside the home and housework)? (Please X one box)
Not at all A little bit Moderately Quite a bit Extremely
7. These questions are about how you feel and how things have been with you
during the past 4 weeks.  For each question, please indicate the one answer that
comes closest to the way you have been feeling. (Please X one box on each line)
How much time during the past 4 weeks:
All Most Some A little None
of the of the of the of the of the
time time time time time
Have you felt calm
and peaceful?
Did you have a lot
of energy?
Have you felt
downhearted and low?
8. During the past 4 weeks, how much of the time has your physical health or
emotional problems interfered with your social activities (like visiting with friends,
relatives, etc)? (Please X one box)
All of Most of Some of A little of None of
the time the time the time the time the time173
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The following questions ask about problems which may have been caused by your right
knee during the past 4 weeks.   (Please X one box for each question.)
9. During the past 4 weeks how would you describe the pain you have from your
right knee?
None Very mild Mild Moderate Severe
10. During the past 4 weeks have you had any trouble with washing and drying
yourself (all over) because of your right knee?
No trouble Very little Moderate Extreme Impossible
at all trouble trouble difficulty to do
11. During the past 4 weeks have you had any trouble getting in and out of a car or
using public transport because of your right knee?  (whichever you tend to use).
No trouble Very little Moderate Extreme Impossible
at all trouble trouble difficulty to do
12. During the past 4 weeks for how long have you been able to walk before the pain
from your right knee becomes severe?  (with or without a stick).
No pain at all, Not at all -
or no pain for 16 to 5 to Around the pain severe
more than 30 mins 30 mins 15 mins house only on walking
13. During the past 4 weeks after a meal (sat at a table), how painful has it been for
you to stand up from a chair because of your right knee?
Not at Slightly Moderately Very
all painful painful painful painful UnbearableNIHR Journals Library www.journalslibrary.nihr.ac.uk
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right knee?
Rarely/ Sometimes or Often, not Most of All of
never just at first just at first the time the time
15. During the past 4 weeks could you kneel down and get up again afterwards?
(thinking of your right knee)
Yes, With little With moderate With extreme No,
easily difficulty difficulty difficulty impossible
16. During the past 4 weeks have you been troubled by pain from your right knee in
bed at night?
No Only 1 or Some Most Every
nights 2 nights nights nights night
17. During the past 4 weeks how much has pain from your right knee interfered with
your usual work (including housework)?
Not at all A little bit Moderately Greatly Totally
18. During the past 4 weeks have you felt that your right knee might suddenly “give
way” or let you down?
Rarely/ Sometimes, or Often, not Most of All of
never just at first just at first the time the time
19. During the past 4 weeks could you do the household shopping on your own?
(thinking of your knee)
Yes, With little With moderate With extreme No,
easily difficulty difficulty difficulty impossible
20. During the past 4 weeks could you walk down a flight of stairs? (thinking of your
knee)
Yes, With little With moderate With extreme No,
easily difficulty difficulty difficulty impossible175
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We would like to know about any medical problems that you have had with your right
knee.
21. Since leaving hospital, have you been back to the hospital outpatients to see an
orthopaedic surgeon for any reason relating to your right knee?
No If No, go to question 22
Yes If Yes, how many times?
(e.g.   0   1   ) Number of times
22. Since leaving hospital, have you visited a physiotherapist for any reason relating
to your right knee?
No If No, go to question 23
Yes If Yes, how many times? Number of times
23. Since leaving hospital, have you been to see your General Practitioner for any
reason relating to your right knee?
No If No, go to question 24
Yes If Yes, how many times? Number of times
24. Since your operation have you been admitted into any hospital for any reason?
No If No, go to final section
Yes If Yes, please give (rough) date, hospital and reason, if possible
Day Month Year
Hospital
Reason
Day Month Year
Hospital
ReasonNIHR Journals Library www.journalslibrary.nihr.ac.uk
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Thank you for completing this questionnaire. It really will help us to find out how we
can best help people who have knee operations like yours.
We would like to contact you again in about nine months time. If your circumstances
are likely to change, please let us know below:
House Name
House Number
Street Name
District
Town/City
County
Postcode
Telephone No
(including code)
Once you have completed this questionnaire please return it in the pre-paid
envelope provided to the following address:
KAT Co-ordinating Office, Health Services Research Unit (FLea),
University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB25 2ZQ177
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CONFIDENTIAL
KAT STUDY
PARTICIPANT ANNUAL FORM
We are going to ask you a few questions about your general health
followed by some specific questions about your knee.  We would
also like to know if you have needed to consult any medical services
over the past year.
Even though you may have had both knees replaced, when
answering the following questions, please think only of your right
knee (not both knees).
This study is funded by the NHS Research and Development Health Technology
Assessment Programme
RIGHTNIHR Journals Library www.journalslibrary.nihr.ac.uk
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1. By placing a cross (X) in one box in each group below, please indicate which
statement best describes your own health state today.  Do not X more than
one box in each group.
Mobility
I have no problems in walking about
I have some problems in walking about
I am confined to bed
Self-Care
I have no problems with self care
I have some problems washing and dressing myself
I am unable to wash myself
Usual activities (e.g. work, study, housework, family or leisure activities)
I have no problems with performing my usual activities
I have some problems with performing my usual activities
I am unable to perform my usual activities
Pain / Discomfort
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
Anxiety / Depression
I am not anxious or depressed
I am moderately anxious or depressed
I am extremely anxious or depressed179
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The following questions ask for your views about your health, how you feel and how well
you are able to do your usual activities.
If you are unsure about how to answer any questions please give the best answer you can
and make any of your own comments if you like.  Do not spend too much time in answering
as your immediate response is likely to be the most accurate.
2. In general, would you say your health is (Please X one box)
Excellent Very Good Good Fair Poor
3. The following questions are about activities you might do during a typical day.
Does your health now limit you in these activities?  If so, how much?
(Please X one box on each line)
Yes, Yes, No, not
limited limited limited
a lot a little at all
Moderate activities, such as moving a table,
pushing a vacuum cleaner, bowling or playing golf
Climbing several flights of stairs
4. During the past 4 weeks, have you had any of the following problems with
your work or other regular daily activities as a result of your physical health?
(Please X one box on each line)
All Most Some A little None
of the of the of the of the of the
time time time time time
Accomplished less than you
would like
Were you limited in the kind of
work or other activities
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work or other regular daily activities as a result of any emotional problems (such
as feeling depressed or anxious)? (Please X one box on each line)
All Most Some A little None
of the of the of the of the of the
time time time time time
Accomplished less than you
would like
Didn’t do work or other activities
as carefully as usual
6. During the past 4 weeks how much did pain interfere with your normal work
(including work both outside the home and housework)? (Please X one box)
Not at all A little bit Moderately Quite a bit Extremely
7. These questions are about how you feel and how things have been with you
during the past 4 weeks.  For each question, please indicate the one answer that
comes closest to the way you have been feeling. (Please X one box on each line)
How much time during the past 4 weeks:
All Most Some A little None
of the of the of the of the of the
time time time time time
Have you felt calm
and peaceful?
Did you have a lot
of energy?
Have you felt
downhearted and low?
8. During the past 4 weeks, how much of the time has your physical health or
emotional problems interfered with your social activities (like visiting with friends,
relatives, etc)? (Please X one box)
All of Most of Some of A little of None of
the time the time the time the time the time181
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The following questions ask about problems which may have been caused by your right
knee during the past 4 weeks.   (Please X one box for each question.)
9. During the past 4 weeks how would you describe the pain you have from your
right knee?
None Very mild Mild Moderate Severe
10. During the past 4 weeks have you had any trouble with washing and drying
yourself (all over) because of your right knee?
No trouble Very little Moderate Extreme Impossible
at all trouble trouble difficulty to do
11. During the past 4 weeks have you had any trouble getting in and out of a car or
using public transport because of your right knee?  (whichever you tend to use).
No trouble Very little Moderate Extreme Impossible
at all trouble trouble difficulty to do
12. During the past 4 weeks for how long have you been able to walk before the pain
from your right knee becomes severe?  (with or without a stick).
No pain at all, Not at all -
or no pain for 16 to 5 to Around the pain severe
more than 30 mins 30 mins 15 mins house only on walking
13. During the past 4 weeks after a meal (sat at a table), how painful has it been for
you to stand up from a chair because of your right knee?
Not at Slightly Moderately Very
all painful painful painful painful UnbearableNIHR Journals Library www.journalslibrary.nihr.ac.uk
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right knee?
Rarely/ Sometimes or Often, not Most of All of
never just at first just at first the time the time
15. During the past 4 weeks could you kneel down and get up again afterwards?
(thinking of your right knee)
Yes, With little With moderate With extreme No,
easily difficulty difficulty difficulty impossible
16. During the past 4 weeks have you been troubled by pain from your right knee in
bed at night?
No Only 1 or Some Most Every
nights 2 nights nights nights night
17. During the past 4 weeks how much has pain from your right knee interfered with
your usual work (including housework)?
Not at all A little bit Moderately Greatly Totally
18. During the past 4 weeks have you felt that your right knee might suddenly “give
way” or let you down?
Rarely/ Sometimes, or Often, not Most of All of
never just at first just at first the time the time
19. During the past 4 weeks could you do the household shopping on your own?
(thinking of your knee)
Yes, With little With moderate With extreme No,
easily difficulty difficulty difficulty impossible
20. During the past 4 weeks could you walk down a flight of stairs? (thinking of your
knee)
Yes, With little With moderate With extreme No,
easily difficulty difficulty difficulty impossible183
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We would like to know about any medical problems that you have had with your right knee.
21. In the last year, have you been back to the hospital outpatients to see an
orthopaedic surgeon for any reason relating to your right knee?
No If No, go to question 22
Yes If Yes, how many times?
(e.g.   0   1   ) Number of times
22. In the last year, have you visited a physiotherapist for any reason relating to
your right knee?
No If No, go to question 23
Yes If Yes, how many times? Number of times
23. In the last year, have you been to see your General Practitioner for any reason
relating to your right knee?
No If No, go to question 24
Yes If Yes, how many times? Number of times
24. In the last year, have you been admitted into any hospital for any reason?
No If No, go to final section
Yes If Yes, please give (rough) date, hospital and reason, if possible
Day Month Year
Hospital
Reason
Day Month Year
Hospital
Reason
Day Month Year
Hospital
ReasonNIHR Journals Library www.journalslibrary.nihr.ac.uk
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Thank you for completing this questionnaire. It really will help us to find out how we
can best help people who have knee operations like yours.
We would like to contact you again in about a years time. If your circumstances or
those of your best contact are likely to change, please let us know by filling in the
enclosed sheet.
Once you have completed all parts of this questionnaire please return it in the
pre-paid envelope provided to the following address:
KAT Co-ordinating Office, Health Services Research Unit,
University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen AB25 2ZQ185
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CONFIDENTIAL
KAT STUDY
PARTICIPANT DETAILS FORM
For completion by local KAT researcher
This study is funded by the NHS Research and Development Health Technology
Assessment Programme.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Please check faxed patient information and write amendments below, if necessary.
Title (Mr, Mrs etc)      Surname
First Names
Date of Birth Day Month Year
House Name
House Number
Street Name
District
Town/City
County
Postcode
Telephone No
(including code)
Place of Birth (including county)
Marital Status Single Married Divorced Widowed
Sex Maiden name if female and ever married
Male Female
NHS Number Hospital Number (if known)
CHI Number (Scotland only)195
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Check faxed details and amend if necessary.
Surname
First Name(s) (if known)
House Name
House Number
Street Name
District
Town/City
County
Postcode
Telephone No
(including code)
’BEST CONTACT’ (friend or family member)
Title (Mr, Mrs etc)      Surname
First Names
House Name
House Number
Street Name
District
Town/City
County
Postcode
Telephone No
(including code)
Relationship to participantNIHR Journals Library www.journalslibrary.nihr.ac.uk
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1. Weight kgs
2. Height cms
3. Type of knee arthritis? Osteoarthritis (Cross X one box)
Rheumatoid
4. Is the arthritis in? Single knee
Both knees
General
5. Are there any other conditions which are affecting
the participant’s mobility? No
Yes
If Yes, please specify
6. Has the participant had any previous knee surgery? No
Yes
If Yes, was it
Ipsilateral osteotomy
Ipsilateral patellectomy
Contralateral previous knee replacement
Other
If Other, please specify
Please send this completed form, together with the participant entry questionnaire, the
surgeon’s form, and the hospital care form, to the KAT co-ordinating office, when the
participant leaves hospital. Prepaid envelopes are provided.197
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methods for missing data for analyses of costs and
cost-effectivenessTABLE 42 Variables imputed using mean imputation or conditional mean imputation prior to multiple imputations
Variable
% (n)
non-zero
cases
that are
missing Description
Mean imputation
function used
Variable
amalgamated into
nounitstransfused 22 (7/32) Number of units of blood
products transfused after
end of primary knee
replacement surgery but
before discharge
Missing number of
units for patients who
were transfused was
assumed to equal 2.32
(mean number of units
used by patients who
were transfused during
their primary admission)
N/A
unitstransfusedadm‘j’ 20 (1/5) Number of units of blood
transfused during the jth
readmission
Missing number of
units for patients who
were transfused was
assumed to equal 2.32
(mean number of units
used by patients who
were transfused during
their primary admission)
Total cost
readmission‘j’
patellaprice‘j’ 13 (9/67) Price of patellar
components used in the
jth readmission
Missing patella list
prices for patients who
used patella were
assumed to equal
£163.36 (mean cost of
patellas used in
revision surgery)
Total cost
readmission‘j’
tibialinsertprice‘j’ 19 (19/100) Price of tibial tray
components used in the
jth readmission
Missing insert list prices
for patients who used a
tibial insert were
assumed to equal
£411.84 (mean cost of
inserts used in revision
surgery)
Total cost
readmission‘j’
tibialtrayprice‘j’ 14 (12/83) Price of tibial insert
components used in the
jth readmission
Missing tray list prices
for patients who used
a tibial tray were
assumed to equal
£1025.10 (mean cost
of trays used in revision
surgery)
Total cost
readmission‘j’
continued
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TABLE 42 Variables imputed using mean imputation or conditional mean imputation prior to multiple
imputations (continued )
Variable
% (n)
non-zero
cases
that are
missing Description
Mean imputation
function used
Variable
amalgamated into
femurprice‘j’ 10 (8/81) Price of femoral
components used in the
jth readmission
Missing femoral list
prices for patients who
used a femoral
component were
assumed to equal
£2151.55 (mean cost
of femurs used in
revision surgery)
Total cost
readmission‘j’
otherprice‘j’ 7 (13/180) Price of each other
component (e.g.
augments and blocks)
used in the jth
readmission
Missing list prices of
other components for
patients who used an
other component were
assumed to equal
£561.26 per
component (mean cost
of other components
used in revision surgery)
Total cost
readmission‘j’
LOS‘j’ for washout 11 (2/19) Length of stay for
patients’ jth readmission
if that readmission is for
washout only
Length of stay was
assumed to be 9 days
(mean length of stay
for the 17 cases with
known length of stay)
Total cost
readmission‘j’
LOS‘j’ for 2nd stage
of two-state revision
7 (2/29) Length of stay for
patients’ jth readmission
if that readmission is for
the second stage of a
two-stay revision
Length of stay was
assumed to be 13.3
days (mean length of
stay for the 27 cases
with known length
of stay)
Total cost
readmission‘j’
Diedduringyear1or2 0 (0)a Dummy equal to 1 if the
patient died during one
of these 2 years; 0
otherwise. Most missing
data represent patients
who were still alive when
the database was closed
on 8 June. Some data
were missing at earlier
time points because
some Scottish patients
declined consent for
death monitoring in
2006
Remaining life
expectancy at last
observation was
estimated for each
patient administratively
censored before year
10 based on their sex,
country and age at last
observation, based on
ONS life tables.36 For
multiple imputation,
administratively
censored patients were
assumed to have died
in year y or y + 1 if their
remaining life
expectancy plus the
year when they were
last observed was
≤ y + 1, but > y – 1
None
IPW was used in place
of imputed survival
indicators in base-case
costs and QALY
calculations. However,
complete data on
survival were needed
to run multiple
imputation of other
values, in order to
condition EQ-5D and
ambulatory
consultation numbers
Diedduringyear2or3 0 (0)a
Diedduringyear3or4 0 (0)a
Diedduringyear4or5 0 (10)a
Diedduringyear5or6 1 (20)a
Diedduringyear6or7 1 (29)a
Diedduringyear7or8 2 (34)a
Diedduringyear8or9 2 (35)a
Diedduringyear9or10 8 (182)a
Diedduringyear10or11 44 (984)a
Diedduringyear11or12 66 (1485)a
a Equals the number patients for whom vital status is not shown at this time point across all 2252 patients.
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